{ "version": "2.2", "instance": { "mor-20231231.htm": { "nsprefix": "mor", "nsuri": "http://www.morphosys.com/20231231", "dts": { "inline": { "local": [ "mor-20231231.htm" ] }, "schema": { "local": [ "mor-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "mor-20231231_cal.xml" ] }, "definitionLink": { "local": [ "mor-20231231_def.xml" ] }, "labelLink": { "local": [ "mor-20231231_lab.xml" ] }, "presentationLink": { "local": [ "mor-20231231_pre.xml" ] } }, "keyStandard": 329, "keyCustom": 350, "axisStandard": 40, "axisCustom": 8, "memberStandard": 57, "memberCustom": 169, "hidden": { "total": 115, "http://www.morphosys.com/20231231": 99, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 12, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 971, "entityCount": 1, "segmentCount": 243, "elementCount": 1185, "unitCount": 13, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1927, "http://xbrl.sec.gov/dei/2023": 43, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.morphosys.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.morphosys.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorLocation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorLocation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "longName": "0000003 - Statement - Consolidated Statement of Profit or Loss", "shortName": "Consolidated Statement of Profit or Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromSaleOfGoods", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "longName": "0000004 - Statement - Consolidated Statement of Comprehensive Income", "shortName": "Consolidated Statement of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R5": { "role": "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "longName": "0000005 - Statement - Consolidated Balance Sheet", "shortName": "Consolidated Balance Sheet", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:TradeReceivablesAndContractAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R6": { "role": "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "longName": "0000006 - Statement - Consolidated Balance Sheet (Parenthetical)", "shortName": "Consolidated Balance Sheet (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statement of Changes in Stockholders' Equity", "shortName": "Consolidated Statement of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-9", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "longName": "0000008 - Statement - Consolidated Statement of Cash Flows", "shortName": "Consolidated Statement of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R9": { "role": "http://www.morphosys.com/role/GeneralInformation", "longName": "0000009 - Disclosure - General Information", "shortName": "General Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Material Accounting Policies", "shortName": "Summary of Material Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.morphosys.com/role/NotestotheStatementofProfitorLoss", "longName": "0000011 - Disclosure - Notes to the Statement of Profit or Loss", "shortName": "Notes to the Statement of Profit or Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfAnalysisOfIncomeStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfAnalysisOfIncomeStatementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheet", "longName": "0000012 - Disclosure - Notes to the Balance Sheet", "shortName": "Notes to the Balance Sheet", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "mor:NotesToTheBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:NotesToTheBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroup", "longName": "0000013 - Disclosure - Remuneration System for the Management Board and Employees of the Group", "shortName": "Remuneration System for the Management Board and Employees of the Group", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.morphosys.com/role/AdditionalNotes", "longName": "0000014 - Disclosure - Additional Notes", "shortName": "Additional Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Material Accounting Policies (Policies)", "shortName": "Summary of Material Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "mor:DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Material Accounting Policies (Tables)", "shortName": "Summary of Material Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables", "longName": "9954473 - Disclosure - Notes to the Profit or Loss Statement (Tables)", "shortName": "Notes to the Profit or Loss Statement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfRevenuesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfRevenuesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetTables", "longName": "9954474 - Disclosure - Notes to the Balance Sheet (Tables)", "shortName": "Notes to the Balance Sheet (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables", "longName": "9954475 - Disclosure - Remuneration System for the Management Board and Employees of the Group (Tables)", "shortName": "Remuneration System for the Management Board and Employees of the Group (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.morphosys.com/role/AdditionalNotesTables", "longName": "9954476 - Disclosure - Additional Notes (Tables)", "shortName": "Additional Notes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesConsolidatedCompaniesandScopeofConsolidationNarrativeDetails", "longName": "9954477 - Disclosure - Summary of Material Accounting Policies - Consolidated Companies and Scope of Consolidation Narrative (Details)", "shortName": "Summary of Material Accounting Policies - Consolidated Companies and Scope of Consolidation Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": null, "uniqueAnchor": null }, "R22": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesFinancialInstrumentsNarrativeDetails", "longName": "9954478 - Disclosure - Summary of Material Accounting Policies - Financial Instruments - Narrative (Details)", "shortName": "Summary of Material Accounting Policies - Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": null, "uniqueAnchor": null }, "R23": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "longName": "9954479 - Disclosure - Summary of Material Accounting Policies - Summary of Estimated Useful Life of Property Plant and Equipment (Detail)", "shortName": "Summary of Material Accounting Policies - Summary of Estimated Useful Life of Property Plant and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c-47", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail", "longName": "9954480 - Disclosure - Summary of Material Accounting Policies - Summary of Useful Lives of Intangible Assets Including Goodwill Narrative (Detail)", "shortName": "Summary of Material Accounting Policies - Summary of Useful Lives of Intangible Assets Including Goodwill Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-55", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "longName": "9954481 - Disclosure - Summary of Material Accounting Policies - Summary of Useful Lives of Intangible Assets Including Goodwill (Detail)", "shortName": "Summary of Material Accounting Policies - Summary of Useful Lives of Intangible Assets Including Goodwill (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-55", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "ifrs-full:AmortisationRateIntangibleAssetsOtherThanGoodwill", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R26": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesImpairmentofNonFinancialAssetsAdditionalInformationDetails", "longName": "9954482 - Disclosure - Summary of Material Accounting Policies - Impairment of Non-Financial Assets - Additional Information (Details)", "shortName": "Summary of Material Accounting Policies - Impairment of Non-Financial Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": null, "uniqueAnchor": null }, "R27": { "role": "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesStockholdersEquityAdditionalInformationDetails", "longName": "9954483 - Disclosure - Summary of Material Accounting Policies - Stockholders Equity - Additional Information (Details)", "shortName": "Summary of Material Accounting Policies - Stockholders Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": null, "uniqueAnchor": null }, "R28": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "longName": "9954485 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Revenue (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-66", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRevenuesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R29": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "longName": "9954486 - Disclosure - Notes to the Profit or Loss Statement -Revenue Narrative (Detail)", "shortName": "Notes to the Profit or Loss Statement -Revenue Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R30": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail", "longName": "9954487 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Regional Distribution of Revenue (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Regional Distribution of Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRegionalDistributionOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R31": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails", "longName": "9954488 - Disclosure - Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations (Details)", "shortName": "Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SatisfactionOfPerformanceObligationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R32": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsAdditionalDetailsDetails", "longName": "9954489 - Disclosure - Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations - Additional Details (Details)", "shortName": "Notes to the Profit or Loss Statement - Summary of Satisfaction of Performance Obligations - Additional Details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "longName": "9954490 - Disclosure - Notes to the Profit or Loss Statement - Summary of Cost of Sales (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Cost of Sales (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CostOfSales", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "ifrs-full:CostOfSales", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R34": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "longName": "9954491 - Disclosure - Notes to the Profit or Loss Statement - Summary of Research and Development Expenses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Research and Development Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-120", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "mor:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R35": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail", "longName": "9954492 - Disclosure - Notes to the Profit or Loss Statement - Summary of Selling Expenses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Selling Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:SellingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-120", "name": "ifrs-full:SellingExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "mor:DisclosureOfSellingExpenseTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R36": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "longName": "9954493 - Disclosure - Notes to the Profit or Loss Statement - Summary of General and Administrative Expenses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of General and Administrative Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-120", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "mor:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R37": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "longName": "9954494 - Disclosure - Notes to the Profit or Loss Statement - Summary of Personnel Expenses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Personnel Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesAdditionalinformationDetails", "longName": "9954495 - Disclosure - Notes to the Profit or Loss Statement - Summary of Personnel Expenses - Additional information (Details)", "shortName": "Notes to the Profit or Loss Statement - Summary of Personnel Expenses - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R39": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail", "longName": "9954496 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Average Number Of Employees (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Average Number Of Employees (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfEmployees", "unitRef": "employees", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:AverageNumberOfEmployeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfEmployees", "unitRef": "employees", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:AverageNumberOfEmployeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofAverageNumberOfEmployeesAdditionalInformationDetails", "longName": "9954497 - Disclosure - Notes to the Profit or Loss Statement - Summary of Average Number Of Employees - Additional Information (Details)", "shortName": "Notes to the Profit or Loss Statement - Summary of Average Number Of Employees - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employees", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "employees", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails", "longName": "9954498 - Disclosure - Notes to the Profit or Loss Statement - Impairment of Goodwill (Details)", "shortName": "Notes to the Profit or Loss Statement - Impairment of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail", "longName": "9954499 - Disclosure - Notes to the Profit or Loss Statement - Summary of Other Income and Expenses, Finance Income and Expenses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Other Income and Expenses, Finance Income and Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NetForeignExchangeGain", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:NetForeignExchangeGain", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "longName": "9954500 - Disclosure - Notes to the Profit or Loss Statement - Summary of Income Taxes - Additional Information (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "mor:CorporateTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:FederalCorporateIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R44": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "longName": "9954501 - Disclosure - Notes to the Profit or Loss Statement - Summary of Income Taxes (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Income Taxes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "mor:DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail", "longName": "9954502 - Disclosure - Notes to the Profit or Loss Statement - Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AccountingProfit", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R46": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail", "longName": "9954503 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-170", "name": "mor:PriorYearTaxLossesCarryforwards", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "mor:PriorYearTaxLossesCarryforwards", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesAdditionalInformationDetails", "longName": "9954504 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses - Additional Information (Details)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Detailed Information About In Limited Unlimited Carry Forward Tax Losses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "mor:TaxLossesRelativeToUSTaxGroup", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:TaxLossesRelativeToUSTaxGroup", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail", "longName": "9954505 - Disclosure - Notes to the Profit or Loss Statement - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Detail)", "shortName": "Notes to the Profit or Loss Statement - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:DeferredTaxLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R49": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "longName": "9954506 - Disclosure - Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes (Detail)", "shortName": "Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-192", "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-192", "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesAdditionalInformationDetails", "longName": "9954507 - Disclosure - Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes - Additional Information (Details)", "shortName": "Notes to the Profit or Loss Statement - Schedule of Changes in Deferred Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "mor:DeferredTaxItemsRecognizedAgainstEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:DeferredTaxItemsRecognizedAgainstEquity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail", "longName": "9954508 - Disclosure - Notes to the Profit or Loss Statement - Earnings Per Share - Additional Information (Detail)", "shortName": "Notes to the Profit or Loss Statement - Earnings Per Share - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:NumberOfRestrictedStockUnitsUnvested", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R52": { "role": "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail", "longName": "9954509 - Disclosure - Notes to the Profit or Loss Statement - Summary Of Reconciliation Of Earning Per Share (Detail)", "shortName": "Notes to the Profit or Loss Statement - Summary Of Reconciliation Of Earning Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R53": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails", "longName": "9954510 - Disclosure - Notes to the Balance Sheet - Summary of Cash and Cash Equivalents (Details)", "shortName": "Notes to the Balance Sheet - Summary of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Cash", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:Cash", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "longName": "9954511 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-204", "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-204", "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "longName": "9954512 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-210", "name": "mor:NetGainFromDisposalOfAvailableforsaleFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-210", "name": "mor:NetGainFromDisposalOfAvailableforsaleFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "longName": "9954513 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentLoansAndReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentLoansAndReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostAdditionalInformationDetails", "longName": "9954514 - Disclosure - Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Financial Assets at Amortized Cost - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestRevenueExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "longName": "9954515 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Receivable - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Accounts Receivable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-220", "name": "ifrs-full:ReceivablesFromContractsWithCustomers", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-218", "name": "mor:AccountsReceivableNonInterestBearingPaymentTermsPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R59": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "longName": "9954516 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Receivable by Region (Details)", "shortName": "Notes to the Balance Sheet - Summary of Accounts Receivable by Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsReceivableByRegionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsReceivableByRegionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R60": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails", "longName": "9954517 - Disclosure - Notes to the Balance Sheet - Summary of Income Tax Receivables (Details)", "shortName": "Notes to the Balance Sheet - Summary of Income Tax Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "mor:CurrentIncomeTaxReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "longName": "9954518 - Disclosure - Notes to the Balance Sheet - Summary of Other Receivables - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Receivables - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherReceivables", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails", "longName": "9954519 - Disclosure - Notes to the Balance Sheet - Summary of Other Receivables (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails", "longName": "9954520 - Disclosure - Notes to the Balance Sheet - Summary of Inventories (Details)", "shortName": "Notes to the Balance Sheet - Summary of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInventoriesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInventoriesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesAdditionalInformationDetails", "longName": "9954521 - Disclosure - Notes to the Balance Sheet - Summary of Inventories - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Inventories - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInventoriesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails", "longName": "9954522 - Disclosure - Notes to the Balance Sheet - Summary of Current Prepaid Expenses and Other Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Current Prepaid Expenses and Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-3", "name": "mor:ReceivablesFromInputTaxSurplus", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:ReceivablesFromInputTaxSurplus", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails", "longName": "9954523 - Disclosure - Notes to the Balance Sheet - Summary of Non-Current Prepaid Expenses (Details)", "shortName": "Notes to the Balance Sheet - Summary of Non-Current Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "mor:NoncurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:NoncurrentPrepaidExpenses", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails", "longName": "9954524 - Disclosure - Notes to the Balance Sheet - Summary of Prepaid Assets and Other Assets - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Prepaid Assets and Other Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentRestrictedCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentRestrictedCashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "longName": "9954525 - Disclosure - Notes to the Balance Sheet - Summary of Property, Plant and Equipment (Details)", "shortName": "Notes to the Balance Sheet - Summary of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPropertyPlantAndEquipmentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R69": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlanandEquipmentAdditionalInformationDetails", "longName": "9954526 - Disclosure - Notes to the Balance Sheet - Summary of Property, Plan and Equipment - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Property, Plan and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "longName": "9954527 - Disclosure - Notes to the Balance Sheet - Summary of Depreciation (Details)", "shortName": "Notes to the Balance Sheet - Summary of Depreciation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DepreciationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDepreciationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DepreciationExpense", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDepreciationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails", "longName": "9954528 - Disclosure - Notes to the Balance Sheet - Summary of Right of use Assets and Lease Liabilities (Details)", "shortName": "Notes to the Balance Sheet - Summary of Right of use Assets and Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:RightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionsToRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R72": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails", "longName": "9954529 - Disclosure - Notes to the Balance Sheet - Summary of Impact of Lease Agreements (Details)", "shortName": "Notes to the Balance Sheet - Summary of Impact of Lease Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "mor:DepreciationRightOfUseAssetsAfterCurrencyTranslation", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DepreciationRightOfUseAssetsAfterCurrencyTranslation", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "longName": "9954530 - Disclosure - Notes to the Balance Sheet - Summary of Depreciation of Right-of-Use Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Depreciation of Right-of-Use Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DepreciationRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-309", "name": "ifrs-full:DepreciationRightofuseAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R74": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails", "longName": "9954531 - Disclosure - Notes to the Balance Sheet - Summary of Maturity Analysis of Lease Liabilities (Details)", "shortName": "Notes to the Balance Sheet - Summary of Maturity Analysis of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-3", "name": "mor:NetLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:NetLeaseLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetLeassesAdditionalInformationDetails", "longName": "9954532 - Disclosure - Notes to the Balance Sheet - Leasses Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Leasses Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-3", "name": "mor:FutureLeasePaymentsDiscounted", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:FutureLeasePaymentsDiscounted", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "longName": "9954533 - Disclosure - Notes to the Balance Sheet - Summary of Intangible Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-387", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R77": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "longName": "9954534 - Disclosure - Notes to the Balance Sheet - Intangible assets - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Intangible assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "longName": "9954535 - Disclosure - Notes to the Balance Sheet - Summary of Amortization of Intangible Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "mor:AmortizationChargeForTheYear", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-309", "name": "mor:AmortizationChargeForTheYear", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R79": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "longName": "9954536 - Disclosure - Notes to the Balance Sheet - Summary of In process R&D Programs (Details)", "shortName": "Notes to the Balance Sheet - Summary of In process R&D Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-396", "name": "mor:MilestonePaymentsWereCapitalized", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-396", "name": "mor:MilestonePaymentsWereCapitalized", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "longName": "9954537 - Disclosure - Notes to the Balance Sheet - Summary of Internally generated intangible assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Internally generated intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R81": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "longName": "9954538 - Disclosure - Notes to the Balance Sheet - Summary of Goodwill (Details)", "shortName": "Notes to the Balance Sheet - Summary of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-408", "name": "mor:ReductionInCashFlowForecast", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R82": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "longName": "9954539 - Disclosure - Notes to the Balance Sheet - Summary of Investment in Associates - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Investment in Associates - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProceedsFromSalesOfInterestsInAssociates", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:MilestoneShares", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R83": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "longName": "9954540 - Disclosure - Notes to the Balance Sheet - Summary of Financial Information Investment in Associates (Details)", "shortName": "Notes to the Balance Sheet - Summary of Financial Information Investment in Associates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "ifrs-full:CurrentAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialInformationInvestmentInAssociatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R84": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "longName": "9954541 - Disclosure - Notes to the Balance Sheet - Summary of Investments in Associates (Details)", "shortName": "Notes to the Balance Sheet - Summary of Investments in Associates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:InvestmentsInAssociatesAccountedForUsingEquityMethod", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:DecreaseThroughSaleOfSharesOfInvestmentInAssociates", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInvestmentsInAssociatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R85": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxAssetsDetails", "longName": "9954542 - Disclosure - Notes to the Balance Sheet - Summary of Deferred Tax Assets (Details)", "shortName": "Notes to the Balance Sheet - Summary of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R86": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails", "longName": "9954543 - Disclosure - Notes to the Balance Sheet - Summary of Accounts Payables (Details)", "shortName": "Notes to the Balance Sheet - Summary of Accounts Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-3", "name": "mor:TradeAccountsPayable", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:AccruedLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R87": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails", "longName": "9954544 - Disclosure - Notes to the Balance Sheet - Summary of Accrued Expenses (Details)", "shortName": "Notes to the Balance Sheet - Summary of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-3", "name": "mor:AuditFeesAndOtherAuditRelatedCosts", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-416", "name": "mor:ExternalLaboratoryServices", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccruedExpensesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R88": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails", "longName": "9954545 - Disclosure - Notes to the Balance Sheet - Summary of Audit fees (Details)", "shortName": "Notes to the Balance Sheet - Summary of Audit fees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1", "name": "mor:AuditFees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:AuditFees", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAuditFeesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetails", "longName": "9954546 - Disclosure - Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-3", "name": "mor:TaxLiabilitiesCurrentAndNonCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:TaxLiabilitiesCurrentAndNonCurrent", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "longName": "9954547 - Disclosure - Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions (Details)", "shortName": "Notes to the Balance Sheet - Summary of Tax Liabilities and Other Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:OtherShorttermProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionalProvisionsOtherProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfTaxLiabilitiesCurrentAndNonCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R91": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "longName": "9954548 - Disclosure - Notes to the Balance Sheet Summary of Tax Liabilities and Other Provisions - Additional Information(Details) (Details)", "shortName": "Notes to the Balance Sheet Summary of Tax Liabilities and Other Provisions - Additional Information(Details) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherLongtermProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-427", "name": "ifrs-full:OtherLongtermProvisions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R92": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails", "longName": "9954549 - Disclosure - Notes to the Balance Sheet - Summary of Contract Liabilities (Details)", "shortName": "Notes to the Balance Sheet - Summary of Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:ContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "ifrs-full:ContractLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R93": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxLiabilitiesDetails", "longName": "9954550 - Disclosure - Notes to the Balance Sheet - Summary of Deferred Tax Liabilities (Details)", "shortName": "Notes to the Balance Sheet - Summary of Deferred Tax Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NetDeferredTaxLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R94": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "longName": "9954551 - Disclosure - Notes to the Balance Sheet - Summary of Bonds (Details)", "shortName": "Notes to the Balance Sheet - Summary of Bonds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IssueOfConvertibleInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:IssueOfConvertibleInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "longName": "9954552 - Disclosure - Notes to the Balance Sheet - Summary of Financial Assets from Collaborations - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Financial Assets from Collaborations - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-3", "name": "mor:PercentageOnShareOfProfitLossOfAssociatesAndJointVentures", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:IncomeFromNetCashEffects", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R96": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails", "longName": "9954553 - Disclosure - Notes to the Balance Sheet - Summary of Financial Assets from Collaborations (Details)", "shortName": "Notes to the Balance Sheet - Summary of Financial Assets from Collaborations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-442", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R97": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "longName": "9954554 - Disclosure - Notes to the Balance Sheet - Summary of Sensitivity Analysis Financial Assets from Collaborations (Details)", "shortName": "Notes to the Balance Sheet - Summary of Sensitivity Analysis Financial Assets from Collaborations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-446", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-446", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "longName": "9954555 - Disclosure - Notes to the Balance Sheet - Summary of Financial Liabilities from Future Payments to Royalty Pharma (Details)", "shortName": "Notes to the Balance Sheet - Summary of Financial Liabilities from Future Payments to Royalty Pharma (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-3", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-454", "name": "mor:CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R99": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails", "longName": "9954556 - Disclosure - Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability (Details)", "shortName": "Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-6", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-459", "name": "ifrs-full:AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R100": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "longName": "9954557 - Disclosure - Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Royalty Pharma - Financial Liability - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-454", "name": "mor:PercentageOfRoyaltiesFromNetSales", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R101": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "longName": "9954558 - Disclosure - Notes to the Balance Sheet - Summary of Sensitivity Analysis Royalty Pharma - Financial Liability (Details)", "shortName": "Notes to the Balance Sheet - Summary of Sensitivity Analysis Royalty Pharma - Financial Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-464", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-464", "name": "ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "longName": "9954559 - Disclosure - Notes to the Balance Sheet - Summary of Development Funding Bond (Details)", "shortName": "Notes to the Balance Sheet - Summary of Development Funding Bond (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-6", "name": "mor:FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-469", "name": "mor:CashReceiptsFromDevelopmentFundingBond", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentFundingBondTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R103": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "longName": "9954560 - Disclosure - Notes to the Balance Sheet - Summary of Development Funding Bond - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Development Funding Bond - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-26", "name": "mor:MarketInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-456", "name": "mor:MarketInequity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R104": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "longName": "9954561 - Disclosure - Notes to the Balance Sheet - Summary of DFB, Initial Measurement Loss (Details)", "shortName": "Notes to the Balance Sheet - Summary of DFB, Initial Measurement Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-473", "name": "mor:DevelopmentFundingBondMeasurementLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-474", "name": "mor:DevelopmentFundingBondMeasurementLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R105": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "longName": "9954562 - Disclosure - Notes to the Balance Sheet - Summary of Common Stock (Details)", "shortName": "Notes to the Balance Sheet - Summary of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:IssuedCapital", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R106": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "longName": "9954563 - Disclosure - Notes to the Balance Sheet - Summary of Authorized Capital (Details)", "shortName": "Notes to the Balance Sheet - Summary of Authorized Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NumberOfSharesAuthorised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "longName": "9954564 - Disclosure - Notes to the Balance Sheet - Summary of Conditional Capital (Details)", "shortName": "Notes to the Balance Sheet - Summary of Conditional Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-3", "name": "mor:NumberOfSharesOfConditionalCapital", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:NumberOfSharesOfConditionalCapital", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockDetails", "longName": "9954565 - Disclosure - Notes to the Balance Sheet - Summary of Treasury Stock (Details)", "shortName": "Notes to the Balance Sheet - Summary of Treasury Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-26", "name": "mor:NumberOfTreasuryShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:ScheduleOfTreasuryStockTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R109": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "longName": "9954566 - Disclosure - Notes to the Balance Sheet - Summary of Treasury Stock - Additional Information (Details)", "shortName": "Notes to the Balance Sheet - Summary of Treasury Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-26", "name": "mor:NumberOfTreasuryShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:ScheduleOfTreasuryStockTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R110": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "longName": "9954567 - Disclosure - Notes to the Balance Sheet - Summary of Additional Paid-in Capital (Details)", "shortName": "Notes to the Balance Sheet - Summary of Additional Paid-in Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:AdditionalPaidinCapital", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-492", "name": "ifrs-full:ShareIssueRelatedCost", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R111": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails", "longName": "9954568 - Disclosure - Notes to the Balance Sheet - Summary of Other Comprehensive Income Reserve (Details)", "shortName": "Notes to the Balance Sheet - Summary of Other Comprehensive Income Reserve (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:ReserveOfChangeInValueOfTimeValueOfOptions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R112": { "role": "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails", "longName": "9954569 - Disclosure - Notes to the Balance Sheet - Summary of Accumulated Deficit (Details)", "shortName": "Notes to the Balance Sheet - Summary of Accumulated Deficit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfEarningsPerShareTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R113": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "longName": "9954570 - Disclosure - RS - Summary of equity-settled 2017 Stock Option Plan Group (Details)", "shortName": "RS - Summary of equity-settled 2017 Stock Option Plan Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-564", "name": "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R114": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "longName": "9954571 - Disclosure - RS - Summary of equity-settled 2018 Stock Option Plan (Details)", "shortName": "RS - Summary of equity-settled 2018 Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-564", "name": "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": null }, "R115": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "longName": "9954572 - Disclosure - RS - Summary of equity-settled 2019 Stock Option Plan (Details)", "shortName": "RS - Summary of equity-settled 2019 Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-564", "name": "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-513", "name": "ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "unitRef": "stockoptions", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R116": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "longName": "9954573 - Disclosure - RS - Summary of equity-settled 2020 Stock Option Plan (Details)", "shortName": "RS - Summary of equity-settled 2020 Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-524", "name": "mor:SubscriptionRight", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-524", "name": "mor:SubscriptionRight", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "longName": "9954574 - Disclosure - RS - Summary of equity-settled 2021 Stock Option Plan (Details)", "shortName": "RS - Summary of equity-settled 2021 Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-530", "name": "mor:NumberOfGrantedSubscriptionRights", "unitRef": "rights", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-530", "name": "mor:NumberOfGrantedSubscriptionRights", "unitRef": "rights", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R118": { "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "longName": "9954575 - Disclosure - RS - Summary of Development of Stock Option Plans and Fair Value (Details)", "shortName": "RS - Summary of Development of Stock Option Plans and Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-536", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-536", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfStockOptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R119": { "role": "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "longName": "9954576 - Disclosure - RS - Fair Value Stock Options - Additional Information (Details)", "shortName": "RS - Fair Value Stock Options - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": null, "uniqueAnchor": null }, "R120": { "role": "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "longName": "9954577 - Disclosure - RS - Summary of Fair Value of equity-settled Stock Option Plans (Details)", "shortName": "RS - Summary of Fair Value of equity-settled Stock Option Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-513", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-513", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R121": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "longName": "9954578 - Disclosure - RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR AG (Details)", "shortName": "RS - Summary of equity-settled 2019 Long-term Incentive Plan MOR AG (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-564", "name": "mor:NumberOfSharesIssuedToRelatedPartiesDuringPeriodAdditions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-563", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R122": { "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "longName": "9954579 - Disclosure - RS - Summary of Development of Long-term Incentive Plans and FV (Details)", "shortName": "RS - Summary of Development of Long-term Incentive Plans and FV (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-570", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-570", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R123": { "role": "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "longName": "9954580 - Disclosure - RS - Development of Long-Term Incentive Plans and FV - Additional Information (Details)", "shortName": "RS - Development of Long-Term Incentive Plans and FV - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": null, "uniqueAnchor": null }, "R124": { "role": "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "longName": "9954581 - Disclosure - RS - Summary of Fair Value of equity-settled Long-term Incentive Plan (Details)", "shortName": "RS - Summary of Fair Value of equity-settled Long-term Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "c-571", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-571", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R125": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "longName": "9954582 - Disclosure - RS - Summary of equity-settled 2021 Restricted Stock Unit Plans (Details)", "shortName": "RS - Summary of equity-settled 2021 Restricted Stock Unit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-580", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R126": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "longName": "9954583 - Disclosure - RS - Summary of equity-settled 2022 Restricted Stock Unit Plan (Details)", "shortName": "RS - Summary of equity-settled 2022 Restricted Stock Unit Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-591", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R127": { "role": "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails", "longName": "9954584 - Disclosure - RS - Summary of equity-settled 2023 Restricted Stock Unit Plan (Details)", "shortName": "RS - Summary of equity-settled 2023 Restricted Stock Unit Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-605", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R128": { "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "longName": "9954585 - Disclosure - RS - Summary of Development of equity-settled Restricted Stock Unit Plans (Details)", "shortName": "RS - Summary of Development of equity-settled Restricted Stock Unit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "c-615", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-615", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R129": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "longName": "9954586 - Disclosure - RS - Summary of cash-settled 2020 Restricted Stock Unit Plan (Details)", "shortName": "RS - Summary of cash-settled 2020 Restricted Stock Unit Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-623", "name": "mor:TargetAchievement", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R130": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "longName": "9954587 - Disclosure - RS - Summary of cash-settled 2020 Performance Share Unit Program (Details)", "shortName": "RS - Summary of cash-settled 2020 Performance Share Unit Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "c-631", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-631", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R131": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "longName": "9954588 - Disclosure - RS -Summary of cash-settled 2021 Performance Share Unit Program (Details)", "shortName": "RS -Summary of cash-settled 2021 Performance Share Unit Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "c-639", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-639", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R132": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "longName": "9954589 - Disclosure - RS - Summary of cash-settled 2022 Performance Share Unit Program (Details)", "shortName": "RS - Summary of cash-settled 2022 Performance Share Unit Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "c-3", "name": "mor:PercentageOfBeneficiariesLeavingCompany", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-645", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R133": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "longName": "9954590 - Disclosure - RS - Summary of cash-settled 2023 Performance Share Unit Program (Details)", "shortName": "RS - Summary of cash-settled 2023 Performance Share Unit Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "c-3", "name": "mor:PercentageOfBeneficiariesLeavingCompany", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-659", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R134": { "role": "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "longName": "9954591 - Disclosure - RS - Summary of cash-settled Long-term Incentive Cash Plan (Details)", "shortName": "RS - Summary of cash-settled Long-term Incentive Cash Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "c-672", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-672", "name": "mor:PerformanceCriteriaPercentageShareUnitPlan", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R135": { "role": "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "longName": "9954592 - Disclosure - RS - Summary of Development of cash-settled Performance Share Unit Programs (Details)", "shortName": "RS - Summary of Development of cash-settled Performance Share Unit Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "c-676", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-676", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R136": { "role": "http://www.morphosys.com/role/RSDevelopmentofCashSettledProgramsandFVAdditionalInformationDetails", "longName": "9954593 - Disclosure - RS - Development of Cash-Settled Programs and FV - Additional Information (Details)", "shortName": "RS - Development of Cash-Settled Programs and FV - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": null, "uniqueAnchor": null }, "R137": { "role": "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "longName": "9954594 - Disclosure - RS - Summary of Fair Value of cash-settled Performance Share Unit Programs (Details)", "shortName": "RS - Summary of Fair Value of cash-settled Performance Share Unit Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "c-634", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-634", "name": "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019", "unitRef": "eurPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R138": { "role": "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "longName": "9954595 - Disclosure - RS - Related Parties - Additional Information (Details)", "shortName": "RS - Related Parties - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-715", "name": "ifrs-full:Revenue", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R139": { "role": "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "longName": "9954596 - Disclosure - RS - Summary of Related Parties (Details)", "shortName": "RS - Summary of Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "c-729", "name": "mor:NumberOfSharesIssuedToRelatedParties", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-729", "name": "mor:NumberOfSharesIssuedToRelatedParties", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R140": { "role": "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "longName": "9954597 - Disclosure - RS - Summary of Stock Options of Related Parties (Details)", "shortName": "RS - Summary of Stock Options of Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "c-729", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-564", "name": "mor:ShareBasedCompensationByShareBasedPaymentArrangementAdjustmentDueToPerformanceCriteria", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R141": { "role": "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "longName": "9954598 - Disclosure - RS - Summary of Performance Shares of Related Parties (Details)", "shortName": "RS - Summary of Performance Shares of Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "c-764", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-764", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R142": { "role": "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails", "longName": "9954599 - Disclosure - RS - Summary of Remuneration of Key Management Personnel (Details)", "shortName": "RS - Summary of Remuneration of Key Management Personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R143": { "role": "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "longName": "9954600 - Disclosure - RS - Summary of Remuneration of Supervisory Board (Details)", "shortName": "RS - Summary of Remuneration of Supervisory Board (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "c-732", "name": "mor:RemunerationOfSupervisoryBoard", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-732", "name": "mor:RemunerationOfSupervisoryBoard", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R144": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "longName": "9954601 - Disclosure - Additional Notes - Summary of Obligations arising from Leases (Details)", "shortName": "Additional Notes - Summary of Obligations arising from Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "c-3", "name": "mor:FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R145": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails", "longName": "9954602 - Disclosure - Additional Notes - Summary of Contingent Liabilities - Narrative (Details)", "shortName": "Additional Notes - Summary of Contingent Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "c-822", "name": "mor:MilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-824", "name": "mor:DeferredIncomeFromObligationsToRoyaltyPharma", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R146": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "longName": "9954603 - Disclosure - Additional Notes - Summary of Fair Value Level of Financial Assets and Liabilities (Details)", "shortName": "Additional Notes - Summary of Fair Value Level of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:OtherFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "mor:SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R147": { "role": "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails", "longName": "9954604 - Disclosure - Additional Notes - Carrying Amount of Financial Instruments (Details)", "shortName": "Additional Notes - Carrying Amount of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R148": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "longName": "9954605 - Disclosure - Additional Notes - Summary of Changes In Fair Value Measurement Financial Assets (Details)", "shortName": "Additional Notes - Summary of Changes In Fair Value Measurement Financial Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-852", "name": "ifrs-full:FinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "mor:SummaryOfChangesInFairValueMeasurementFinancialAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R149": { "role": "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "longName": "9954606 - Disclosure - Additional Notes - Equity Investments Narrative (Details)", "shortName": "Additional Notes - Equity Investments Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R150": { "role": "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "longName": "9954607 - Disclosure - Additional Notes - Net Gains or Losses from Financial Instruments (Details)", "shortName": "Additional Notes - Net Gains or Losses from Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "150", "firstAnchor": { "contextRef": "c-1", "name": "mor:GainLossOnFinancialInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:GainLossOnFinancialInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R151": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails", "longName": "9954608 - Disclosure - Additional Notes - Summary of Interest Income and Expense of Financial Instruments (Details)", "shortName": "Additional Notes - Summary of Interest Income and Expense of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "151", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R152": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "longName": "9954609 - Disclosure - Additional Notes - Summary of Credit risk - Additional Information (Details)", "shortName": "Additional Notes - Summary of Credit risk - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "152", "firstAnchor": { "contextRef": "c-3", "name": "mor:MaximumExposureToCreditRiskOnDebtInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:MaximumExposureToCreditRiskOnDebtInstruments", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R153": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "longName": "9954610 - Disclosure - Additional Notes - Summary of Changes in Impairment Losses for Credit Risk (Details)", "shortName": "Additional Notes - Summary of Changes in Impairment Losses for Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "153", "firstAnchor": { "contextRef": "c-884", "name": "mor:ImpairmentLossOnFinancialAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-872", "name": "mor:ImpairmentLossOnFinancialAsset", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R154": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "longName": "9954611 - Disclosure - Additional Notes - Summary of Gross Carrying Amount of Financial Assets by Credit Risk (Details)", "shortName": "Additional Notes - Summary of Gross Carrying Amount of Financial Assets by Credit Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "154", "firstAnchor": { "contextRef": "c-897", "name": "mor:GrossCarryingAmountOfFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-897", "name": "mor:GrossCarryingAmountOfFinancialAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R155": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "longName": "9954612 - Disclosure - Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities (Details)", "shortName": "Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "155", "firstAnchor": { "contextRef": "c-3", "name": "mor:TradeAccountsPayable", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-905", "name": "mor:TradeAccountsPayable", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R156": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesAdditionalInformationDetails", "longName": "9954613 - Disclosure - Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities - Additional Information (Details)", "shortName": "Additional Notes - Summary of Contractual Cash Flows of Financial Liabilities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "156", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R157": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "longName": "9954614 - Disclosure - Additional Notes - Summary of Exposure to Foreign Currency Risk (Details)", "shortName": "Additional Notes - Summary of Exposure to Foreign Currency Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "157", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-909", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfForeignCurrencyRiskTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R158": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "longName": "9954615 - Disclosure - Additional Notes - Summary of Sensitivity Analysis of Foreign Exchange Rate (Details)", "shortName": "Additional Notes - Summary of Sensitivity Analysis of Foreign Exchange Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "158", "firstAnchor": { "contextRef": "c-913", "name": "mor:ForeignExchangeSensitivityAnalysis", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-913", "name": "mor:ForeignExchangeSensitivityAnalysis", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R159": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails", "longName": "9954616 - Disclosure - Additional Notes - Summary of Sensitivity Analysis of Variable Interest Rate (Details)", "shortName": "Additional Notes - Summary of Sensitivity Analysis of Variable Interest Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "159", "firstAnchor": { "contextRef": "c-919", "name": "mor:ForeignExchangeSensitivityAnalysis", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-919", "name": "mor:ForeignExchangeSensitivityAnalysis", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R160": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementAdditionalInformationDetails", "longName": "9954617 - Disclosure - Additional Notes - Summary of Capital Management - Additional Information (Details)", "shortName": "Additional Notes - Summary of Capital Management - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "160", "firstAnchor": { "contextRef": "c-3", "name": "mor:EquityCapitalPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCapitalManagementTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "mor:LiabilitiesToBanks", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R161": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "longName": "9954618 - Disclosure - Additional Notes - Summary of Capital Management (Details)", "shortName": "Additional Notes - Summary of Capital Management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "161", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Equity", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:LiabilitiesCapitalPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "mor:SummaryOfCapitalManagementTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R162": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "longName": "9954619 - Disclosure - Additional Notes - Summary of Net Liabilities and Other Changes which are presented in Operating Activities (Details)", "shortName": "Additional Notes - Summary of Net Liabilities and Other Changes which are presented in Operating Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "162", "firstAnchor": { "contextRef": "c-935", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-925", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } }, "R163": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "longName": "9954620 - Disclosure - Additional Notes - Summary of Geographical Disclosures (Details)", "shortName": "Additional Notes - Summary of Geographical Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "163", "firstAnchor": { "contextRef": "c-950", "name": "mor:NoncurrentAssetsExcludingDeferredTaxAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-950", "name": "mor:NoncurrentAssetsExcludingDeferredTaxAssets", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R164": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "longName": "9954621 - Disclosure - Additional Notes - Summary of Agreements Related to Proprietary Clinical Development (Details)", "shortName": "Additional Notes - Summary of Agreements Related to Proprietary Clinical Development (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "164", "firstAnchor": { "contextRef": "c-954", "name": "mor:AdditionalPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-954", "name": "mor:AdditionalPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R165": { "role": "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "longName": "9954622 - Disclosure - Additional Notes - Summary of Agreements Related to Clinical Development trough Partners (Details)", "shortName": "Additional Notes - Summary of Agreements Related to Clinical Development trough Partners (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "165", "firstAnchor": { "contextRef": "c-1", "name": "mor:PaymentsFromHIBio", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mor:PaymentsFromHIBio", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true, "unique": true } }, "R166": { "role": "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "longName": "9954623 - Disclosure - Additional Notes - Subsequent Events, Narrative (Details)", "shortName": "Additional Notes - Subsequent Events, Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "166", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RepaymentsOfBondsNotesAndDebentures", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-965", "name": "ifrs-full:RepaymentsOfBondsNotesAndDebentures", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mor-20231231.htm", "unique": true } } }, "tag": { "mor_A2017StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2017StockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2017 Stock Option Plan", "label": "2017 Stock Option Plan [Member]", "documentation": "Two thousand seventeen stock option plan." } } }, "auth_ref": [] }, "mor_A2018StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2018StockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2018 Stock Option Plan", "label": "2018 Stock Option Plan [Member]", "documentation": "Two thousand eighteen stock option plan." } } }, "auth_ref": [] }, "mor_A2019AprilStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2019AprilStockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2019 Stock Option Plan", "label": "2019 April Stock Option Plan [Member]", "documentation": "Two Thousand Nineteen Stock Option Plan." } } }, "auth_ref": [] }, "mor_A2019LongTermIncentivePlanMORAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2019LongTermIncentivePlanMORAGMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2019 Long-Term Incentive Program", "label": "2019 Long-term Incentive Plan MOR AG [Member]", "documentation": "2019 Long-term Incentive Plan MOR AG" } } }, "auth_ref": [] }, "mor_A2019OctoberStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2019OctoberStockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 2019 Stock Option Plan", "label": "2019 October Stock Option Plan [Member]", "documentation": "October Two Thousand Nineteen Stock Option Plan." } } }, "auth_ref": [] }, "mor_A2019StockOptionPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2019StockOptionPlansMember", "presentation": [ "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 stock option plans", "label": "2019 Stock Option Plans [Member]", "documentation": "2019 Stock Option Plans" } } }, "auth_ref": [] }, "mor_A2020AprilPerformanceShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2020AprilPerformanceShareUnitMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2020 Performance Share Unit Program", "label": "2020 April Performance Share Unit [Member]", "documentation": "2020 April Performance Share Unit" } } }, "auth_ref": [] }, "mor_A2020AprilRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2020AprilRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US Inc.\u00a0\u2013\u00a0April\u00a02020 Restricted Stock Unit Plan", "label": "2020 April Restricted Stock Unit Plan [Member]", "documentation": "2020 April Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2020JunePerformanceShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2020JunePerformanceShareUnitMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2020 Performance Share Unit Program", "label": "2020 June Performance Share Unit [Member]", "documentation": "2020 June Performance Share Unit" } } }, "auth_ref": [] }, "mor_A2020OctoberRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2020OctoberRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US Inc. \u2013 October 2020 Restricted Stock Unit Plan", "label": "2020 October Restricted Stock Unit Plan [Member]", "documentation": "2020 October Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2020StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2020StockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2020 Stock Option Plan", "label": "2020 stock Option Plan [Member]", "documentation": "2020 stock Option Plan" } } }, "auth_ref": [] }, "mor_A2021AprilPerformanceShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2021AprilPerformanceShareUnitMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2021 Performance Share Unit Program", "label": "2021 April Performance Share Unit [Member]", "documentation": "2021 April Performance Share Unit" } } }, "auth_ref": [] }, "mor_A2021AprilRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2021AprilRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US Inc.\u00a0\u2013\u00a0April\u00a02021 Restricted Stock Unit Plan", "label": "2021 April Restricted Stock Unit Plan [Member]", "documentation": "2021 April Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2021OctoberPerformanceShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2021OctoberPerformanceShareUnitMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 2021 Performance Share Unit Program", "label": "2021 October Performance Share Unit [Member]", "documentation": "2021 October Performance Share Unit" } } }, "auth_ref": [] }, "mor_A2021OctoberRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2021OctoberRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US Inc. \u2013 October 2021 Restricted Stock Unit Plan", "label": "2021 October Restricted Stock Unit Plan [Member]", "documentation": "2021 October Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2021StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2021StockOptionPlanMember", "presentation": [ "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 2021 Stock Option Plan", "label": "2021 Stock Option Plan [Member]", "documentation": "2021 Stock Option Plan" } } }, "auth_ref": [] }, "mor_A2022JunePerformanceShareUnitProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2022JunePerformanceShareUnitProgramMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "June 2022 Performance Share Unit Program", "label": "2022 June Performance Share Unit Program [Member]", "documentation": "2022 June Performance Share Unit Program" } } }, "auth_ref": [] }, "mor_A2022JuneRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2022JuneRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US \u2013 June 2022 Restricted Stock Unit Plan", "label": "2022 June Restricted Stock Unit Plan [Member]", "documentation": "2022 June Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2022OctoberPerformanceShareUnitProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2022OctoberPerformanceShareUnitProgramMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 2022 Performance Share Unit Program", "label": "2022 October Performance Share Unit Program [Member]", "documentation": "2022 October Performance Share Unit Program" } } }, "auth_ref": [] }, "mor_A2022OctoberRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2022OctoberRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US - October 2022 Restricted Stock Unit Plan", "label": "2022 October Restricted Stock Unit Plan [Member]", "documentation": "2022 October Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2023AprilPerformanceShareUnitProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2023AprilPerformanceShareUnitProgramMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 April Performance Share Unit Program", "label": "2023 April Performance Share Unit Program [Member]", "documentation": "2023 April Performance Share Unit Program" } } }, "auth_ref": [] }, "mor_A2023AprilRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2023AprilRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US \u2013 April 2023 Restricted Stock Unit Plan", "label": "2023 April Restricted Stock Unit Plan [Member]", "documentation": "2023 April Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2023OctoberPerformanceSharesUnitProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2023OctoberPerformanceSharesUnitProgramMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 October Performance Shares Unit Program", "label": "2023 October Performance Shares Unit Program [Member]", "documentation": "2023 October Performance Shares Unit Program" } } }, "auth_ref": [] }, "mor_A2023OctoberRestrictedStockUnitPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2023OctoberRestrictedStockUnitPlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MorphoSys US Inc. \u2013 October 2023 Restricted Stock Unit Plan", "label": "2023 October Restricted Stock Unit Plan [Member]", "documentation": "2023 October Restricted Stock Unit Plan" } } }, "auth_ref": [] }, "mor_A2023PerformanceShareUnitProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A2023PerformanceShareUnitProgramMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Performance Share Unit Program", "label": "2023 Performance Share Unit Program [Member]", "documentation": "2023 Performance Share Unit Program" } } }, "auth_ref": [] }, "mor_A325MillionEuroUnsecuredConvertibleBondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "A325MillionEuroUnsecuredConvertibleBondMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "325 million euro, unsecured convertible bond", "label": "325 million Euro, Unsecured Convertible Bond [Member]", "documentation": "325 million Euro, Unsecured Convertible Bond" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Earnings Before Income Taxes", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r49", "r50" ] }, "mor_AccountsPayableAndAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccountsPayableAndAccrualsCurrent", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": "mor_ForeignCurrencyRiskExposureNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accruals", "negatedTerseLabel": "Accounts Payable and Accruals", "label": "Accounts payable and accruals current", "documentation": "Accounts payable and accruals current." } } }, "auth_ref": [] }, "mor_AccountsPayableAndAccruedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccountsPayableAndAccruedExpensesCurrent", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accounts payable and accrued expenses current", "documentation": "Accounts payable and accrued expenses current." } } }, "auth_ref": [] }, "mor_AccountsReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccountsReceivableLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Line Items]", "label": "Accounts Receivable [Line Items]", "documentation": "Accounts Receivable [Line Items]" } } }, "auth_ref": [] }, "mor_AccountsReceivableNonInterestBearingPaymentTermsPeriod": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccountsReceivableNonInterestBearingPaymentTermsPeriod", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-interest bearing payment terms", "label": "Accounts Receivable Non Interest Bearing Payment Terms Period", "documentation": "Accounts receivables non interest bearing maturity term." } } }, "auth_ref": [] }, "mor_AccountsReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccountsReceivableTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Table]", "label": "Accounts Receivable [Table]", "documentation": "Accounts Receivable [Table]" } } }, "auth_ref": [] }, "mor_AccruedExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedExpensesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses [Line Items]", "label": "Accrued Expenses [Line Items]", "documentation": "Accrued Expenses [Line Items]" } } }, "auth_ref": [] }, "mor_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedExpensesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Expenses [member]", "documentation": "This member stands for accrued expenses." } } }, "auth_ref": [] }, "mor_AccruedExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedExpensesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses [Table]", "label": "Accrued Expenses [Table]", "documentation": "Accrued Expenses [Table]" } } }, "auth_ref": [] }, "mor_AccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals", "label": "Accrued Liabilities", "documentation": "Accrued liabilities." } } }, "auth_ref": [] }, "mor_AccruedLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Accrued Liability Current", "documentation": "Accrued liabiity." } } }, "auth_ref": [] }, "mor_AccruedOutstandingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedOutstandingExpense", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for Outstanding Invoices", "label": "Accrued Outstanding Expense", "documentation": "Accrued outstanding expense." } } }, "auth_ref": [] }, "mor_AccruedPersonnelExpensesForPaymentsToEmployeesAndManagement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedPersonnelExpensesForPaymentsToEmployeesAndManagement", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Personnel Expenses for Payments to Employees and Management", "label": "Accrued personnel expenses for payments to employees and management", "documentation": "Accrued personnel expenses for payments to employees and management." } } }, "auth_ref": [] }, "mor_AccruedRevenueDeductionsFromProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccruedRevenueDeductionsFromProductSales", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for Revenue Deductions from Product Sales", "label": "Accrued Revenue Deductions from Product Sales", "documentation": "Accrued revenue deductions from product sales." } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation, amortisation and impairment", "label": "Accumulated depreciation, amortisation and impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r55", "r64", "r103", "r113", "r116" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Accumulated impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r218", "r233", "r330", "r365", "r371", "r375", "r376" ] }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Reserve", "label": "Accumulated other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r352" ] }, "mor_AccumulatedPeriodOfAbsenceShareBasePaymentCriteria": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AccumulatedPeriodOfAbsenceShareBasePaymentCriteria", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated period of absence share base payment criteria", "label": "Accumulated Period of Absence Share Base Payment Criteria", "documentation": "Accumulated Period of Absence Share Base Payment Criteria" } } }, "auth_ref": [] }, "ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination", "label": "Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination" } }, "en": { "role": { "documentation": "The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r214" ] }, "mor_AcquisitionsNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AcquisitionsNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions, Net of Cash Acquired", "label": "Acquisitions, Net of Cash Acquired", "documentation": "Acquisitions, Net of Cash Acquired" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r366" ] }, "mor_AdditionForLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionForLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions lease liabilities", "label": "Addition For Lease Liabilities", "documentation": "Addition for lease liabilities." } } }, "auth_ref": [] }, "mor_AdditionalInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalInformationLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Information [Line Items]", "label": "Additional Information [Line Items]", "documentation": "Additional Information [Line Items]" } } }, "auth_ref": [] }, "mor_AdditionalInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalInformationTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Information [Table]", "label": "Additional Information [Table]", "documentation": "Additional Information [Table]" } } }, "auth_ref": [] }, "ifrs-full_AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Addition", "label": "Additional liabilities, contingent liabilities recognised in business combination" } }, "en": { "role": { "documentation": "The amount of additional contingent liabilities recognised in business combinations. [Refer: Contingent liabilities recognised in business combination; Business combinations [member]; Contingent liabilities [member]]" } } }, "auth_ref": [ "r216" ] }, "mor_AdditionalNotesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalNotesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Additional Notes [Abstract]", "label": "Additional Notes [Abstract]", "documentation": "Additional Notes" } } }, "auth_ref": [] }, "mor_AdditionalPaidInCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalPaidInCapitalLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Line Items]", "label": "Additional Paid-In Capital [Line Items]", "documentation": "Additional Paid-In Capital [Line Items]" } } }, "auth_ref": [] }, "mor_AdditionalPaidInCapitalTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalPaidInCapitalTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Table]", "label": "Additional Paid-In Capital [Table]", "documentation": "Additional Paid-In Capital [Table]" } } }, "auth_ref": [] }, "ifrs-full_AdditionalPaidinCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalPaidinCapital", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional Paid-in Capital", "terseLabel": "Additional paid-in capital", "label": "Additional paid-in capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r357" ] }, "ifrs-full_AdditionalPaidinCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalPaidinCapitalMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional paid-in capital [member]" } }, "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r352" ] }, "mor_AdditionalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionalPayments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional payments", "label": "Additional Payments", "documentation": "Additional Payments" } } }, "auth_ref": [] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additional provisions, other provisions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r96" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r104" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r56" ] }, "mor_AdditionsPropertyPlantAndEquipmentAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionsPropertyPlantAndEquipmentAndIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital expenditure", "label": "Additions property plant and equipment and intangible assets", "documentation": "Additions property plant and equipment and intangible assets." } } }, "auth_ref": [] }, "mor_AdditionsToFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdditionsToFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions To Financial Assets", "documentation": "Additions To Financial Assets" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r181" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "mor_AdivoGmbHLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdivoGmbHLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adivo GmbH [Line Items]", "label": "Adivo GmbH [Line Items]", "documentation": "Adivo GmbH [Line Items]" } } }, "auth_ref": [] }, "mor_AdivoGmbHTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdivoGmbHTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adivo GmbH [Table]", "label": "Adivo GmbH [Table]", "documentation": "Adivo GmbH [Table]" } } }, "auth_ref": [] }, "mor_AdivoGmbhMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdivoGmbhMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adivo GmbH [Member]", "label": "Adivo GmbH [Member]" } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing earnings per share, diluted (in shares)", "verboseLabel": "Weighted average ordinary shares and potential ordinary shares used in calculating diluted earnings per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r88" ] }, "mor_AdjustmentInImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdjustmentInImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "(Income) from Reversals of Impairments / Impairments on Financial Assets", "label": "Adjustment In Impairment Loss Reversal Of Impairment Loss Recognised On Financial Assets", "documentation": "Adjustment in impairment loss reversal of impairment loss recognised on financial assets." } } }, "auth_ref": [] }, "mor_AdjustmentInNetGainLossOnSalesOfFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdjustmentInNetGainLossOnSalesOfFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net (Gain) / Loss of Other Financial Assets", "label": "Adjustment in net (gain) / loss on sales of financial assets at fair value through profit or loss", "documentation": "Adjustment in net (gain) / loss on sales of financial assets at fair value through profit or loss." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax expense (income) and adjustments for current tax of prior periods", "label": "Adjustments for current tax of prior periods" } }, "en": { "role": { "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods." } } }, "auth_ref": [ "r292" ] }, "mor_AdjustmentsForDecreaseIncreaseInAccountsPayableAndAccrualsTaxProvisionsAndOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInAccountsPayableAndAccrualsTaxProvisionsAndOtherProvisions", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accruals, Lease Liabilities, Tax Liabilities and Provisions", "label": "Adjustments For Decrease Increase In Accounts Payable And Accruals Tax Provisions And Other Provisions", "documentation": "Adjustments for decrease increase in accounts payable and accruals tax provisions and other provisions." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeOtherThanContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeOtherThanContractAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses for payments to key management personnel", "label": "Adjustments for decrease (increase) in accrued income other than contract assets" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in accrued income other than contract assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Accrued income other than contract assets; Profit (loss)]" } } }, "auth_ref": [ "r379" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInDerivativeFinancialAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net (Gain) / Loss on Derivative Financial Instruments", "label": "Adjustments for decrease (increase) in derivative financial assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in derivative financial assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial assets; Profit (loss)]" } } }, "auth_ref": [ "r382" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Receivables, Other Receivables, Inventories and Prepaid Expenses and Other Assets", "label": "Adjustments for decrease (increase) in other operating receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r379" ] }, "mor_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableAndContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableAndContractAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Adjustments for decrease (increase) in trade accounts receivable and contract assets", "documentation": "Adjustments for decrease (increase) in trade accounts receivable and contract assets." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization of Tangible and Intangible Assets and of Right-of-Use Assets", "label": "Adjustments for depreciation and amortisation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r380" ] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expenses from Carrying Amount Adjustments of Financial Liabilities at Amortized cost", "label": "Adjustments for finance costs" } }, "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } } }, "auth_ref": [ "r381" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income from Carrying Amount Adjustments of Financial Liabilities at Amortized cost", "label": "Adjustments for finance income" } }, "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } } }, "auth_ref": [ "r382" ] }, "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in Fair Value Anti-Dilution Asset", "label": "Adjustments for gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]" } } }, "auth_ref": [ "r382" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments of Assets", "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss" } }, "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]" } } }, "auth_ref": [ "r380" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment", "terseLabel": "Impairment", "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories" } }, "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]" } } }, "auth_ref": [ "r382" ] }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment on other receivables", "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) on trade and other receivables recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]" } } }, "auth_ref": [ "r382" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax (Benefit) / Expenses", "label": "Adjustments for income tax expense" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liability", "label": "Adjustments for increase (decrease) in deferred income including contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r379" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to Reconcile Consolidated Net Profit / (Loss) to Net Cash Provided by / (Used in) Operating Activities:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment", "label": "Adjustments for share-based payments" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r380" ] }, "ifrs-full_AggregatedMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedMeasurementMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated measurement [member]", "label": "Aggregated measurement [member]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r111", "r115", "r158" ] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregated time bands [member]", "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r26", "r172", "r185", "r186", "r187", "r188", "r190", "r196", "r228", "r297", "r332", "r334" ] }, "mor_AgreementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements [Axis]", "label": "Agreements [Axis]", "documentation": "Agreements" } } }, "auth_ref": [] }, "mor_AgreementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsDomain", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements", "label": "Agreements [Domain]", "documentation": "Agreements [Domain]" } } }, "auth_ref": [] }, "mor_AgreementsRelatedToClinicalDevelopmentThroughPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsRelatedToClinicalDevelopmentThroughPartnersMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements related to clinical development through partners", "label": "Agreements Related to Clinical Development Through Partners [Member]", "documentation": "Agreements Related to Clinical Development Through Partners" } } }, "auth_ref": [] }, "mor_AgreementsRelatedToPropertyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsRelatedToPropertyLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements related to Property [Line Items]", "label": "Agreements related to Property [Line Items]", "documentation": "Agreements related to Property [Line Items]" } } }, "auth_ref": [] }, "mor_AgreementsRelatedToPropertyTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsRelatedToPropertyTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements related to Property [Table]", "label": "Agreements related to Property [Table]", "documentation": "Agreements related to Property [Table]" } } }, "auth_ref": [] }, "mor_AgreementsRelatedToProprietaryClinicalDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AgreementsRelatedToProprietaryClinicalDevelopmentMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreements related to proprietary clinical development", "label": "Agreements Related to Proprietary Clinical Development [Member]", "documentation": "Agreements Related to Proprietary Clinical Development" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All levels of fair value hierarchy [member]", "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r65", "r159" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationRateIntangibleAssetsOtherThanGoodwill": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationRateIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Rates", "label": "Amortisation rate, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amortisation rate used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r102" ] }, "mor_AmortizationChargeForTheYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmortizationChargeForTheYear", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Charge for the Year", "label": "Amortization Charge for the Year", "documentation": "Amortization Charge for the Year" } } }, "auth_ref": [] }, "mor_AmortizationExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmortizationExpensesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Expenses [Line Items]", "label": "Amortization Expenses [Line Items]", "documentation": "Amortization Expenses [Line Items]" } } }, "auth_ref": [] }, "mor_AmortizationExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmortizationExpensesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization Expenses [Table]", "label": "Amortization Expenses [Table]", "documentation": "Amortization Expenses [Table]" } } }, "auth_ref": [] }, "mor_AmortizationFromEffectiveInterestMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmortizationFromEffectiveInterestMethod", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizations from Effective Interest Method", "label": "Amortization from Effective Interest Method", "documentation": "Amortization from Effective Interest Method" } } }, "auth_ref": [] }, "mor_AmortizationOfIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmortizationOfIntangibleAssetsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of Intangible Assets", "label": "Amortization of intangible assets [member]", "documentation": "Amortization of intangible assets." } } }, "auth_ref": [] }, "mor_AmountWrittenOffDuringPeriodAsUncollectible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AmountWrittenOffDuringPeriodAsUncollectible", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts written off during the Year as uncollectible", "label": "Amount Written Off During Period as Uncollectible", "documentation": "Amount written off during period as uncollectible." } } }, "auth_ref": [] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Analysis of income and expense [abstract]", "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "mor_AndrewChengMDPhDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AndrewChengMDPhDMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Andrew Cheng, M.D., Ph.D.", "label": "Andrew Cheng, M.D., Ph.D. [Member]", "documentation": "Andrew Cheng, M.D., Ph.D." } } }, "auth_ref": [] }, "mor_AntiDilutionRightOtherReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AntiDilutionRightOtherReceivable", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-Dilution Asset", "label": "Anti-dilution right (other receivable)", "documentation": "Anti-dilution right (other receivable)" } } }, "auth_ref": [] }, "mor_AntiDilutiveRightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AntiDilutiveRightMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-Dilution Right HI-Bio", "label": "Anti-Dilutive Right [Member]", "documentation": "Anti-Dilutive Right" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Tax Rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r50" ] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asia", "label": "Asia [Member]", "documentation": "Continent of Asia." } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r22", "r158", "r159", "r162", "r252", "r255" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed", "label": "Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed" } }, "en": { "role": { "documentation": "The amount of assets, other than cash or cash equivalents, in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r126" ] }, "ifrs-full_AssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssociatesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associates", "label": "Associates [member]" } }, "en": { "role": { "documentation": "This member stands for the entities over which the investor has significant influence." } } }, "auth_ref": [ "r77", "r82", "r83", "r157" ] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r111", "r115", "r158" ] }, "mor_AuditFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuditFees", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Audit Fees", "label": "Audit fees", "documentation": "Audit fees" } } }, "auth_ref": [] }, "mor_AuditFeesAndOtherAuditRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuditFeesAndOtherAuditRelatedCosts", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for Audit Fees and other related Costs", "label": "Audit fees and other audit-related costs", "documentation": "Audit fees and other audit-related costs." } } }, "auth_ref": [] }, "mor_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Audit Information [Abstract]", "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.morphosys.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r342", "r343", "r344" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.morphosys.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r342", "r343", "r344" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.morphosys.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r342", "r343", "r344" ] }, "mor_AuthorisedCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorisedCapitalAmount", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorised capital amount", "label": "Authorised Capital Amount", "documentation": "Authorised Capital Amount" } } }, "auth_ref": [] }, "mor_AuthorisedCapitalReductionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorisedCapitalReductionAmount", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorised capital reduction amount", "label": "Authorised Capital Reduction Amount", "documentation": "Authorised Capital Reduction Amount" } } }, "auth_ref": [] }, "mor_AuthorizedCapital2023IIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapital2023IIMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Capital 2023 II", "label": "Authorized Capital 2023 II [Member]", "documentation": "Authorized Capital 2023 II" } } }, "auth_ref": [] }, "mor_AuthorizedCapital2023IMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapital2023IMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Capital 2023 I", "label": "Authorized Capital 2023 I [Member]", "documentation": "Authorized Capital 2023 I" } } }, "auth_ref": [] }, "mor_AuthorizedCapitalIIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapitalIIIMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized capital III", "label": "Authorized Capital III [Member]", "documentation": "Authorized Capital III" } } }, "auth_ref": [] }, "mor_AuthorizedCapitalIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapitalIIMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Capital II", "label": "Authorized Capital II [Member]", "documentation": "Authorized Capital II" } } }, "auth_ref": [] }, "mor_AuthorizedCapitalIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapitalIMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized capital I", "label": "Authorized Capital I [Member]", "documentation": "Authorized Capital I" } } }, "auth_ref": [] }, "mor_AuthorizedCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapitalLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Capital [Line Items]", "label": "Authorized Capital [Line Items]", "documentation": "Authorized Capital [Line Items]" } } }, "auth_ref": [] }, "mor_AuthorizedCapitalTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AuthorizedCapitalTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized Capital [Table]", "label": "Authorized Capital [Table]", "documentation": "Authorized Capital [Table]" } } }, "auth_ref": [] }, "mor_AvailableForSaleFinancialAssetsCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AvailableForSaleFinancialAssetsCost", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Available for sale financial assets cost", "documentation": "Available for sale financial assets cost." } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Tax Rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r50" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofAverageNumberOfEmployeesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of employees", "label": "Average number of employees" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r353" ] }, "mor_AverageNumberOfEmployeesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AverageNumberOfEmployeesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Average Number of Employees", "label": "Average Number of Employees [Table Text Block]", "documentation": "Average Number of Employees" } } }, "auth_ref": [] }, "mor_AverageStateTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "AverageStateTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Average state tax rate", "label": "Average State Tax Rate", "documentation": "Average State Tax Rate" } } }, "auth_ref": [] }, "mor_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Balance sheet location axis." } } }, "auth_ref": [] }, "mor_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Balance sheet location domain." } } }, "auth_ref": [] }, "ifrs-full_BankAndSimilarCharges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BankAndSimilarCharges", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Bank Fees", "label": "Bank and similar charges" } }, "en": { "role": { "documentation": "The amount of bank and similar charges recognised by the entity as an expense." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, basic (in eur per share)", "verboseLabel": "Basic (in eur per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r85", "r86" ] }, "mor_BasisOfConsolidationBeginningDate": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BasisOfConsolidationBeginningDate", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Included in Basis of Consolidation since", "label": "Basis of consolidation beginning date", "documentation": "Basis of consolidation beginning date." } } }, "auth_ref": [] }, "mor_BearerOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BearerOrdinarySharesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bearer ordinary shares", "label": "Bearer Ordinary Shares [Member]", "documentation": "Bearer Ordinary Shares" } } }, "auth_ref": [] }, "mor_BetaFactor": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BetaFactor", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beta factor", "label": "Beta factor", "documentation": "Beta factor." } } }, "auth_ref": [] }, "mor_BoardAndCommitteeMeetingAttendanceFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BoardAndCommitteeMeetingAttendanceFeeMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attendance Fees", "label": "Board and committee meeting attendance fee [member]", "documentation": "Board and committee meeting attendance fee." } } }, "auth_ref": [] }, "mor_BondsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BondsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds [Line Items]", "label": "Bonds [Line Items]", "documentation": "Bonds [Line Items]" } } }, "auth_ref": [] }, "mor_BondsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BondsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds [Table]", "label": "Bonds [Table]", "documentation": "Bonds [Table]" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r357" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings, interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r389" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r165", "r190", "r206", "r315", "r316", "r389" ] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r364" ] }, "mor_BusinessCombinationConsiderationTransferredPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "BusinessCombinationConsiderationTransferredPerShare", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price outstanding common shares (in Eur per share)", "label": "Business Combination, Consideration Transferred Per Share", "documentation": "Business Combination, Consideration Transferred Per Share" } } }, "auth_ref": [] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combinations [axis]", "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r215" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r343", "r344" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CH", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Switzerland", "label": "SWITZERLAND" } } }, "auth_ref": [] }, "mor_CPI0209Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CPI0209Member", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CPI-0209", "label": "CPI-0209 [Member]", "documentation": "CPI-0209" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital reserve", "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r357" ] }, "mor_CapitalizedRDProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CapitalizedRDProgram", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized R&D program", "label": "Capitalized R&D Program", "documentation": "Capitalized R&D Program" } } }, "auth_ref": [] }, "mor_CarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CarMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cars", "label": "Car [Member]" } } }, "auth_ref": [] }, "mor_CarryForwardOfTaxLossesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CarryForwardOfTaxLossesAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carry Forward of Tax Losses [axis]", "label": "Carry Forward of Tax Losses [Axis]", "documentation": "Carry Forward of Tax Losses (Axis)." } } }, "auth_ref": [] }, "mor_CarryForwardOfTaxLossesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CarryForwardOfTaxLossesDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carry Forward of Tax Losses [domain]", "label": "Carry Forward of Tax Losses [Domain]", "documentation": "Carry Forward of Tax Losses (Domain)." } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r55", "r60", "r103", "r107", "r112", "r113", "r114", "r115", "r116", "r218", "r233", "r234" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r60", "r107", "r112", "r114", "r115", "r218", "r233", "r234" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank Balances and Cash in Hand", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r384" ] }, "mor_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalent [member]", "documentation": "Cash and cash equivalent." } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": "mor_ForeignCurrencyRiskExposureNet", "weight": 1.0, "order": 4.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "periodStartLabel": "Cash and Cash Equivalents at the Beginning of the Period", "periodEndLabel": "Cash and Cash Equivalents at the End of the Period", "totalLabel": "Cash and Cash Equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r17", "r131", "r150" ] }, "mor_CashAndCashEquivalentsAccumulatedImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashAndCashEquivalentsAccumulatedImpairments", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment", "label": "Cash and cash equivalents accumulated impairments", "documentation": "Cash and cash equivalents accumulated impairments." } } }, "auth_ref": [] }, "mor_CashFlowsFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashFlowsFinancialLiabilitiesLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows Financial Liabilities [Line Items]", "label": "Cash Flows Financial Liabilities [Line Items]", "documentation": "Cash Flows Financial Liabilities [Line Items]" } } }, "auth_ref": [] }, "mor_CashFlowsFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashFlowsFinancialLiabilitiesTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows Financial Liabilities [Table]", "label": "Cash Flows Financial Liabilities [Table]", "documentation": "Cash Flows Financial Liabilities [Table]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Receipts from Sales of Subsidiaries", "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities" } }, "en": { "role": { "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r124" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by / (Used in) Financing Activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r117", "r132" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities:", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by / (Used in) Investing Activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r117", "r132" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities:", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by / (Used in) Operating Activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r117", "r132" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities:", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "mor_CashIncomeFromSalesOfSharesOfInvestmentInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashIncomeFromSalesOfSharesOfInvestmentInAssociates", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 5.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Income from Sales of Shares of Investment in Associates", "terseLabel": "Income from Sale of Shares", "label": "Cash Income From Sales of Shares Of Investment in Associates", "documentation": "Cash Income From Sales of Shares Of Investment in Associates" } } }, "auth_ref": [] }, "mor_CashPaymentsDevelopmentFundingBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashPaymentsDevelopmentFundingBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash payments development funding bond", "label": "Cash Payments Development Funding Bond", "documentation": "Cash Payments Development Funding Bond" } } }, "auth_ref": [] }, "mor_CashPaymentsForCostsInConnectionWithContractsWithRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashPaymentsForCostsInConnectionWithContractsWithRoyaltyPharma", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma", "label": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma", "documentation": "Cash Payments for Costs in Connection with Contracts with Royalty Pharma" } } }, "auth_ref": [] }, "mor_CashReceiptsFromContractsForFuturePaymentsToRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashReceiptsFromContractsForFuturePaymentsToRoyaltyPharma", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Receipts from Contracts with Royalty Pharma", "label": "Cash Receipts from Contracts for Future Payments to Royalty Pharma", "documentation": "Cash Receipts from Contracts for Future Payments to Royalty Pharma" } } }, "auth_ref": [] }, "mor_CashReceiptsFromDevelopmentFundingBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CashReceiptsFromDevelopmentFundingBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Receipts", "label": "Cash Receipts from Development Funding Bond", "documentation": "Cash Receipts from Development Funding Bond" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of related parties [axis]", "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79" ] }, "mor_ChangeInForeignExchangeRateForFutureRoyaltiesAndNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInForeignExchangeRateForFutureRoyaltiesAndNetSalesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Foreign Exchange Rate for future Royalties and Net Sales", "label": "Change in Foreign Exchange Rate for future Royalties and Net Sales [Member]", "documentation": "Change in Foreign Exchange Rate for future Royalties and Net Sales" } } }, "auth_ref": [] }, "mor_ChangeInManufacturingCostsAndCostsRelatedComponentsCostRelatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInManufacturingCostsAndCostsRelatedComponentsCostRelatedMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Manufacturing Costs and other Cost Components (cost related)", "label": "Change In Manufacturing Costs And Costs Related Components Cost Related [Member]" } } }, "auth_ref": [] }, "mor_ChangeInPatientNumbersAndNumberOfDosesAdministeredCostRelatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInPatientNumbersAndNumberOfDosesAdministeredCostRelatedMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Patient Numbers and Number of Doses administered (cost related)", "label": "Change In Patient Numbers And Number Of Doses Administered Cost Related [Member]" } } }, "auth_ref": [] }, "mor_ChangeInPatientNumbersAndNumberOfDosesAdministeredRevenueRelatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInPatientNumbersAndNumberOfDosesAdministeredRevenueRelatedMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Patient Numbers and Number of Doses administered (revenue related)", "label": "Change In Patient Numbers And Number Of Doses Administered Revenue Related [Member]" } } }, "auth_ref": [] }, "mor_ChangeInPriceObtainedInTheMarketRevenueRelatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInPriceObtainedInTheMarketRevenueRelatedMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Price obtained in the Market (revenue related)", "label": "Change In Price Obtained In The Market Revenue Related [Member]" } } }, "auth_ref": [] }, "mor_ChangeInVariableFactorsOnRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangeInVariableFactorsOnRevenuesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in variable Factors on Revenues", "label": "Change in variable factors on Revenues [Member]", "documentation": "Change in variable factors on Revenues" } } }, "auth_ref": [] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment Balance Carryforward", "label": "Increase (decrease) in equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r7" ] }, "mor_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in Operating Assets and Liabilities:", "label": "Changes in Operating Assets and Liabilities [Abstract]", "documentation": "Changes in Operating Assets and Liabilities" } } }, "auth_ref": [] }, "mor_CharlotteLohmannMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CharlotteLohmannMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charlotte Lohmann", "label": "Charlotte Lohmann [Member]", "documentation": "Charlotte Lohmann" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of assets [axis]", "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r92", "r164", "r183" ] }, "ifrs-full_ClassesOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfAssetsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets [member]", "label": "Assets [member]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r90", "r164", "r183" ] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r197", "r238", "r239", "r264", "r265" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r238", "r239", "r264", "r265" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets and goodwill [axis]", "label": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r373" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r108" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of liabilities [axis]", "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r164" ] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of ordinary shares [axis]", "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r85" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r61" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of other provisions [axis]", "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital [member]", "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r35" ] }, "mor_ClinicalAgreementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ClinicalAgreementsLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Agreements [Line Items]", "label": "Clinical Agreements [Line Items]", "documentation": "Clinical Agreements [Line Items]" } } }, "auth_ref": [] }, "mor_ClinicalAgreementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ClinicalAgreementsTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Agreements [Table]", "label": "Clinical Agreements [Table]", "documentation": "Clinical Agreements [Table]" } } }, "auth_ref": [] }, "mor_ClinicalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ClinicalMilestonePayments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical milestone payments", "label": "Clinical milestone payments", "documentation": "Clinical milestone payments" } } }, "auth_ref": [] }, "mor_CommonStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CommonStockLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Line Items]", "label": "Common Stock [Line Items]", "documentation": "Common Stock [Line Items]" } } }, "auth_ref": [] }, "mor_CommonStockNonBearerSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CommonStockNonBearerSharesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-bearer shares", "label": "Common Stock, Non-bearer Shares [Member]", "documentation": "Common Stock, Non-bearer Shares" } } }, "auth_ref": [] }, "mor_CompanyFactor": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CompanyFactor", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company factor", "label": "Company factor", "documentation": "Company factor" } } }, "auth_ref": [] }, "mor_CompensationOfFormerEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CompensationOfFormerEmployees", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation of former employees", "label": "Compensation of former Employees", "documentation": "Compensation of former Employees" } } }, "auth_ref": [] }, "mor_ComponentsOfDepreciationRightOfUseAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ComponentsOfDepreciationRightOfUseAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Depreciation Right Of Use Assets", "label": "Components Of Depreciation Right Of Use Assets [Table Text Block]", "documentation": "Components Of Depreciation Right Of Use Assets[Text Block]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Items that may be reclassified to Profit or Loss", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Items that will not be reclassified to Profit or Loss", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Comprehensive Income", "terseLabel": "Total Comprehensive Income", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r2", "r39", "r138", "r140", "r147", "r314" ] }, "ifrs-full_ComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves:", "label": "Comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Hardware", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r364" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Software", "terseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r301" ] }, "mor_ConditionalCapital2016IIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConditionalCapital2016IIIMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional capital 2016 III", "label": "Conditional Capital 2016 III [Member]", "documentation": "Conditional Capital 2016 III" } } }, "auth_ref": [] }, "mor_ConditionalCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConditionalCapitalLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Capital [Line Items]", "label": "Conditional Capital [Line Items]", "documentation": "Conditional Capital [Line Items]" } } }, "auth_ref": [] }, "mor_ConditionalCapitalTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConditionalCapitalTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional Capital [Table]", "label": "Conditional Capital [Table]", "documentation": "Conditional Capital [Table]" } } }, "auth_ref": [] }, "ifrs-full_ConsiderationPaidReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConsiderationPaidReceived", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Consideration paid (received)", "label": "Consideration paid (received)" } }, "en": { "role": { "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r125" ] }, "mor_ConstellationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConstellationMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Constellation", "label": "Constellation [Member]", "documentation": "Constellation" } } }, "auth_ref": [] }, "mor_ConstellationPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConstellationPharmaceuticalsIncMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Constellation Pharmaceuticals, Inc., Boston, Massachusetts, USA", "label": "Constellation Pharmaceuticals, Inc. [Member]", "documentation": "Constellation Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "mor_ConstellationSecuritiesCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConstellationSecuritiesCorpMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Constellation Securities Corp., Boston, Massachusetts, USA", "label": "Constellation Securities, Corp. [Member]", "documentation": "Constellation Securities, Corp." } } }, "auth_ref": [] }, "mor_ConsumableSuppliesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConsumableSuppliesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consumable Supplies", "label": "Consumable Supplies [member]", "documentation": "Consumable supplies." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContingentLiabilitiesIncurredInRelationToInterestsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilitiesIncurredInRelationToInterestsInAssociates", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities incurred in relation to interests in associates", "label": "Contingent liabilities incurred in relation to interests in associates" } }, "en": { "role": { "documentation": "The amount of contingent liabilities incurred relating to the entity's interests in associates. [Refer: Associates [member]; Contingent liabilities [member]]" } } }, "auth_ref": [ "r141" ] }, "ifrs-full_ContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities", "label": "Contingent liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } } }, "auth_ref": [ "r101", "r216" ] }, "mor_ContingentPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ContingentPurchasePrice", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent purchase price", "label": "Contingent Purchase Price", "documentation": "Contingent Purchase Price" } } }, "auth_ref": [] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r166", "r168" ] }, "mor_ContractLiabilitiesPrepaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ContractLiabilitiesPrepaymentsReceived", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments Received in the Financial Year", "label": "Contract Liabilities Prepayments Received", "documentation": "Contract liabilities prepayments received." } } }, "auth_ref": [] }, "ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractualCommitmentsForAcquisitionOfIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual commitments for acquisition of intangible assets", "label": "Contractual commitments for acquisition of intangible assets" } }, "en": { "role": { "documentation": "The amount of contractual commitments for the acquisition of intangible assets." } } }, "auth_ref": [ "r109" ] }, "ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlanandEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual commitments for acquisition of property, plant and equipment", "label": "Contractual commitments for acquisition of property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r62" ] }, "mor_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual obligation", "label": "contractual obligation", "documentation": "contractual obligation." } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Obligation, Fiscal Year Maturity", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [] }, "mor_ConvertibleBondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConvertibleBondMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds", "label": "Convertible Bond [Member]" } } }, "auth_ref": [] }, "mor_ConvertibleBondsDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConvertibleBondsDueToRelatedParties", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds", "label": "Convertible bonds due to related parties", "documentation": "Convertible bonds due to related parties." } } }, "auth_ref": [] }, "mor_ConvertibleBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConvertibleBondsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Bonds", "terseLabel": "Bonds", "label": "Convertible bonds [member]", "documentation": "Convertible bonds." } } }, "auth_ref": [] }, "mor_ConvertibleBondsPortionOfVotingInterestAcquirable": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ConvertibleBondsPortionOfVotingInterestAcquirable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible bonds, portion of voting interest acquirable", "label": "Convertible Bonds, Portion Of Voting Interest Acquirable", "documentation": "Convertible Bonds, Portion Of Voting Interest Acquirable" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r302" ] }, "mor_CorporateTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CorporateTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate tax rate", "label": "Corporate tax rate", "documentation": "Corporate tax rate." } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of Sales", "terseLabel": "Cost of sales", "label": "Cost of sales" } }, "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } } }, "auth_ref": [ "r0", "r45" ] }, "mor_CostOfSalesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CostOfSalesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales [line items]", "label": "Cost of sales [line items]", "documentation": "Cost of sales [line items]" } } }, "auth_ref": [] }, "ifrs-full_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CostOfSalesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of sales [member]" } }, "en": { "role": { "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss." } } }, "auth_ref": [ "r350", "r353" ] }, "mor_CostOfSalesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CostOfSalesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales [table]", "label": "Cost of sales [table]", "documentation": "Cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r276" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "mor_CreditRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CreditRiskLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Risk [Line Items]", "label": "Credit Risk [Line Items]", "documentation": "Credit Risk [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r191", "r192", "r193", "r325" ] }, "mor_CreditRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CreditRiskTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Risk [Table]", "label": "Credit Risk [Table]", "documentation": "Credit Risk [Table]" } } }, "auth_ref": [] }, "ifrs-full_CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CumulativeGainLossOnDisposalOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on disposal recognized in equity", "label": "Cumulative gain (loss) on disposal of investments in equity instruments designated at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The cumulative gain (loss) on disposal of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r224" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r191", "r192", "r193", "r194", "r246" ] }, "mor_CurrentAndFormerEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentAndFormerEmployeesMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current and former employees", "label": "Current and Former Employees [Member]", "documentation": "Current and Former Employees" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r27", "r143", "r314" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liability", "verboseLabel": "thereof short-term", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r166" ] }, "mor_CurrentConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentConvertibleBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Bonds", "label": "Current Convertible Bond", "documentation": "Current Convertible Bond." } } }, "auth_ref": [] }, "ifrs-full_CurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current Financial Asset", "label": "Current financial assets" } }, "en": { "role": { "documentation": "The amount of current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_CurrentFinancialAssetsAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssetsAtAmortisedCost", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets AC", "label": "Current financial assets at amortised cost" } }, "en": { "role": { "documentation": "The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets FVTPL", "label": "Current financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_CurrentFinancialAssetsAvailableforsale": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialAssetsAvailableforsale", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market Value", "label": "Current financial assets available-for-sale" } }, "en": { "role": { "documentation": "The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]" } } }, "auth_ref": [ "r280" ] }, "mor_CurrentFinancialAssetsFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentFinancialAssetsFromCollaboration", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets from Collaborations", "label": "Current Financial Assets from Collaboration", "documentation": "Current Financial Assets from Collaboration." } } }, "auth_ref": [] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current financial liabilities", "totalLabel": "Current Financial Liabilities", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentFinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Liabilities FLAC", "label": "Current financial liabilities at amortised cost" } }, "en": { "role": { "documentation": "The amount of current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r242" ] }, "mor_CurrentFinancialLiabilitiesFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentFinancialLiabilitiesFromCollaboration", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Liabilities from Collaborations", "label": "Current Financial Liabilities from Collaboration", "documentation": "Current Financial Liabilities from Collaboration." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "mor_CurrentIncomeTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentIncomeTaxReceivables", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Receivables", "label": "Current Income Tax Receivables", "documentation": "Current income tax receivables." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Money Market Funds", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r357" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r176" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r28", "r145", "r314" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLoansAndReceivables", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current loans and receivables", "label": "Current loans and receivables" } }, "en": { "role": { "documentation": "The amount of current loans and receivables. [Refer: Loans and receivables]" } } }, "auth_ref": [ "r279" ] }, "mor_CurrentPortionOfFinancialLiabilitiesFromCollaborations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentPortionOfFinancialLiabilitiesFromCollaborations", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Collaborations", "label": "Current Portion Of Financial Liabilities From Collaborations", "documentation": "Current portion of financial liabilities from collaborations." } } }, "auth_ref": [] }, "mor_CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentPortionOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "verboseLabel": "Current portion of financial liabilities from future payments to royalty pharma", "negatedTerseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "label": "Current Portion of Financial Liabilities from Future Payments to Royalty Pharma", "documentation": "Current Portion of Financial Liabilities from Future Payments to Royalty Pharma" } } }, "auth_ref": [] }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPortionOfLongtermBorrowings", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds", "label": "Current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails": { "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 7.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Assets", "totalLabel": "Total", "label": "Current prepayments and other current assets" } }, "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentRawMaterialsAndCurrentProductionSupplies", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials, Supplies and Production Materials", "label": "Current raw materials and current production supplies" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]" } } }, "auth_ref": [ "r367" ] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Current tax benefit / (expense)", "label": "Current tax expense (income)" } }, "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r291" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax expense (income) and adjustments for current tax of prior periods", "label": "Current tax expense (income) and adjustments for current tax of prior periods" } }, "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r362" ] }, "mor_CurrentTaxProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentTaxProvisions", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Liabilities", "label": "Current Tax Provisions", "documentation": "The amount of current tax provisions other than provisions." } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": "mor_ForeignCurrencyRiskExposureNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r284", "r285" ] }, "mor_CurrentYearTaxLossesCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "CurrentYearTaxLossesCarryforwards", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax Losses from Current Year", "label": "Current Year Tax Losses Carryforwards", "documentation": "Current Year Tax Losses Carryforwards." } } }, "auth_ref": [] }, "mor_Customer1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "Customer1Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 1", "label": "Customer 1 [Member]", "documentation": "Customer 1" } } }, "auth_ref": [] }, "mor_Customer2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "Customer2Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 2", "label": "Customer 2 [Member]", "documentation": "Customer 2" } } }, "auth_ref": [] }, "mor_Customer3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "Customer3Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer 3", "label": "Customer 3 [Member]", "documentation": "Customer 3" } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DE", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": [] }, "mor_DFBInitialMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DFBInitialMeasurementMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DFB, initial measurement", "label": "DFB, initial measurement [Member]", "documentation": "DFB, initial measurement" } } }, "auth_ref": [] }, "mor_DebtConversionPrice": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DebtConversionPrice", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt conversion price", "label": "Debt Conversion Price", "documentation": "Debt Conversion Price" } } }, "auth_ref": [] }, "mor_DebtCouponRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DebtCouponRate", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt coupon rate", "label": "Debt Coupon Rate", "documentation": "Debt Coupon Rate" } } }, "auth_ref": [] }, "mor_DecreaseEuro10Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DecreaseEuro10Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease of the Euro by 10%", "label": "Decrease Euro 10% [Member]", "documentation": "Decrease Euro 10%" } } }, "auth_ref": [] }, "ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "negatedTerseLabel": "Changes from Adjustments to Planning Assumptions", "label": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities" } }, "en": { "role": { "documentation": "The amount of decrease in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } } }, "auth_ref": [ "r163" ] }, "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DecreaseThroughDerecognitionFinancialAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Receipts", "label": "Decrease through derecognition, financial assets" } }, "en": { "role": { "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]" } } }, "auth_ref": [ "r326", "r328", "r335" ] }, "mor_DecreaseThroughSaleOfSharesOfInvestmentInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DecreaseThroughSaleOfSharesOfInvestmentInAssociates", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sale of shares of investment in associates", "label": "Decrease Through Sale Of Shares Of Investment In Associates", "documentation": "Decrease Through Sale Of Shares Of Investment In Associates" } } }, "auth_ref": [] }, "mor_DecreaseVariableInterestRate10Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DecreaseVariableInterestRate10Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease of the variable Interest Rate by 0.5%", "label": "Decrease Variable Interest Rate 10% [Member]", "documentation": "Decrease Variable Interest Rate 10%" } } }, "auth_ref": [] }, "mor_DeferredIncomeFromObligationsToRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DeferredIncomeFromObligationsToRoyaltyPharma", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income from obligations to royalty pharma", "label": "Deferred income from Obligations to Royalty Pharma", "documentation": "Deferred income from Obligations to Royalty Pharma" } } }, "auth_ref": [] }, "mor_DeferredTaxAssetLiabilityOtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DeferredTaxAssetLiabilityOtherProvisionsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Deferred Tax Asset Liability Other Provisions [member]", "documentation": "Deferred tax asset liability other provisions." } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r21", "r23", "r51" ] }, "mor_DeferredTaxAssetsOnTemporaryDifferencesNotCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DeferredTaxAssetsOnTemporaryDifferencesNotCapitalized", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets on temporary differences not capitalized", "label": "Deferred Tax assets on temporary differences not capitalized", "documentation": "Deferred Tax assets on temporary differences not capitalized" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred Tax Benefit / (Expenses)", "label": "Deferred tax expense (income)" } }, "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income / (Expense)", "negatedTerseLabel": "Income / (Expense)", "label": "Deferred tax expense (income) recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } } }, "auth_ref": [ "r52" ] }, "mor_DeferredTaxItemsRecognizedAgainstEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DeferredTaxItemsRecognizedAgainstEquity", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax items recognized against equity", "label": "Deferred tax items recognized against equity", "documentation": "Deferred tax items recognized against equity" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liability", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r21", "r23", "r51" ] }, "mor_DeferredTaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DeferredTaxMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Deferred Tax [member]", "documentation": "Deferred Tax [member]" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Direct Recognition in Equity", "label": "Deferred tax relating to items credited (charged) directly to equity" } }, "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r48" ] }, "mor_DenominatorInSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DenominatorInSharesAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator (in Shares)", "label": "Denominator In Shares [Abstract]", "documentation": "Denominator In Shares" } } }, "auth_ref": [] }, "mor_DepreciationAdjustmentOfRightOfUseAssetsDueToChangeOfUsefulLife": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DepreciationAdjustmentOfRightOfUseAssetsDueToChangeOfUsefulLife", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of Right-of-Use Assets (Change of Useful Life)", "label": "Depreciation Adjustment of Right-Of-Use-Assets Due To Change Of Useful Life", "documentation": "Depreciation Adjustment of Right-Of-Use-Assets Due To Change Of Useful Life" } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and Amortization", "negatedLabel": "Amortizations from Effective Interest Method", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r1", "r45", "r151", "r250", "r257", "r281" ] }, "mor_DepreciationAndOtherCostsForInfrastructureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DepreciationAndOtherCostsForInfrastructureMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Other Costs for Infrastructure", "label": "Depreciation and Other Costs for Infrastructure[member]", "documentation": "Depreciation and other costs for infrastructure." } } }, "auth_ref": [] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation expense" } }, "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } } }, "auth_ref": [ "r353" ] }, "mor_DepreciationExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DepreciationExpenseLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Expense [Line Items]", "label": "Depreciation Expense [Line Items]", "documentation": "Depreciation Expense [Line Items]" } } }, "auth_ref": [] }, "mor_DepreciationExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DepreciationExpenseTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Expense [Table]", "label": "Depreciation Expense [Table]", "documentation": "Depreciation Expense [Table]" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Charge for the Year", "label": "Depreciation, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r59", "r63" ] }, "ifrs-full_DepreciationRatePropertyPlantAndEquipment": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRatePropertyPlantAndEquipment", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation Rates", "label": "Depreciation rate, property, plant and equipment" } }, "en": { "role": { "documentation": "The depreciation rate used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r54" ] }, "mor_DepreciationRightOfUseAssetsAfterCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DepreciationRightOfUseAssetsAfterCurrencyTranslation", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation of Right-of-Use Assets", "label": "Depreciation Right-of-use Assets after Currency Translation", "documentation": "Depreciation Right-of-use Assets after Currency Translation" } } }, "auth_ref": [] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationRightofuseAssets", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation of Right-of-Use Assets", "terseLabel": "Depreciation of Right-of-Use Assets", "label": "Depreciation, right-of-use assets" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r177" ] }, "mor_DescriptionOfACCOUNTINGPOLICIESAPPLIEDTOLINEITEMSOFTHEINCOMESTATEMENTExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfACCOUNTINGPOLICIESAPPLIEDTOLINEITEMSOFTHEINCOMESTATEMENTExplanatoryPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies applied to Line Items of the Statement of Profit or Loss", "label": "Description of ACCOUNTING POLICIES APPLIED TO LINE ITEMS OF THE INCOME STATEMENT Explanatory [Policy Text Block]", "documentation": "Description of ACCOUNTING POLICIES APPLIED TO LINE ITEMS OF THE INCOME STATEMENT Explanatory" } } }, "auth_ref": [] }, "mor_DescriptionOfAccountingPoliciesAppliedToTheLineItemsOfTheBalanceSheetPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfAccountingPoliciesAppliedToTheLineItemsOfTheBalanceSheetPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies applied to Line Items of the Balance Sheet", "label": "Description of accounting policies applied to the line items of the balance sheet [Policy Text Block]", "documentation": "The description of accounting policies applied to the assets of the balance sheet." } } }, "auth_ref": [] }, "mor_DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfAccountingPolicyForBASISOFANDCHANGESINACCOUNTINGSTANDARDSPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Application and Changes in Accounting Standards", "label": "Description of accounting policy for BASIS OF AND CHANGES IN ACCOUNTING STANDARDS [Policy Text Block]", "documentation": "Description of accounting policy for BASIS OF AND CHANGES IN ACCOUNTING STANDARDS." } } }, "auth_ref": [] }, "mor_DescriptionOfAccountingPolicyForContractLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfAccountingPolicyForContractLiabilitiesPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities", "label": "Description Of Accounting Policy For Contract Liabilities [Policy Text Block]", "documentation": "Description Of Accounting Policy For Contract Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Taxes", "label": "Description of accounting policy for deferred income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Description of accounting policy for expenses [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for expenses." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Foreign Currency Translation", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Description of accounting policy for goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Non-Financial Assets", "label": "Description of accounting policy for impairment of non-financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Benefit / Expenses, Tax Receivable, Tax Liabilities", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Description of accounting policy for measuring inventories [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r68" ] }, "mor_DescriptionOfAccountingPolicyForPrepaidExpensesAndOtherAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfAccountingPolicyForPrepaidExpensesAndOtherAssetsPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Assets", "label": "Description Of Accounting Policy For Prepaid Expenses And Other Assets [Policy Text Block]", "documentation": "Description Of Accounting Policy For Prepaid Expenses And Other Assets" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals and Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r354" ] }, "mor_DescriptionOfAccountingPolicyForRecognitionOfCostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfAccountingPolicyForRecognitionOfCostOfSalesPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Description Of Accounting Policy For Recognition Of Cost Of Sales [Policy Text Block]", "documentation": "Description Of Accounting Policy For Recognition Of Cost Of Sales" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues and Revenues Recognition", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Description of accounting policy for trade and other payables [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r354" ] }, "mor_DescriptionOfConsolidationPrinciplesExplanatoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DescriptionOfConsolidationPrinciplesExplanatoryPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Principles", "label": "Description of consolidation principles explanatory [Policy Text Block]", "documentation": "Description of consolidation principles explanatory." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (in percentage)", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r208" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free Interest Rate in\u00a0%", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r208" ] }, "mor_DevelopmentFundingBondMeasurementLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DevelopmentFundingBondMeasurementLoss", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance development funding bond, measurement loss", "periodEndLabel": "Ending balance development funding bond, measurement loss", "label": "Development Funding Bond, measurement loss", "documentation": "Development Funding Bond, measurement loss" } } }, "auth_ref": [] }, "mor_DevelopmentFundingBondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DevelopmentFundingBondMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development Funding Bond", "label": "Development Funding Bond [Member]", "documentation": "Development Funding Bond" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, diluted (in eur per share)", "verboseLabel": "Diluted (in eur per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r85", "r86" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of convertible instruments on number of ordinary shares (in shares)", "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r370" ] }, "mor_DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureDetailsOfRemunerationToKeyManagerialPersonnelTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Remuneration of Key Management Personnel", "label": "Disclosure Details Of Remuneration To Key Managerial Personnel [Table Text Block]", "documentation": "Disclosure Details Of Remuneration To Key Managerial Personnel [Text Block]" } } }, "auth_ref": [] }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillLineItems", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Line Items]", "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Line Items]" } } }, "auth_ref": [] }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTable", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table]", "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table]" } } }, "auth_ref": [] }, "mor_DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureDetailsOfUsefulLivesOfIntangibleAssetsIncludingGoodwillTableTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Useful Lives Of Intangible Assets Including Goodwill", "label": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Table Text Block]", "documentation": "Disclosure Details Of Useful Lives Of Intangible Assets Including Goodwill [Text Block]" } } }, "auth_ref": [] }, "mor_DisclosureOfAccountingPoliciesForKeyEstimatesAndAssumptionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfAccountingPoliciesForKeyEstimatesAndAssumptionsPolicyTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Key Estimates and Assumptions", "label": "Disclosure of accounting policies for key estimates and assumptions [Policy Text Block]", "documentation": "Disclosure of accounting policies for key estimates and assumptions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAdditionalInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAdditionalInformationExplanatory", "presentation": [ "http://www.morphosys.com/role/AdditionalNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Notes", "label": "Disclosure of additional information [text block]" } }, "en": { "role": { "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them." } } }, "auth_ref": [ "r9" ] }, "mor_DisclosureOfAnalysisOfIncomeStatementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfAnalysisOfIncomeStatementExplanatory", "presentation": [ "http://www.morphosys.com/role/NotestotheStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Notes to the Statement of Profit or Loss", "label": "Disclosure of analysis of Income Statement [text block]", "documentation": "Disclosure of analysis of Income Statement [text block]" } } }, "auth_ref": [] }, "mor_DisclosureOfAnalysisOfRevenuelineItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfAnalysisOfRevenuelineItemLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Analysis Of Revenue Line Item [Line Items]", "label": "Disclosure Of Analysis Of Revenue Line Item [Line Items]", "documentation": "Disclosure Of Analysis Of Revenue [Line Item]" } } }, "auth_ref": [] }, "mor_DisclosureOfAnalysisOfRevenuetableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfAnalysisOfRevenuetableTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Analysis Of Revenue [Table]", "label": "Disclosure Of Analysis Of Revenue Table [Table]", "documentation": "Disclosure Of Analysis Of Revenue [Table] ." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities in business combination [line items]", "label": "Disclosure of contingent liabilities in business combination [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesInBusinessCombinationTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities in business combination [table]", "label": "Disclosure of contingent liabilities in business combination [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities in business combinations." } } }, "auth_ref": [ "r213", "r216" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [line items]", "label": "Disclosure of contingent liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [table]", "label": "Disclosure of contingent liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } } }, "auth_ref": [ "r100" ] }, "mor_DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDeferredTaxAssetsAndDeferredTaxLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Deferred Tax Liabilities", "label": "Disclosure of deferred tax assets and deferred tax liabilities [Table Text Block]", "documentation": "Disclosure of deferred tax assets and deferred tax liabilities." } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutCostOfSalesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cost of Sales", "label": "Disclosure Of Detailed Information About Cost Of Sales [Table Text Block]", "documentation": "Disclosure of detailed information about cost of sales." } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of General and Administrative Expenses", "label": "Disclosure Of Detailed Information About General And Administrative Expense Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About General And Administrative Expense Explanatory" } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutInLimitedAndUnlimitedCarryForwardOfTaxLossesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutInLimitedAndUnlimitedCarryForwardOfTaxLossesExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Detailed Information about In Limited Unlimited Carry Forward Tax Losses", "label": "Disclosure of Detailed InformationAbout In Limited And Unlimited Carry Forward Of Tax Losses Explanatory [Table Text Block]", "documentation": "Disclosure of Detailed InformationAbout In Limited And Unlimited Carry Forward Of Tax Losses Explanatory." } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutInSignificantInvestmentsInSubsidiariesExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Consolidation Methods", "label": "Disclosure of Detailed Information About In Significant Investments In Subsidiaries Explanatory [Table Text Block]", "documentation": "Disclosure of Detailed Information About In Significant Investments In Subsidiaries Explanatory." } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutOtherIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Income and Expenses, Finance Income and Expenses", "label": "Disclosure of detailed information about other income and expenses [Table Text Block]", "documentation": "Disclosure of detailed information about other income and expenses." } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutPersonnelExpensesExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Personnel Expenses", "label": "Disclosure of Detailed Information about Personnel Expenses Explanatory [Table Text Block]", "documentation": "Disclosure of Detailed Information about Personnel Expenses Explanatory [text block]" } } }, "auth_ref": [] }, "mor_DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpenseExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Research and Development Expenses", "label": "Disclosure Of Detailed Information About Research and Development Expense Explanatory [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Research and Development Expense Explanatory" } } }, "auth_ref": [] }, "mor_DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Estimated Useful Life of Property Plant and Equipment", "label": "Disclosure Of Estimated Useful Lives Of Property Plant And Equipment Explanatory [Table Text Block]", "documentation": "The disclosure of estimated useful lives of property plant and equipment." } } }, "auth_ref": [] }, "mor_DisclosureOfFairValueOfPerformanceSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfFairValueOfPerformanceSharesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of LTI Plans", "label": "Disclosure Of Fair Value of Performance Shares [Table Text Block]", "documentation": "Disclosure of share options assumptions related to savings related schemes explanatory." } } }, "auth_ref": [] }, "mor_DisclosureOfGeneralAndAdministrativeExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfGeneralAndAdministrativeExpenseLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of general and administrative expense [Line items]", "label": "Disclosure of general and administrative expense [Line items]", "documentation": "Line items represents information about general and administrative expense." } } }, "auth_ref": [] }, "mor_DisclosureOfGeneralAndAdministrativeExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfGeneralAndAdministrativeExpenseTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of General and Administrative Expense [table]", "label": "Disclosure of General and Administrative Expense [table]", "documentation": "Schedule disclosing information about general and administrative expense." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.morphosys.com/role/GeneralInformation" ], "lang": { "en-us": { "role": { "terseLabel": "General Information", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r12" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [line items]", "label": "Disclosure of geographical areas [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of geographical areas [table]", "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r261" ] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity - Issued Capital", "label": "Disclosure of issued capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r349" ] }, "mor_DisclosureOfLeasesByLesseeExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfLeasesByLesseeExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Future Minimum Payments for Leases", "label": "Disclosure Of Leases By Lessee Explanatory [Table Text Block]", "documentation": "Disclosure Of Leases By Lessee Explanatory." } } }, "auth_ref": [] }, "mor_DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line Items]", "label": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line Items]", "documentation": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Line items]." } } }, "auth_ref": [] }, "mor_DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfLimitedAndUnlimitedCarryForwardOfTaxLossesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [table]", "label": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Table]", "documentation": "Disclosure of Limited And Unlimited Carry Forward of Tax Losses [Table]." } } }, "auth_ref": [] }, "mor_DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfMajorComponentsOfIncomeTaxTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Income Taxes and Benefits", "label": "Disclosure of Major Components of Income Tax [Table Text Block]", "documentation": "The disclosure of major components of income tax." } } }, "auth_ref": [] }, "mor_DisclosureOfMaterialAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfMaterialAccountingPoliciesLineItems", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of material accounting policies [line items]", "label": "Disclosure of material accounting policies [Line Items]", "documentation": "Disclosure of significant accounting policies [line items]" } } }, "auth_ref": [] }, "mor_DisclosureOfMaterialAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfMaterialAccountingPoliciesTable", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of material accounting policies [table]", "label": "Disclosure of material accounting policies [Table]", "documentation": "Disclosure of significant accounting policies [table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Material Accounting Policies", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r10" ] }, "mor_DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfMaturityAnalysisOfLeaseLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Maturity Analysis Of Lease Liabilities", "label": "Disclosure Of Maturity Analysis Of Lease Liabilities [Table Text Block]", "documentation": "Disclosure Of Maturity Analysis Of Lease Liabilities Explanatory." } } }, "auth_ref": [] }, "mor_DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfNewAndRevisedStandardsAndInterpretationsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of New and Revised Standards and Interpretations", "label": "Disclosure of new and revised standards and interpretations [Table Text Block]", "documentation": "Disclosure of new and revised standards and interpretations." } } }, "auth_ref": [] }, "mor_DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfNewAndRevisedStandardsAndInterpretationsWhichWereNotYetMandatoryForFinancialYearOrWereNotYetAdoptedByEuropeanUnionWereNotAppliedExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of New and Revised Standards and Interpretations not yet Mandatorily Applicable", "label": "Disclosure of new and revised standards and interpretations, which were not yet mandatory for financial year or were not yet adopted by European Union, were not applied explanatory [Table Text Block]", "documentation": "Disclosure of new and revised standards and interpretations, which were not yet mandatory for financial year or were not yet adopted by European Union, were not applied." } } }, "auth_ref": [] }, "mor_DisclosureOfOperatingLeaseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfOperatingLeaseLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating lease [Line Items]", "label": "Disclosure of operating lease [Line Items]", "documentation": "Disclosure of operating lease [Line Items]" } } }, "auth_ref": [] }, "mor_DisclosureOfOperatingLeaseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfOperatingLeaseTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating lease [table]", "label": "Disclosure of operating lease [table]", "documentation": "Disclosure of operating lease [table]." } } }, "auth_ref": [] }, "mor_DisclosureOfPersonnelExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfPersonnelExpenseLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of personnel expense [line items]", "label": "Disclosure of personnel expense [line items]", "documentation": "Line items represents information about personnel expense." } } }, "auth_ref": [] }, "mor_DisclosureOfPersonnelExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfPersonnelExpenseTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of personnel expense [table]", "label": "Disclosure of personnel expense [table]", "documentation": "Schedule disclosing information about personnel expense." } } }, "auth_ref": [] }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetExplanatoryTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Deferred Taxes", "label": "Disclosure Of Reconciliation Of Changes In Deferred Tax Liability Asset Explanatory [Table Text Block]", "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset." } } }, "auth_ref": [] }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [line items]", "label": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [line items]", "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset line items." } } }, "auth_ref": [] }, "mor_DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfReconciliationOfChangesInDeferredTaxLiabilityAssetTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [table]", "label": "Disclosure of Reconciliation of Changes in Deferred Tax Liability Asset [table]", "documentation": "Disclosure of reconciliation of changes in deferred tax liability asset [table]" } } }, "auth_ref": [] }, "mor_DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfReconciliationOfExpectedIncomeTaxExpenseWithActualIncomeTaxExpenseTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reconciliation of Expected Income Tax Expense with Actual Income Tax Expense", "label": "Disclosure of reconciliation of expected income tax expense with actual income tax expense [Table Text Block]", "documentation": "Disclosure of reconciliation of expected income tax expense with actual income tax expense [text block]" } } }, "auth_ref": [] }, "mor_DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfRemunerationSystemForManagementBoardAndEmployeesOfGroupExplanatory", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroup" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration System for the Management Board and Employees of the Group", "label": "Disclosure of remuneration system for management board and employees of group [Text block]", "documentation": "Disclosure of remuneration system for management board and employees of group." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity - Reserves", "label": "Disclosure of reserves within equity [text block]" } }, "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } } }, "auth_ref": [ "r36" ] }, "mor_DisclosureOfSellingExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfSellingExpenseTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Selling Expenses", "label": "Disclosure of selling expense [Table Text Block]", "documentation": "Disclosure of selling expense ." } } }, "auth_ref": [] }, "mor_DisclosureOfSellingExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfSellingExpensesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of selling expenses [line items]", "label": "Disclosure of selling expenses [line items]", "documentation": "Disclosure of selling expenses." } } }, "auth_ref": [] }, "mor_DisclosureOfSellingExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfSellingExpensesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of selling expenses [table]", "label": "Disclosure of selling expenses [table]", "documentation": "Disclosure of selling and expenses." } } }, "auth_ref": [] }, "mor_DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisclosureOfSensitivityAnalysisOfFairValueMeasurementDueToChangesInMulipleUnobervableInputsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Sensitivity Analysis Of Financial Liabilities from Collaborations", "label": "Disclosure Of Sensitivity Analysis Of Fair Value Measurement Due To Changes In Muliple Unobervable Inputs [Table Text Block]", "documentation": "Disclosure Of Sensitivity Analysis Of Fair Value Measurement Due To Changes In Muliple Unobervable Inputs [Table Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of associates [line items]", "label": "Disclosure of associates [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of associates [table]", "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r82", "r83", "r157" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [abstract]", "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "auth_ref": [] }, "mor_DiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DiscountRate", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Discount rate", "documentation": "Discount rate" } } }, "auth_ref": [] }, "mor_DisposalOfLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisposalOfLeases", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Leases", "label": "Disposal of Leases", "documentation": "Disposal of Leases" } } }, "auth_ref": [] }, "mor_DisposalOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisposalOfRightOfUseAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals", "label": "Disposal of Right of use Assets", "documentation": "Disposal of Right of use Assets." } } }, "auth_ref": [] }, "mor_DisposalsForLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DisposalsForLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals, lease liabilities", "label": "Disposals For Lease Liabilities", "documentation": "Disposals For Lease Liabilities." } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposals", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "terseLabel": "Disposals", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r57" ] }, "ifrs-full_DividendsReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DividendsReceived", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Received", "label": "Dividends received" } }, "en": { "role": { "documentation": "The amount of dividends received." } } }, "auth_ref": [ "r142" ] }, "ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends recognized for investments recognized in profit loss", "label": "Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period" } }, "en": { "role": { "documentation": "The amount of dividends related to investments in equity instruments that the entity has designated at fair value through other comprehensive income, held at the end of the reporting period. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]" } } }, "auth_ref": [ "r222" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r343" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r342", "r343", "r344" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r342", "r343", "r344", "r346" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Restatement Recovery Analysis [Flag]", "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r342", "r343", "r344", "r346" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r338" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r343" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r345" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "mor_DrGeorgeGolumbeskiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DrGeorgeGolumbeskiMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "George Golumbeski, Ph.D.", "label": "Dr George Golumbeski [member]", "documentation": "George Golumbeski." } } }, "auth_ref": [] }, "mor_DrMarcCluzelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "DrMarcCluzelMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marc Cluzel, M.D., Ph.D.", "label": "Dr Marc Cluzel [member]", "documentation": "Dr Marc Cluzel." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share (in \u20ac)", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate Differences on Cash", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r120", "r121" ] }, "mor_EffectiveTradeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "EffectiveTradeTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Effective trade tax rate", "label": "Effective trade tax rate", "documentation": "Effective trade tax rate." } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits expense", "label": "Employee benefits expense" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r1", "r45", "r281" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Line Items]", "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses [Table]", "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r340" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r340" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r340" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r340" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r347" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r340" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r340" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r348" ] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for associates [member]", "label": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r82", "r83", "r157" ] }, "ifrs-full_EntitysTotalForBusinessCombinationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForBusinessCombinationsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for business combinations [member]", "label": "Entity's total for business combinations [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r215", "r219" ] }, "ifrs-full_EntitysTotalForInternalCreditGradesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForInternalCreditGradesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for internal credit grades [member]", "label": "Entity's total for internal credit grades [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Internal credit grades' axis if no other member is used." } } }, "auth_ref": [ "r329", "r336" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for related parties [member]", "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Entity's total for subsidiaries [member]", "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r82", "r83", "r156" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Stockholders\u2019 Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r22", "r31", "r137", "r139", "r158", "r159", "r162" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "terseLabel": "Total Capital", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "mor_EquityCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "EquityCapitalPercentage", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity capital (in percentage)", "label": "Equity capital percentage", "documentation": "Equity capital percentage." } } }, "auth_ref": [] }, "mor_EquityInAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "EquityInAssociate", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Group Share in Equity (2023: 12.1%; 2022: 15.0%)", "label": "Equity in associate", "documentation": "Equity in associate" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r8" ] }, "mor_EuropeExcludingGermanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "EuropeExcludingGermanyMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Europe (excluding Germany)", "label": "Europe (Excluding Germany) [Member]", "documentation": "Europe (Excluding Germany)" } } }, "auth_ref": [] }, "mor_ExecutiveCommitteeAndManagementBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExecutiveCommitteeAndManagementBoardMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive committee and management board", "label": "Executive Committee And Management Board [Member]", "documentation": "Executive Committee And Management Board" } } }, "auth_ref": [] }, "mor_ExecutiveCommitteeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExecutiveCommitteeMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive committee", "label": "Executive Committee [Member]", "documentation": "Executive Committee" } } }, "auth_ref": [] }, "mor_ExerciseOfConvertibleBondsIssuedToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExerciseOfConvertibleBondsIssuedToRelatedParties", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of Stock Options Issued", "label": "Exercise of convertible bonds issued to related parties", "documentation": "Exercise of convertible bonds issued to related parties." } } }, "auth_ref": [] }, "mor_ExerciseOfConvertibleBondsIssuedToRelatedPartiesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExerciseOfConvertibleBondsIssuedToRelatedPartiesShares", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of convertible bonds issued to related parties (in shares)", "label": "Exercise of convertible bonds issued to related parties, shares", "documentation": "Exercise of convertible bonds issued to related parties, shares." } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesAdditionalinformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of outstanding share options (in EUR per share)", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r206" ] }, "mor_ExpectedLicensingPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpectedLicensingPayments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected licensing payments", "label": "Expected Licensing Payments", "documentation": "Expected Licensing Payments" } } }, "auth_ref": [] }, "mor_ExpectedVolatilityDevelopmentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpectedVolatilityDevelopmentTerm", "presentation": [ "http://www.morphosys.com/role/RSDevelopmentofCashSettledProgramsandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility development term", "label": "Expected Volatility Development Term", "documentation": "Expected Volatility Development Term" } } }, "auth_ref": [] }, "mor_ExpenseCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpenseCategoriesAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expense Categories [axis]", "label": "Expense Categories [axis]", "documentation": "Expense Categories [axis]" } } }, "auth_ref": [] }, "mor_ExpenseCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpenseCategoriesDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expense Categories [domain]", "label": "Expense Categories [domain]", "documentation": "Expense Categories [domain]" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expense from cash-settled share-based payment transactions", "terseLabel": "Expense from cash-settled share-based payment transactions", "label": "Expense from cash-settled share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from cash-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense from equity-settled share-based payment transactions", "label": "Expense from equity-settled share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses for Leases of Low Value Assets", "label": "Expense relating to leases of low-value assets for which recognition exemption has been used" } }, "en": { "role": { "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets." } } }, "auth_ref": [ "r180" ] }, "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses for Short Term Leases", "label": "Expense relating to short-term leases for which recognition exemption has been used" } }, "en": { "role": { "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease." } } }, "auth_ref": [ "r179" ] }, "mor_ExpensedAcquisitionOrProductionCostOfInventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpensedAcquisitionOrProductionCostOfInventoriesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expensed Acquisition or Production Cost of Inventories", "label": "Expensed Acquisition or Production Cost of Inventories [Member]", "documentation": "Expensed Acquisition or Production Cost of Inventories ." } } }, "auth_ref": [] }, "mor_ExpensesForLegalAdvice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpensesForLegalAdvice", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for Legal Fees", "label": "Expenses for legal advice", "documentation": "Expenses for legal advice." } } }, "auth_ref": [] }, "mor_ExpirationTermForLastValidClaimTafasitamabLicensedPatent": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpirationTermForLastValidClaimTafasitamabLicensedPatent", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration term tafasitamab patent", "label": "Expiration Term For Last Valid Claim Tafasitamab Licensed Patent", "documentation": "Expiration Term For Last Valid Claim Tafasitamab Licensed Patent" } } }, "auth_ref": [] }, "mor_ExpiryOrDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExpiryOrDeconsolidation", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail": { "parentTag": "mor_TaxLossesCarryforwards", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Deferred Tax Assets on Total Tax Losses", "label": "Expiry Or Deconsolidation", "documentation": "Expiry Or Deconsolidation ." } } }, "auth_ref": [] }, "mor_ExternalLaboratoryServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExternalLaboratoryServices", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for External Laboratory Services", "label": "External laboratory services", "documentation": "External laboratory services." } } }, "auth_ref": [] }, "mor_ExternalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ExternalServicesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "External Services", "label": "External Services [member]", "documentation": "External services." } } }, "auth_ref": [] }, "mor_FairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FairValue", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Fair Value", "documentation": "Fair Value" } } }, "auth_ref": [] }, "mor_FairValueLevelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FairValueLevelLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Level [Line Items]", "label": "Fair Value Level [Line Items]", "documentation": "Fair Value Level [Line Items]" } } }, "auth_ref": [] }, "mor_FairValueLevelTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FairValueLevelTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Level [Table]", "label": "Fair Value Level [Table]", "documentation": "Fair Value Level [Table]" } } }, "auth_ref": [] }, "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of Adivo GmbH", "label": "Investments in equity instruments designated at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r221", "r243" ] }, "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FairValueOfInvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAtDateOfDerecognition", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value before sale", "label": "Fair value of investments in equity instruments designated at fair value through other comprehensive income at date of derecognition" } }, "en": { "role": { "documentation": "The fair value at the date of the derecognition of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]" } } }, "auth_ref": [ "r223" ] }, "mor_FederalCorporateIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FederalCorporateIncomeTaxRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Federal corporate income tax rate", "label": "Federal corporate income tax rate", "documentation": "Federal corporate income tax rate." } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 5.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance Expenses", "negatedTotalLabel": "Finance Expenses", "verboseLabel": "Reimbursement costs", "label": "Finance costs" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r41" ] }, "mor_FinanceExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinanceExpensesAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Expenses", "label": "Finance Expenses [Abstract]", "documentation": "Finance Expenses" } } }, "auth_ref": [] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Income", "totalLabel": "Finance Income", "label": "Finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r361" ] }, "mor_FinanceIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinanceIncomeAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Income", "label": "Finance Income [Abstract]", "documentation": "Finance Income" } } }, "auth_ref": [] }, "mor_FinancialAssetFromEscrow": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetFromEscrow", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Financial Asset from Escrow Account", "label": "Financial Asset from Escrow", "documentation": "Financial Asset from Escrow" } } }, "auth_ref": [] }, "mor_FinancialAssetFromEscrowAccountMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetFromEscrowAccountMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Asset from Escrow Account", "label": "Financial Asset from Escrow Account [Member]", "documentation": "Financial Asset from Escrow Account" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Financial assets", "totalLabel": "Total", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r229", "r233", "r234", "r236", "r330" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortised cost, category", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening balance", "periodEndLabel": "Closing balance", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets", "label": "Financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FVTPL", "label": "Financial assets at fair value through profit or loss, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, category [member]", "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r244" ] }, "mor_FinancialAssetsFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetsFromCollaboration", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": "mor_ForeignCurrencyRiskExposureNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets from Collaborations", "label": "Financial Assets from Collaboration", "documentation": "Financial Assets from Collaboration." } } }, "auth_ref": [] }, "mor_FinancialAssetsFromCollaborationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetsFromCollaborationsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets from Collaborations [Line Items]", "label": "Financial Assets from Collaborations [Line Items]", "documentation": "Financial Assets from Collaborations [Line Items]" } } }, "auth_ref": [] }, "mor_FinancialAssetsFromCollaborationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetsFromCollaborationsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets from collaborations", "label": "Financial Assets from Collaborations [Member]", "documentation": "Financial Assets from Collaborations" } } }, "auth_ref": [] }, "mor_FinancialAssetsFromCollaborationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialAssetsFromCollaborationsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets from Collaborations [Table]", "label": "Financial Assets from Collaborations [Table]", "documentation": "Financial Assets from Collaborations [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets, class", "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r197", "r238", "r239", "r264", "r265" ] }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets pledged as collateral for liabilities or contingent liabilities", "label": "Financial assets pledged as collateral for liabilities or contingent liabilities" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]" } } }, "auth_ref": [ "r225" ] }, "ifrs-full_FinancialEffectOfCorrectionsOfAccountingErrorsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialEffectOfCorrectionsOfAccountingErrorsMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) due to corrections of prior period errors", "label": "Increase (decrease) due to corrections of prior period errors [member]" } }, "en": { "role": { "documentation": "This member stands for the financial effect of corrections of prior period errors." } } }, "auth_ref": [ "r135", "r136" ] }, "mor_FinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialInstrumentsLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments [Line Items]", "label": "Financial instruments [Line Items]", "documentation": "Financial instruments [Line Items]" } } }, "auth_ref": [] }, "mor_FinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialInstrumentsTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesCarryingAmountofFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments [Table]", "label": "Financial instruments [Table]", "documentation": "Financial instruments [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Financial Liabilities (excluding Accounts Payable)", "negatedTotalLabel": "Total", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FLAC", "label": "Financial liabilities at amortised cost, class [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r245" ] }, "mor_FinancialLiabilitiesFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromCollaboration", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": "mor_ForeignCurrencyRiskExposureNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Collaborations", "negatedTerseLabel": "Financial Liabilities from Collaborations", "label": "Financial Liabilities from Collaboration", "documentation": "Financial Liabilities from Collaboration." } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesFromCollaborationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromCollaborationsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Collaborations", "label": "Financial Liabilities From Collaborations [Member]", "documentation": "Financial liabilities from collaborations member." } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesFromCollaborationsNetOfCurrentPortion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromCollaborationsNetOfCurrentPortion", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Collaborations", "label": "Financial Liabilities From Collaborations Net Of Current Portion", "documentation": "Financial liabilities from collaborations net of current portion." } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongAndShortTerm", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "periodStartLabel": "Beginning balance financial liabilities royalty pharma", "periodEndLabel": "Ending balance financial liabilities royalty pharma", "label": "Financial Liabilities from Future Payments to Royalty Pharma, long and short-term", "documentation": "Financial Liabilities from Future Payments to Royalty Pharma, long and short-term" } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaLongTerm", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "negatedTerseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "label": "Financial Liabilities from Future Payments to Royalty Pharma, Long-term", "documentation": "Financial Liabilities from Future Payments to Royalty Pharma, Long-term" } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Future Payments to Royalty Pharma", "label": "Financial Liabilities from Future Payments to Royalty Pharma [Member]", "documentation": "Financial Liabilities from Future Payments to Royalty Pharma" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities, class [member]", "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r238", "r239", "r264", "r265" ] }, "mor_FinancialLiabilitiesRoyaltyPharmaLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesRoyaltyPharmaLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities Royalty Pharma [Line Items]", "label": "Financial Liabilities Royalty Pharma [Line Items]", "documentation": "Financial Liabilities Royalty Pharma [Line Items]" } } }, "auth_ref": [] }, "mor_FinancialLiabilitiesRoyaltyPharmaTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FinancialLiabilitiesRoyaltyPharmaTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Liabilities from Future Payments [Table]", "label": "Financial Liabilities Royalty Pharma [Table]", "documentation": "Financial Liabilities Royalty Pharma [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinishedGoods", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished Goods", "label": "Current finished goods" } }, "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } } }, "auth_ref": [ "r286", "r367" ] }, "mor_FixedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FixedCompensationMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Compensation", "label": "Fixed Compensation [member]", "documentation": "Fixed compensation." } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and Fixtures", "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "mor_ForeignCurrencyGainsFromFinancialAssetsFromCollaborations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyGainsFromFinancialAssetsFromCollaborations", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign Exchange Gains", "label": "Foreign Currency Gains from Financial Assets from Collaborations", "documentation": "Foreign Currency Gains from Financial Assets from Collaborations." } } }, "auth_ref": [] }, "mor_ForeignCurrencyLossesFromFinancialLiabilitiesFromCollaborations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyLossesFromFinancialLiabilitiesFromCollaborations", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign Exchange Losses", "label": "Foreign Currency Losses From Financial Liabilities From Collaborations", "documentation": "Foreign Currency Losses From Financial Liabilities From Collaborations ." } } }, "auth_ref": [] }, "mor_ForeignCurrencyRiskExposureNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyRiskExposureNet", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Foreign currency risk exposure, net", "documentation": "Foreign currency risk exposure, net." } } }, "auth_ref": [] }, "mor_ForeignCurrencyRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyRiskLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Risk [Line Items]", "label": "Foreign Currency Risk [Line Items]", "documentation": "Foreign Currency Risk [Line Items]" } } }, "auth_ref": [] }, "mor_ForeignCurrencyRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyRiskTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Risk [Table]", "label": "Foreign Currency Risk [Table]", "documentation": "Foreign Currency Risk [Table]" } } }, "auth_ref": [] }, "mor_ForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences", "label": "Foreign Currency Translation", "documentation": "Foreign Currency Translation" } } }, "auth_ref": [] }, "mor_ForeignCurrencyTranslationDifferencesMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignCurrencyTranslationDifferencesMembersMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences", "label": "Foreign Currency Translation Differences Members [Member]", "documentation": "Foreign Currency Translation Differences Members" } } }, "auth_ref": [] }, "mor_ForeignExchangeGainLossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignExchangeGainLossLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain (loss), lease liabilities", "label": "Foreign Exchange gain (loss) - Lease Liabilities", "documentation": "Foreign Exchange gain (loss) - Lease Liabilities" } } }, "auth_ref": [] }, "mor_ForeignExchangeGainLossRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignExchangeGainLossRightOfUseAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences from Consolidation", "label": "Foreign Exchange gain (loss) - Right of use Assets", "documentation": "Foreign Exchange gain (loss) - Right of use Assets" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss", "label": "Foreign exchange loss" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r11", "r70" ] }, "mor_ForeignExchangeRatesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignExchangeRatesLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Rates [Line Items]", "label": "Foreign Exchange Rates [Line Items]", "documentation": "Foreign Exchange Rates [Line Items]" } } }, "auth_ref": [] }, "mor_ForeignExchangeRatesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignExchangeRatesTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Rates [Table]", "label": "Foreign Exchange Rates [Table]", "documentation": "Foreign Exchange Rates [Table]" } } }, "auth_ref": [] }, "mor_ForeignExchangeSensitivityAnalysis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ForeignExchangeSensitivityAnalysis", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange, sensitivity analysis", "label": "Foreign Exchange, Sensitivity Analysis", "documentation": "Foreign Exchange, Sensitivity Analysis" } } }, "auth_ref": [] }, "mor_FutureLeasePaymentsDiscounted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FutureLeasePaymentsDiscounted", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetLeassesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future lease payments discounted", "label": "Future Lease Payments Discounted", "documentation": "Future Lease Payments Discounted" } } }, "auth_ref": [] }, "mor_FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FutureMinimumLeasesPaymentsOfLowValueAssetsAndOtherShortTermLeases", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases of Low-Value Assets and Short-Term Leases", "label": "Future Minimum Leases Payments Of Low Value Assets And Other Short Term Leases", "documentation": "Future minimum lease payments of low value assets and other short term leases." } } }, "auth_ref": [] }, "mor_FuturePaymentCommitmentsForClinicalStudies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FuturePaymentCommitmentsForClinicalStudies", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future payment commitments for clinical studies", "label": "Future payment commitments for clinical studies", "documentation": "Future payment commitments for clinical studies." } } }, "auth_ref": [] }, "mor_FuturePaymentCommitmentsForClinicalStudiesExpectedDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "FuturePaymentCommitmentsForClinicalStudiesExpectedDecrease", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future payment commitments, expected decrease", "label": "Future Payment Commitments For Clinical Studies, Expected Decrease", "documentation": "Future Payment Commitments For Clinical Studies, Expected Decrease" } } }, "auth_ref": [] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "GB", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "mor_GainFromRepurchaseOfConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GainFromRepurchaseOfConvertibleBond", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gain from Repurchase of own Convertible Bonds", "label": "Gain From Repurchase Of Convertible Bond", "documentation": "Gain From Repurchase Of Convertible Bond" } } }, "auth_ref": [] }, "mor_GainLossOnFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GainLossOnFinancialInstruments", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gains or losses from financial instruments", "label": "Gain Loss On Financial Instruments", "documentation": "Gain loss on financial instruments." } } }, "auth_ref": [] }, "mor_GainOnRepurchaseAndInterestExpenseFromConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GainOnRepurchaseAndInterestExpenseFromConvertibleBond", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on Repurchase and interest expense from Convertible Bond", "label": "Gain On Repurchase And Interest Expense From Convertible Bond", "documentation": "Gain On Repurchase And Interest Expense From Convertible Bond" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences from Consolidation", "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax" } }, "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r43" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences from Consolidation", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r11", "r70" ] }, "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeExcludingExchangeDifferencesFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeExcludingExchangeDifferencesFairValueMeasurementAssets", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(losses) recognized in other comprehensive income", "label": "Gains (losses) recognised in other comprehensive income excluding exchange differences, fair value measurement, assets" } }, "en": { "role": { "documentation": "The gains (losses) excluding exchange differences, recognised in other comprehensive income, on the fair value measurement of assets. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r386" ] }, "ifrs-full_GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesRecognisedInProfitOrLossExcludingExchangeDifferencesFairValueMeasurementAssets", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains/(losses) recognized in profit or loss statement", "label": "Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, assets" } }, "en": { "role": { "documentation": "The gains (losses) excluding exchange differences, recognised in profit or loss, on the fair value measurement of assets. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r385" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gains from Measurement at Fair Value", "label": "Gains on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r361" ] }, "ifrs-full_GainsOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsOnDisposalsOfNoncurrentAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains on disposals of non-current assets", "label": "Gains on disposals of non-current assets" } }, "en": { "role": { "documentation": "The gain on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r353" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "General and Administrative", "terseLabel": "General and administrative expenses", "label": "General and administrative expense" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r353" ] }, "mor_GeneralAndAdministrativeExpense1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GeneralAndAdministrativeExpense1Member", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General And Administrative Expense1 [member]", "documentation": "General and administrative expense1." } } }, "auth_ref": [] }, "mor_GeneralAndAdministrativeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GeneralAndAdministrativeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative", "label": "General and administrative [Member]", "documentation": "General and administrative." } } }, "auth_ref": [] }, "mor_GeneralImpairmentModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GeneralImpairmentModelMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General\u00a0Impairment\u00a0Model", "label": "General impairment model [member]", "documentation": "General impairment model." } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r261", "r295", "r317", "r321" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [member]", "label": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r261", "r295", "r317", "r321" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r14", "r93", "r94", "r218" ] }, "mor_GoodwillAcquiredLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GoodwillAcquiredLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Acquired [Line Items]", "label": "Goodwill Acquired [Line Items]", "documentation": "Goodwill Acquired [Line Items]" } } }, "auth_ref": [] }, "mor_GoodwillAcquiredTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GoodwillAcquiredTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Acquired [Table]", "label": "Goodwill Acquired [Table]", "documentation": "Goodwill Acquired [Table]" } } }, "auth_ref": [] }, "ifrs-full_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GoodwillMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r299" ] }, "mor_GrossCarryingAmountByCreditRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossCarryingAmountByCreditRiskLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount by Credit Risk [Line Items]", "label": "Gross Carrying Amount by Credit Risk [Line Items]", "documentation": "Gross Carrying Amount by Credit Risk [Line Items]" } } }, "auth_ref": [] }, "mor_GrossCarryingAmountByCreditRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossCarryingAmountByCreditRiskTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount by Credit Risk [Table]", "label": "Gross Carrying Amount by Credit Risk [Table]", "documentation": "Gross Carrying Amount by Credit Risk [Table]" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Gross carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r55", "r103", "r113", "r116", "r218", "r234", "r236", "r330" ] }, "mor_GrossCarryingAmountOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossCarryingAmountOfFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross carrying amount", "label": "Gross carrying amount of financial assets", "documentation": "Gross carrying amount of financial assets." } } }, "auth_ref": [] }, "mor_GrossGainsLossesOnFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossGainsLossesOnFinancialInstruments", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Gross Gains (Losses) on Financial Instruments", "documentation": "Gross Gains (Losses) on Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Profit", "label": "Gross profit" } }, "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } } }, "auth_ref": [ "r282" ] }, "mor_GrossUnrealizedGainsOnFinancialAssetsAvailableforsale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossUnrealizedGainsOnFinancialAssetsAvailableforsale", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Profit", "label": "Gross unrealized gains on financial assets available-for-sale", "documentation": "Gross unrealized gains on financial assets available-for-sale." } } }, "auth_ref": [] }, "mor_GrossUnrealizedGainsOnLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossUnrealizedGainsOnLoansAndReceivables", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Interest Income (+) / Expense (-)", "label": "Gross unrealized gains on loans and receivables", "documentation": "Gross unrealized gains on loans and receivables." } } }, "auth_ref": [] }, "mor_GrossUnrealizedLossesOnFinancialAssetsAvailableforsale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossUnrealizedLossesOnFinancialAssetsAvailableforsale", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses", "label": "Gross unrealized losses on financial assets available-for-sale", "documentation": "Gross unrealized losses on financial assets available-for-sale." } } }, "auth_ref": [] }, "mor_GrossUnrealizedLossesOnLoansAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "GrossUnrealizedLossesOnLoansAndReceivables", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment", "label": "Gross unrealized losses on loans and receivables", "documentation": "Gross unrealized losses on loans and receivables." } } }, "auth_ref": [] }, "mor_HIBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "HIBioMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HI-Bio", "label": "HI-Bio [Member]", "documentation": "HI-Bio" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r342", "r343", "r344" ] }, "mor_ImpactOnProfitOrLossDueToAdoptionOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpactOnProfitOrLossDueToAdoptionOfLease", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Impact On Profit Or Loss Due To Adoption Of Lease", "documentation": "Impact On Profit Or Loss Due To Adoption Of Lease." } } }, "auth_ref": [] }, "mor_ImpairmentAmortizationAndOtherCostsOfIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentAmortizationAndOtherCostsOfIntangibleAssetsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Amortization and Other Costs of Intangible Assets", "label": "Impairment, amortization and other costs of intangible assets [member]", "documentation": "Impairment, amortization and other costs of intangible assets." } } }, "auth_ref": [] }, "mor_ImpairmentAndReversalsOfImpairmentOnInventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentAndReversalsOfImpairmentOnInventoriesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment (+) and Reversals of Impairment (-) on Inventories", "label": "Impairment And Reversals Of Impairment On Inventories [Member]", "documentation": "Impairment And Reversals Of Impairment On Inventories [Member] ." } } }, "auth_ref": [] }, "mor_ImpairmentLossOfIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentLossOfIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Impairment Loss of Intangible Assets and Goodwill", "documentation": "Impairment Loss of Intangible Assets and Goodwill" } } }, "auth_ref": [] }, "mor_ImpairmentLossOnFinancialAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentLossOnFinancialAsset", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Impairment loss on financial asset", "documentation": "Impairment loss on financial asset." } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss recognised in profit or loss", "label": "Impairment loss recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]" } } }, "auth_ref": [ "r89", "r91" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementImpairmentofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment of Goodwill", "terseLabel": "Impairment of goodwill", "label": "Impairment loss recognised in profit or loss, goodwill" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Impairment loss recognised in profit or loss, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } } }, "auth_ref": [ "r44", "r58" ] }, "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment on anti-dilution right", "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss" } }, "en": { "role": { "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]" } } }, "auth_ref": [ "r45" ] }, "mor_ImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedOnFinancialAssets", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets", "label": "Impairment Loss Reversal Of Impairment Loss Recognised On Financial Assets", "documentation": "Impairment loss reversal of impairment loss recognised on financial assets." } } }, "auth_ref": [] }, "mor_ImpairmentLossesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentLossesLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment losses [Line Items]", "label": "Impairment losses [Line Items]", "documentation": "Impairment losses [Line Items]" } } }, "auth_ref": [] }, "mor_ImpairmentLossesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentLossesTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment losses [Table]", "label": "Impairment losses [Table]", "documentation": "Impairment losses [Table]" } } }, "auth_ref": [] }, "mor_ImpairmentOnResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ImpairmentOnResearchAndDevelopmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development (Impairment)", "label": "Impairment On Research And Development [Member]", "documentation": "Impairment On Research And Development [Member]." } } }, "auth_ref": [] }, "mor_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process R&D Programs and Internally Generated Intangible Assets", "label": "In Process Research And Development [Member]" } } }, "auth_ref": [] }, "mor_IncomeFromNetCashEffects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomeFromNetCashEffects", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income from net cash effects", "label": "Income From Net Cash Effects", "documentation": "Income From Net Cash Effects" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Profit or loss [abstract]", "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "mor_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [axis]", "label": "Income Statement Location [axis]", "documentation": "Income statement location." } } }, "auth_ref": [] }, "mor_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Income Statement Location Domain" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 8.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Income Tax Benefit / (Expenses)", "terseLabel": "Income Tax Benefit / (Expenses)", "negatedTotalLabel": "Total Income Tax Benefit / (Expenses)", "negatedTerseLabel": "Total Income Tax Benefit / (Expenses)", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r42", "r47", "r49", "r50", "r81", "r154", "r251" ] }, "mor_IncomeTaxReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomeTaxReceivablesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax Receivables [Line Items]", "label": "Income tax Receivables [Line Items]", "documentation": "Income tax Receivables [Line Items]" } } }, "auth_ref": [] }, "mor_IncomeTaxReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomeTaxReceivablesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIncomeTaxReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax Receivables [Table]", "label": "Income tax Receivables [Table]", "documentation": "Income tax Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income Taxes Paid (-) / Received (+)", "label": "Income taxes paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } } }, "auth_ref": [ "r383" ] }, "mor_IncomestatementlocationaxisAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncomestatementlocationaxisAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "IncomeStatementLocationAxis [Axis]", "documentation": "IncomeStatementLocationAxis ." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase / (Decrease) in Cash and Cash Equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r131" ] }, "mor_IncreaseDecreaseInImpairmentLossForCreditRiskRecognizedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseInImpairmentLossForCreditRiskRecognizedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in Impairment Losses for Credit Risks recognized in Profit or Loss during the Year", "label": "Increase (decrease) in impairment loss for credit risk recognized in profit or loss", "documentation": "Increase (decrease) in impairment loss for credit risk recognized in profit or loss." } } }, "auth_ref": [] }, "mor_IncreaseDecreaseInImpairmentStages": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseInImpairmentStages", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change between Impairment Stages", "label": "Increase (Decrease) in impairment stages", "documentation": "Increase (Decrease) in impairment stages." } } }, "auth_ref": [] }, "mor_IncreaseDecreaseInNumberThroughTransferOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseInNumberThroughTransferOfTreasuryShares", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer in the year (in shares)", "negatedTerseLabel": "Transfer in the year (in shares)", "label": "Increase (decrease) in number through transfer of treasury shares", "documentation": "Increase (decrease) in number through transfer of treasury shares." } } }, "auth_ref": [] }, "mor_IncreaseDecreaseInTreasuryStockAmountDueToTransfer": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseInTreasuryStockAmountDueToTransfer", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (decrease) in trasury stock amount due to transfer", "label": "(Increase) decrease in treasury stock amount due to transfer", "documentation": "Increase (decrease) in treasury stock amount due to transfer." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) through changes in fair values, liabilities arising from financing activities", "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r129" ] }, "mor_IncreaseDecreaseThroughDisposalOfInvestmentEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseThroughDisposalOfInvestmentEquity", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on the Disposal of an Investment", "label": "Increase (Decrease) Through Disposal Of Investment, Equity", "documentation": "Increase (Decrease) Through Disposal Of Investment, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences", "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r128" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows", "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r127" ] }, "mor_IncreaseDecreaseThroughGainOnRepurchaseOfConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseDecreaseThroughGainOnRepurchaseOfConvertibleBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on Repurchase from Convertible Bond", "label": "Increase (Decrease) Through Gain On Repurchase Of Convertible Bond", "documentation": "Increase (Decrease) Through Gain On Repurchase Of Convertible Bond" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Differences from Consolidation", "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r106" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes from Adjustments to Planning Assumptions", "label": "Increase (decrease) through other changes, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r130" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses through Share-based Payment Transactions and Issue of Convertible Instruments", "negatedTerseLabel": "Expenses through Share-based Payment Transactions and Issue of Convertible Instruments", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r6" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Increase (decrease) through transfers, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r372" ] }, "mor_IncreaseInCapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseInCapitalReserve", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in capital reserve", "label": "Increase in Capital Reserve", "documentation": "Increase in Capital Reserve" } } }, "auth_ref": [] }, "ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities", "label": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities" } }, "en": { "role": { "documentation": "The amount of increase in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions." } } }, "auth_ref": [ "r163" ] }, "mor_IncreaseOfEuro10Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseOfEuro10Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase of the Euro by 10%", "label": "Increase of Euro 10% [Member]", "documentation": "Increase of Euro 10%" } } }, "auth_ref": [] }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Leases", "label": "Increase through new leases, liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r309", "r312" ] }, "ifrs-full_IncreaseThroughOriginationOrPurchaseFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseThroughOriginationOrPurchaseFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Increase through origination or purchase, financial assets" } }, "en": { "role": { "documentation": "The increase in financial assets resulting from origination or purchase. [Refer: Financial assets]" } } }, "auth_ref": [ "r326", "r327", "r335" ] }, "mor_IncreaseVariableInterestRate10Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncreaseVariableInterestRate10Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase of the variable Interest Rate by 0.5%", "label": "Increase Variable Interest Rate 10% [Member]", "documentation": "Increase Variable Interest Rate 10%" } } }, "auth_ref": [] }, "mor_IncyteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IncyteMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incyte", "label": "Incyte [Member]", "documentation": "Incyte [member]." } } }, "auth_ref": [] }, "mor_InprocessResearchAndDevelopmentProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InprocessResearchAndDevelopmentProjectsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-process R&D Programs", "label": "In-process research and development projects [member]", "documentation": "In-process research and development projects." } } }, "auth_ref": [] }, "mor_IntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IntangibleAssetMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible asset [member]", "documentation": "Intangible asset." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Carrying amount", "label": "Intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwillMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets and goodwill [member]", "label": "Intangible assets and goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r373" ] }, "mor_IntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IntangibleAssetsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Line Items]", "label": "Intangible Assets [Line Items]", "documentation": "Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r14", "r107" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets other than goodwill [member]", "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r108", "r299", "r319" ] }, "mor_IntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IntangibleAssetsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Table]", "label": "Intangible Assets [Table]", "documentation": "Intangible Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsUnderDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsUnderDevelopment", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets under development", "label": "Intangible assets under development" } }, "en": { "role": { "documentation": "The amount of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r303" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Other Interest Expenses", "negatedTerseLabel": "Interest Expenses", "terseLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r153", "r249", "r257" ] }, "ifrs-full_InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseForFinancialLiabilitiesNotAtFairValueThroughProfitOrLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Effective Interest Expenses from Financial Liabilities at Amortized Cost", "label": "Interest expense for financial liabilities not at fair value through profit or loss" } }, "en": { "role": { "documentation": "The amount of interest expense for financial liabilities that are not at fair value through profit or loss. [Refer: At fair value [member]; Interest expense; Financial liabilities]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest Expenses on Lease Liabilities", "terseLabel": "Interest Expenses on Lease Liabilities", "label": "Interest expense on lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_InterestExpenseOnOtherFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnOtherFinancialLiabilities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails": { "parentTag": "mor_GrossGainsLossesOnFinancialInstruments", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest Expenses FLAC", "label": "Interest expense on other financial liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on other financial liabilities. [Refer: Interest expense; Other financial liabilities]" } } }, "auth_ref": [ "r353" ] }, "mor_InterestExpensesOnFinancialAssetsAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InterestExpensesOnFinancialAssetsAtAmortisedCost", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails": { "parentTag": "mor_GrossGainsLossesOnFinancialInstruments", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest Expenses AC", "label": "Interest Expenses on Financial Assets at Amortised Cost", "documentation": "Interest Expenses on Financial Assets at Amortised Cost" } } }, "auth_ref": [] }, "ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails": { "parentTag": "mor_GrossGainsLossesOnFinancialInstruments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income AC", "label": "Interest revenue for financial assets measured at amortised cost" } }, "en": { "role": { "documentation": "The amount of revenue arising from interest for financial assets that are measured at amortised cost. [Refer: Interest income; Financial assets at amortised cost]" } } }, "auth_ref": [ "r226" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest Paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r122" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r122" ] }, "ifrs-full_InterestRevenueExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestRevenueExpense", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income", "label": "Interest income (expense)" } }, "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } } }, "auth_ref": [ "r252", "r257", "r361" ] }, "mor_InterestRevenueForFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InterestRevenueForFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails": { "parentTag": "mor_GrossGainsLossesOnFinancialInstruments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofInterestIncomeandExpenseofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income FLAC", "label": "Interest Revenue for Financial Liabilities", "documentation": "Interest Revenue for Financial Liabilities" } } }, "auth_ref": [] }, "ifrs-full_InternalCreditGradesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InternalCreditGradesAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal credit grades [axis]", "label": "Internal credit grades [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r329", "r336" ] }, "mor_InternallyGeneratedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InternallyGeneratedIntangibleAssetsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetIntangibleassetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInternallygeneratedintangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internally Generated Intangible Assets", "label": "Internally Generated Intangible Assets [Member]", "documentation": "Internally Generated Intangible Assets" } } }, "auth_ref": [] }, "mor_IntialConversionOfCovertibleBondsToOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IntialConversionOfCovertibleBondsToOrdinaryShares", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial conversion of covertible bonds to ordinary shares (in shares)", "label": "Intial Conversion of Covertible Bonds to Ordinary Shares", "documentation": "Debt Instrument Convertible Number of Equity Instruments" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "terseLabel": "Total", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r16", "r69", "r284" ] }, "mor_InvestmentsFixedTermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InvestmentsFixedTermDeposits", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Fixed Term Deposits", "label": "Investments, fixed term deposits", "documentation": "Investments, fixed term deposits" } } }, "auth_ref": [] }, "mor_InvestmentsInAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InvestmentsInAffiliatesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares in Affiliated Companies", "label": "Investments In Affiliates [Member]", "documentation": "Investments In Affiliates" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsInAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentsInAssociatesAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Associates", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Investments in associates accounted for using equity method" } }, "en": { "role": { "documentation": "The amount of investments in associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income [axis]", "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r221" ] }, "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity instruments designated at fair value through other comprehensive income [member]", "label": "Investments in equity instruments designated at fair value through other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for investments in equity instruments that the entity has designated at fair value through other comprehensive income. It also represents the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r221", "r243" ] }, "mor_InvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InvestmentsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Line Items]", "label": "Investments [Line Items]", "documentation": "Investments [Line Items]" } } }, "auth_ref": [] }, "mor_InvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "InvestmentsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Table]", "label": "Investments [Table]", "documentation": "Investments [Table]" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of convertible instruments", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r351" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital Increase, Net of Issuance Cost", "terseLabel": "Issue of equity", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r6" ] }, "mor_IssueOfEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "IssueOfEquityShares", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital increase, net of issuance cost (in shares)", "label": "Issue of equity shares", "documentation": "Issue of equity shares." } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r287" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r8" ] }, "mor_JeanpaulKressMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "JeanpaulKressMDMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jean-Paul Kress, M.D.", "label": "JeanPaul Kress M D [Member]", "documentation": "Jean-Paul Kress, M.D." } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel compensation", "totalLabel": "Total Compensation", "label": "Key management personnel compensation" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r76" ] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Post-employment benefits", "terseLabel": "Total Post-Employment Benefits", "label": "Key management personnel compensation, post-employment benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term incentive compensation", "terseLabel": "Total Share-Based Payment", "label": "Key management personnel compensation, share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Short-Term Employee Benefits", "label": "Key management personnel compensation, short-term employee benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationTerminationBenefits", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Termination Benefits", "label": "Key management personnel compensation, termination benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r74" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key management personnel", "label": "Key management personnel of entity or parent [member]" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r78" ] }, "mor_KrisjaVermeylenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "KrisjaVermeylenMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Krisja Vermeylen", "label": "Krisja Vermeylen [member]", "documentation": "Krisja Vermeylen." } } }, "auth_ref": [] }, "mor_LaboratoryAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LaboratoryAndOfficeEquipmentMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Low-value Office and Laboratory Equipment", "label": "Laboratory and Office Equipment [member]", "documentation": "Laboratory and office equipment." } } }, "auth_ref": [] }, "mor_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory Equipment", "label": "Laboratory Equipment [member]", "documentation": "Laboratory equipment." } } }, "auth_ref": [] }, "mor_LaboratoryServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LaboratoryServicesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments for External Laboratory Services", "label": "Laboratory services [member]", "documentation": "Laboratory services." } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "More than 5 Years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r185", "r186", "r196", "r332", "r333", "r337" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Between One and Five Years", "label": "Later than one year and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r331", "r337" ] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 1 Year", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance lease liabilities", "periodEndLabel": "Ending balance lease liabilities", "terseLabel": "Lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r176" ] }, "mor_LeaseLiabilitiesChangeInValueIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LeaseLiabilitiesChangeInValueIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities change in value", "label": "Lease Liabilities Change in Value Increase (Decrease)", "documentation": "Lease Liabilities Change in Value Increase (Decrease)" } } }, "auth_ref": [] }, "mor_LeaseLiabilitiesMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LeaseLiabilitiesMMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "label": "Lease Liabilities M [Member]", "documentation": "Lease Liabilities M" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r310", "r313" ] }, "mor_LeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LeasePayments", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lease Payments", "label": "Lease Payments", "documentation": "Lease Payments" } } }, "auth_ref": [] }, "mor_LeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LeasesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Leases [Member]", "documentation": "Leases." } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 of fair value hierarchy", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r65", "r159" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 of fair value hierarchy", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 of fair value hierarchy", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r159" ] }, "ifrs-full_LevelOfParticipationOfEntityComparedWithOtherParticipatingEntities": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelOfParticipationOfEntityComparedWithOtherParticipatingEntities", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level of participation of entity compared with other participating entities", "label": "Level of participation of entity compared with other participating entities" } }, "en": { "role": { "documentation": "The description of an indication of the level of participation of the entity in a defined benefit plan compared with other participating entities. Examples of measures that might provide such an indication include the entity's proportion of the total contributions to the plan or the entity's proportion of the total number of active members, retired members, and former members entitled to benefits, if that information is available. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r66" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r65", "r159" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "terseLabel": "Total Liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r22", "r158", "r159", "r162", "r252", "r256" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Liabilities arising from financing activities, period start", "negatedPeriodEndLabel": "Liabilities arising from financing activities, period end", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r311" ] }, "mor_LiabilitiesCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LiabilitiesCapitalPercentage", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities capital (in percentage)", "label": "Liabilities capital percentage", "documentation": "Liabilities capital percentage." } } }, "auth_ref": [] }, "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesFromSharebasedPaymentTransactions2011", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities from share-based payment transactions", "label": "Liabilities from share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_LiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities [member]", "label": "Liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r164" ] }, "mor_LiabilitiesToBanks": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LiabilitiesToBanks", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCapitalManagementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities to banks", "label": "Liabilities To Banks", "documentation": "Liabilities To Banks" } } }, "auth_ref": [] }, "mor_LiabilityComponentOfConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LiabilityComponentOfConvertibleBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability component of convertible bond", "label": "Liability Component of Convertible Bond", "documentation": "Liability Component of Convertible Bond" } } }, "auth_ref": [] }, "mor_LiabilityForSeverancePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LiabilityForSeverancePayment", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for severance payment", "label": "Liability for severance payment", "documentation": "Liability for severance payment" } } }, "auth_ref": [] }, "ifrs-full_LicencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LicencesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Licences [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r374" ] }, "mor_LicenseFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicenseFeesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License Fees", "label": "License Fees [member]", "documentation": "License fees." } } }, "auth_ref": [] }, "mor_LicenseMilestonesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicenseMilestonesAndOtherMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses, Milestones and Other", "label": "License, Milestones and Other [Member]", "documentation": "License, Milestones and Other" } } }, "auth_ref": [] }, "mor_LicensePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicensePayments", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails": { "parentTag": "mor_AccruedLiabilityCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals for License Payments", "label": "License payments", "documentation": "License payments." } } }, "auth_ref": [] }, "mor_LicensesForMarketedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicensesForMarketedProductsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses for Marketed Products", "label": "Licenses for Marketed Products [Member]", "documentation": "Licenses\u00a0for Marketed Products Member." } } }, "auth_ref": [] }, "mor_LicensesMilestonesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicensesMilestonesAndOther", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses, Milestones and Other", "label": "Licenses, Milestones and Other", "documentation": "Licenses, Milestones and Other" } } }, "auth_ref": [] }, "mor_LicensingPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LicensingPayments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing payments", "label": "Licensing Payments", "documentation": "Licensing Payments" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "mor_LongTermCashIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LongTermCashIncentivePlanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term cash incentive plan", "label": "Long-Term Cash Incentive Plan [Member]", "documentation": "Long-Term Cash Incentive Plan" } } }, "auth_ref": [] }, "mor_LongTermIncentivePlansLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LongTermIncentivePlansLineItems", "presentation": [ "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Incentive Plans [Line Items]", "label": "Long-term Incentive Plans [Line Items]", "documentation": "Long-term Incentive Plans [Line Items]" } } }, "auth_ref": [] }, "mor_LongTermIncentivePlansTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LongTermIncentivePlansTable", "presentation": [ "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Incentive Plans [Table]", "label": "Long-term Incentive Plans [Table]", "documentation": "Long-term Incentive Plans [Table]" } } }, "auth_ref": [] }, "mor_LongTermRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LongTermRestrictedCash", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Restricted Cash", "label": "Long term restricted cash", "documentation": "Long term restricted cash." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds", "label": "Non-current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Losses from Measurement at Fair Value", "label": "Losses on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r361" ] }, "mor_LowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LowMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Low", "label": "Low [member]", "documentation": "Low [member]" } } }, "auth_ref": [] }, "mor_LucindaCrabtreePhDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "LucindaCrabtreePhDMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lucinda Crabtree PhD", "label": "Lucinda Crabtree PhD [Member]", "documentation": "Lucinda Crabtree PhD" } } }, "auth_ref": [] }, "mor_MOR210Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MOR210Member", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MOR210", "label": "MOR210 [Member]", "documentation": "MOR210" } } }, "auth_ref": [] }, "ifrs-full_MajorBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorBusinessCombinationMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Major business combination", "label": "Major business combination [member]" } }, "en": { "role": { "documentation": "This member stands for major business combinations. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r289" ] }, "mor_ManagementBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ManagementBoardMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management Board", "label": "Management Board [member]", "documentation": "Management board." } } }, "auth_ref": [] }, "mor_MarketInequity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MarketInequity", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Addition", "label": "Market Inequity", "documentation": "Market Inequity" } } }, "auth_ref": [] }, "mor_MarketInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MarketInterestRate", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market interest rate", "label": "Market Interest Rate", "documentation": "Market Interest Rate" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r26", "r172", "r185", "r186", "r187", "r188", "r190", "r196", "r228", "r237", "r297", "r332" ] }, "mor_MaturityOfLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaturityOfLeaseLiabilitiesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity of Lease Liabilities [Line Items]", "label": "Maturity of Lease Liabilities [Line Items]", "documentation": "Maturity of Lease Liabilities [Line Items]" } } }, "auth_ref": [] }, "mor_MaturityOfLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaturityOfLeaseLiabilitiesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity of Lease Liabilities [Table]", "label": "Maturity of Lease Liabilities [Table]", "documentation": "Maturity of Lease Liabilities [Table]" } } }, "auth_ref": [] }, "mor_MaturityTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaturityTotalMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity, total", "label": "Maturity, total [Member]", "documentation": "Maturity, total" } } }, "auth_ref": [] }, "mor_MaximumAuthorisedTermForShareCapitalIncrease": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaximumAuthorisedTermForShareCapitalIncrease", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum authorised term for share capital increase", "label": "Maximum Authorised Term for Share Capital Increase", "documentation": "Maximum Authorised Term for Share Capital Increase" } } }, "auth_ref": [] }, "mor_MaximumExposureToCreditRiskOnDebtInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaximumExposureToCreditRiskOnDebtInstruments", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum credit risk corresponded to carrying amounts of debt instruments", "label": "Maximum exposure to credit risk on debt instruments", "documentation": "Maximum exposure to credit risk on debt instruments." } } }, "auth_ref": [] }, "mor_MaximumExposureToCreditRiskOnFinancialGuarantees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaximumExposureToCreditRiskOnFinancialGuarantees", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum credit risk of financial guarantees", "label": "Maximum exposure to credit risk on financial guarantees", "documentation": "Maximum exposure to credit risk on financial guarantees." } } }, "auth_ref": [] }, "mor_MaximumIncreaseInCreditRiskPremiumBasisPoints": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaximumIncreaseInCreditRiskPremiumBasisPoints", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum increase in credit risk premium", "label": "Maximum Increase In Credit Risk Premium, Basis Points", "documentation": "Maximum Increase In Credit Risk Premium, Basis Points" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [] }, "mor_MaximumTermForExerciseOfOptionsGrantedForShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MaximumTermForExerciseOfOptionsGrantedForShareBasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum term for exercise options", "label": "Maximum Term For Exercise Of Options Granted For Share-Based Payment Arrangement", "documentation": "Maximum Term For Exercise Of Options Granted For Share-Based Payment Arrangement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement [axis]", "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r111", "r115", "r158" ] }, "mor_MichaelBrosnanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MichaelBrosnanMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Michael Brosnan", "label": "Michael Brosnan [member]", "documentation": "Michael Brosnan." } } }, "auth_ref": [] }, "mor_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MilestonePayment", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoProprietaryClinicalDevelopmentDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Milestone payment", "documentation": "Milestone payment" } } }, "auth_ref": [] }, "mor_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MilestonePayments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments", "label": "Milestone Payments", "documentation": "Milestone Payments" } } }, "auth_ref": [] }, "mor_MilestonePaymentsWereCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MilestonePaymentsWereCapitalized", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments were capitalized", "label": "Milestone payments were Capitalized", "documentation": "Milestone payments were Capitalized" } } }, "auth_ref": [] }, "mor_MilestoneShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MilestoneShares", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone shares", "label": "Milestone shares", "documentation": "Milestone shares" } } }, "auth_ref": [] }, "mor_MilestonesPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MilestonesPaymentsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone Payments", "label": "Milestones Payments [Member]", "documentation": "Milestones Payments [Member] ." } } }, "auth_ref": [] }, "mor_MinimumAcceptanceThresholdOfShareCapital": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MinimumAcceptanceThresholdOfShareCapital", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum acceptance threshold of share capital", "label": "Minimum Acceptance Threshold Of Share Capital", "documentation": "Minimum Acceptance Threshold Of Share Capital" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [] }, "mor_MiscellaneousExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MiscellaneousExpenses", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expenses from Other Items", "label": "Miscellaneous Expenses", "documentation": "Miscellaneous expenses." } } }, "auth_ref": [] }, "mor_MiscellaneousOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MiscellaneousOperatingIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Income from Other Items", "label": "Miscellaneous operating income", "documentation": "Miscellaneous operating income." } } }, "auth_ref": [] }, "mor_MoneyMarketFunds1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MoneyMarketFunds1Member", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds 1 [member]", "documentation": "Money market funds." } } }, "auth_ref": [] }, "mor_MorphosysAgMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MorphosysAgMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Morphosys AG", "label": "Morphosys AG [Member]", "documentation": "Morphosys AG" } } }, "auth_ref": [] }, "mor_MorphosysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MorphosysMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Morphosys", "label": "Morphosys [Member]", "documentation": "Morphosys [Member]." } } }, "auth_ref": [] }, "mor_MorphosysShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MorphosysShareMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Morphosys share", "label": "Morphosys Share [Member]", "documentation": "Morphosys Share" } } }, "auth_ref": [] }, "mor_MorphosysUsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "MorphosysUsIncMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "MorphoSys US Inc., Boston, Massachusetts, USA", "label": "MorphoSys US Inc. [member]", "documentation": "MorphoSys US inc." } } }, "auth_ref": [] }, "mor_NASDAQBiotechIndexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NASDAQBiotechIndexMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NASDAQ biotech index", "label": "NASDAQ Biotech Index [member]", "documentation": "NASDAQ Biotech index." } } }, "auth_ref": [] }, "ifrs-full_NetDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDeferredTaxLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Liability", "label": "Net deferred tax liabilities" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r363" ] }, "mor_NetFinancialLiabilitiesFromCollaborationsReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NetFinancialLiabilitiesFromCollaborationsReversal", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net financial liabilities from collaborations, reversal", "label": "Net Financial Liabilities From Collaborations, Reversal", "documentation": "Net Financial Liabilities From Collaborations, Reversal" } } }, "auth_ref": [] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on Foreign Exchange", "label": "Net foreign exchange gain" } }, "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r356", "r369" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_OtherExpenseByNature", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on Foreign Exchange", "label": "Net foreign exchange loss" } }, "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r356", "r369" ] }, "mor_NetGainFromDisposalOfAvailableforsaleFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NetGainFromDisposalOfAvailableforsaleFinancialAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain from disposal of available-for-sale financial assets", "label": "Net gain from disposal of availableforsale financial assets", "documentation": "Net gain from disposal of available-for-sale financial assets." } } }, "auth_ref": [] }, "mor_NetLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NetLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net lease liabilities", "label": "Net Lease Liabilities", "documentation": "Net lease liabilities." } } }, "auth_ref": [] }, "mor_NetLiabilitiesAndOtherChangesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NetLiabilitiesAndOtherChangesLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Liabilities and other Changes [Line Items]", "label": "Net Liabilities and other Changes [Line Items]", "documentation": "Net Liabilities and other Changes [Line Items]" } } }, "auth_ref": [] }, "mor_NetLiabilitiesAndOtherChangesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NetLiabilitiesAndOtherChangesTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Liabilities and other Changes [Table]", "label": "Net Liabilities and other Changes [Table]", "documentation": "Net Liabilities and other Changes [Table]" } } }, "auth_ref": [] }, "mor_NominalAmountBondIssuedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NominalAmountBondIssuedPercentage", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal amount bond", "label": "Nominal Amount Bond Issued Percentage", "documentation": "Nominal Amount Bond Issued Percentage" } } }, "auth_ref": [] }, "mor_NonCashEffectiveNetChangeInFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonCashEffectiveNetChangeInFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharma", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma", "label": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma", "documentation": "Non Cash Effective Net Change in Financial Liabilities from Future Payments to Royalty Pharma" } } }, "auth_ref": [] }, "mor_NonCashEffectiveNetChangesInFinancialAssetsOrFinancialLiabilitiesFromCollaborations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonCashEffectiveNetChangesInFinancialAssetsOrFinancialLiabilitiesFromCollaborations", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Non Cash Effective Net Change in Financial Assets / Liabilities from Collaborations", "label": "Non Cash Effective Net Changes In Financial Assets Or Financial Liabilities From Collaborations", "documentation": "Non Cash Effective Net Changes In Financial Assets Or Financial Liabilities From Collaborations ." } } }, "auth_ref": [] }, "mor_NonCashIncomeFromCapitalizationOfInvestmentInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonCashIncomeFromCapitalizationOfInvestmentInAssociates", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non Cash Income from Capitalization of Investment in Associates", "label": "Non Cash Income from Capitalization of Investment in Associates", "documentation": "Non Cash Income from Capitalization of Investment in Associates" } } }, "auth_ref": [] }, "mor_NonContractualObligationFiscalYearMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonContractualObligationFiscalYearMaturityTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Contractual Obligation Fiscal Year Maturity", "label": "Non-Contractual Obligation Fiscal Year Maturity [Table Text Block]", "documentation": "Non-Contractual Obligation Fiscal Year Maturity" } } }, "auth_ref": [] }, "mor_NonCurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonCurrentInvestments", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets", "label": "Non-current Investments", "documentation": "Non-current Investments" } } }, "auth_ref": [] }, "mor_NonCurrentPrepaidExpensesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NonCurrentPrepaidExpensesAndOtherAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid Expenses and Other Assets", "totalLabel": "Total", "terseLabel": "Prepaid Expenses and Other Assets", "label": "Non current Prepaid Expenses and Other Assets", "documentation": "Non current prepaid expenses and other assets." } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r46" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [member]", "label": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r46" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Current Assets", "terseLabel": "Non-Current Assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r27", "r144", "r314" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current Assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "mor_NoncurrentAssetsExcludingDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NoncurrentAssetsExcludingDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets, excluding deferred tax assets", "label": "Non-current assets, excluding deferred tax assets", "documentation": "Non-current assets, excluding deferred tax assets." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "thereof long-term", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r166" ] }, "mor_NoncurrentConvertibleBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NoncurrentConvertibleBond", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Bonds", "label": "Noncurrent Convertible Bond", "documentation": "Noncurrent Convertible Bond." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Non-Current Financial Asset", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r229" ] }, "ifrs-full_NoncurrentFinancialAssetsAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialAssetsAtAmortisedCost", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets", "label": "Non-current financial assets at amortised cost" } }, "en": { "role": { "documentation": "The amount of non-current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_NoncurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current Financial Liabilities", "negatedTotalLabel": "Non-Current Financial Liabilities", "label": "Non-current financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r229" ] }, "mor_NoncurrentFinancialLiabilitiesFromCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NoncurrentFinancialLiabilitiesFromCollaboration", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Liabilities from Collaborations", "label": "Noncurrent Financial Liabilities from Collaboration", "documentation": "Noncurrent Financial Liabilities from Collaboration." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r176" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Current Liabilities", "terseLabel": "Non-Current Liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r28", "r146", "r314" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Current Liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "mor_NoncurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NoncurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails": { "parentTag": "mor_NonCurrentPrepaidExpensesAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Non-current prepaid expenses", "documentation": "Non-current prepaid expenses" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentRestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current restricted cash", "label": "Non-current restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofMaturityAnalysisofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less than 1 Year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r24", "r185", "r186", "r196", "r332", "r337" ] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Notes and other explanatory information [abstract]", "label": "Notes and other explanatory information [abstract]" } } }, "auth_ref": [] }, "mor_NotesToTheBalanceSheetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NotesToTheBalanceSheetTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Notes to the Balance Sheet", "label": "Notes to the Balance Sheet [Text Block]", "documentation": "Notes to the Balance Sheet" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal value of the convertible bond", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r353" ] }, "mor_NovartisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NovartisMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis", "label": "Novartis [Member]", "documentation": "Novartis" } } }, "auth_ref": [] }, "mor_NumberOfAmericanDepositorySharesHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfAmericanDepositorySharesHeld", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of American Depository Shares held", "label": "Number Of American Depository Shares Held", "documentation": "Number Of American Depository Shares Held" } } }, "auth_ref": [] }, "mor_NumberOfBondsIssued": { "xbrltype": "integerItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfBondsIssued", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of bonds issued", "label": "Number Of Bonds Issued", "documentation": "Number Of Bonds Issued" } } }, "auth_ref": [] }, "mor_NumberOfCashGeneratingUnits": { "xbrltype": "integerItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfCashGeneratingUnits", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesImpairmentofNonFinancialAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of cash generating units", "label": "Number Of Cash Generating Units", "documentation": "Number Of Cash Generating Units" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r353" ] }, "mor_NumberOfEmployeesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfEmployeesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Employees [Line Items]", "label": "Number Of Employees [Line Items]", "documentation": "Number Of Employees [Line Item] ." } } }, "auth_ref": [] }, "mor_NumberOfEmployeesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfEmployeesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number Of Employees [Table]", "label": "Number Of Employees [Table]", "documentation": "Number Of Employees [Table] ." } } }, "auth_ref": [] }, "mor_NumberOfGrantedSubscriptionRights": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfGrantedSubscriptionRights", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of granted subscription rights", "label": "Number Of Granted Subscription Rights", "documentation": "Number Of Granted Subscription Rights" } } }, "auth_ref": [] }, "mor_NumberOfInstrumentsExercisableOnReportingDate": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfInstrumentsExercisableOnReportingDate", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments exercisable on reporting date (in shares)", "label": "Number of instruments exercisable on reporting date", "documentation": "Number of instruments exercisable on reporting date" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable shares (in shares)", "label": "Number of instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } } }, "auth_ref": [ "r323", "r324" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions (in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r210", "r388" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion to Shares (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeitures (in shares)", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r198", "r203", "r206" ] }, "mor_NumberOfPerformancePeriods": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfPerformancePeriods", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance periods", "label": "Number Of Performance Periods", "documentation": "Number Of Performance Periods" } } }, "auth_ref": [] }, "mor_NumberOfPerformanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfPerformanceShares", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance shares (in shares)", "label": "Number of Performance Shares", "documentation": "Number of Performance Shares" } } }, "auth_ref": [] }, "mor_NumberOfRestrictedSharesExercisableInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfRestrictedSharesExercisableInShareBasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of restricted shares exercisable in share based payment arrangement (in shares)", "label": "Number of Restricted Shares Exercisable in Share Based Payment Arrangement", "documentation": "Number of Restricted Shares Exercisable in Share Based Payment Arrangement" } } }, "auth_ref": [] }, "mor_NumberOfRestrictedStockUnitsUnvested": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfRestrictedStockUnitsUnvested", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of restricted stock units unvested (in shares)", "label": "Number of restricted stock units unvested", "documentation": "Number of restricted stock units unvested" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable stock options (in shares)", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r204" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercises (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "terseLabel": "Expired (in shares)", "verboseLabel": "Adjustment due to performance criteria (in shares)", "label": "Number of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r202" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeitures (in shares)", "negatedTerseLabel": "Forfeitures (in shares)", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r200" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions (in shares)", "verboseLabel": "Granted (in shares)", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized shares (in shares)", "label": "Number of shares authorised" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r32" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares Issued (in shares)", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r351" ] }, "mor_NumberOfSharesIssuedToRelatedParties": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfSharesIssuedToRelatedParties", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number Of Shares Issued To Related Parties", "documentation": "Number of shares issued to related parties." } } }, "auth_ref": [] }, "mor_NumberOfSharesIssuedToRelatedPartiesDuringPeriodAdditions": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfSharesIssuedToRelatedPartiesDuringPeriodAdditions", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions (in shares)", "label": "Number Of Shares Issued To Related Parties During Period Additions", "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [] }, "mor_NumberOfSharesIssuedToRelatedPartiesSales": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfSharesIssuedToRelatedPartiesSales", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales (in shares)", "label": "Number Of Shares Issued To Related Parties Sales", "documentation": "Number of shares issued to related parties sales." } } }, "auth_ref": [] }, "mor_NumberOfSharesOfConditionalCapital": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfSharesOfConditionalCapital", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of conditional capital (in shares)", "label": "Number of shares of Conditional Capital", "documentation": "Number of shares of Conditional Capital" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r34" ] }, "mor_NumberOfSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfSubsidiaries", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesConsolidatedCompaniesandScopeofConsolidationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of subsidiaries", "label": "Number Of Subsidiaries", "documentation": "Number Of Subsidiaries" } } }, "auth_ref": [] }, "mor_NumberOfTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfTreasuryShares", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock shares (in shares)", "label": "Number Of Treasury Shares", "documentation": "Number of treasury shares." } } }, "auth_ref": [] }, "mor_NumberOfVotingRightsAtAnnualGeneralMeeting": { "xbrltype": "decimalItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumberOfVotingRightsAtAnnualGeneralMeeting", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of voting rights at annual general meeting", "label": "Number of Voting Rights At Annual General Meeting", "documentation": "Number of Voting Rights At Annual General Meeting" } } }, "auth_ref": [] }, "mor_NumeratorAbstractAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "NumeratorAbstractAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator (in \u20ac)", "label": "Numerator Abstract [Abstract]", "documentation": "Numerator [Abstract] ." } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Office Equipment", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r294" ] }, "mor_OffsettingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OffsettingMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting", "label": "Offsetting [Member]", "documentation": "Offsetting Member." } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total Operating Expenses", "label": "Operating expense" } }, "en": { "role": { "documentation": "The amount of all operating expenses." } } }, "auth_ref": [ "r361" ] }, "mor_OperatingExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OperatingExpenseAbstract", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Operating Expense [abstract]", "documentation": "Operating expense." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares [member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r85", "r360" ] }, "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAdjustmentsToReconcileProfitLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other Cash and Non-Cash Expenses (+) / Income (-)", "label": "Other adjustments to reconcile profit (loss)" } }, "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]" } } }, "auth_ref": [ "r119" ] }, "ifrs-full_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Other Assets", "label": "Other assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r357" ] }, "mor_OtherAuditRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherAuditRelatedCosts", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fees for Other Assurance Services", "label": "Other audit-related costs", "documentation": "Other audit-related costs" } } }, "auth_ref": [] }, "mor_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "other commitment", "documentation": "other commitment." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income", "terseLabel": "Other Comprehensive Income", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r5", "r38", "r43", "r149" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in Fair Value of Shares through Other Comprehensive Income", "label": "Other comprehensive income, net of tax, available-for-sale financial assets" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to available-for-sale financial assets. [Refer: Financial assets available-for-sale; Other comprehensive income]" } } }, "auth_ref": [ "r277", "r278" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign Currency Translation Differences from Consolidation", "terseLabel": "Foreign Currency Translation Differences from Consolidation", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r29", "r43" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value of Shares through Other Comprehensive Income", "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r29", "r43" ] }, "srt_OtherCurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OtherCurrencyMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Currency [Member]", "documentation": "Currency classified as other." } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities", "label": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_OtherCurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentNonfinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Non-Financial Assets", "label": "Other current non-financial assets" } }, "en": { "role": { "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r357" ] }, "mor_OtherCurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherCurrentPrepayments", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails": { "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Prepayments", "label": "Other Prepayments", "documentation": "Other current prepayments." } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_OtherDisposalsOfAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherDisposalsOfAssetsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other disposals of assets", "label": "Other disposals of assets [member]" } }, "en": { "role": { "documentation": "This member stands for disposals of assets that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r290" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Other Expenses", "negatedTotalLabel": "Other Expenses", "label": "Other expenses, by nature" } }, "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r45", "r281" ] }, "mor_OtherExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherExpensesAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Expenses", "label": "Other Expenses [Abstract]", "documentation": "Other Expenses" } } }, "auth_ref": [] }, "mor_OtherFeesAndOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherFeesAndOtherServices", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuditfeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Fees for Other Services", "label": "Other fees and other services", "documentation": "Other fees and other services" } } }, "auth_ref": [] }, "ifrs-full_OtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets", "label": "Other financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r15" ] }, "mor_OtherFinancialAssetsAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherFinancialAssetsAtAmortisedCostMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesNetGainsorLossesfromFinancialInstrumentsDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AC", "label": "Other financial assets at amortised cost [member]", "documentation": "Other financial assets at amortised cost." } } }, "auth_ref": [] }, "mor_OtherFinancialAssetsAtAmortizedCostLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherFinancialAssetsAtAmortizedCostLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets at Amortized Cost [Line Items]", "label": "Other Financial Assets at Amortized Cost [Line Items]", "documentation": "Other Financial Assets at Amortized Cost [Line Items]" } } }, "auth_ref": [] }, "mor_OtherFinancialAssetsAtAmortizedCostTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherFinancialAssetsAtAmortizedCostTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Financial Assets at Amortized Cost [Table]", "label": "Other Financial Assets at Amortized Cost [Table]", "documentation": "Other Financial Assets at Amortized Cost [Table]" } } }, "auth_ref": [] }, "mor_OtherFinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherFinancialAssetsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial assets", "label": "Other financial assets [Member]", "documentation": "Other financial assets" } } }, "auth_ref": [] }, "ifrs-full_OtherFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Other Financial Liabilities", "label": "Other financial liabilities" } }, "en": { "role": { "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r20" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "totalLabel": "Other Income", "label": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r80", "r281", "r282" ] }, "mor_OtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherIncomeAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "label": "Other Income [Abstract]", "documentation": "Other Income" } } }, "auth_ref": [] }, "mor_OtherInterestExpenseLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherInterestExpenseLeaseLiability", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails": { "parentTag": "mor_ImpactOnProfitOrLossDueToAdoptionOfLease", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofImpactofLeaseAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expenses on Lease Liabilities", "label": "Other Interest Expense (Lease Liability)", "documentation": "Other Interest Expense (Lease Liability)" } } }, "auth_ref": [] }, "mor_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherLiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities", "label": "Other Liabilities [member]", "documentation": "Other liabilities ." } } }, "auth_ref": [] }, "ifrs-full_OtherLongtermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherLongtermProvisions", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "periodStartLabel": "Non-current provision period start", "periodEndLabel": "Non-current provision period end", "label": "Other non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } } }, "auth_ref": [ "r30" ] }, "mor_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other" } } }, "auth_ref": [] }, "mor_OtherNonTaxProvisionsCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherNonTaxProvisionsCurrentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions, current", "label": "Other Non-Tax Provisions, Current [Member]", "documentation": "Other Non-Tax Provisions, Current" } } }, "auth_ref": [] }, "mor_OtherNonTaxProvisionsNonCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherNonTaxProvisionsNonCurrentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions, non-current", "label": "Other Non-Tax Provisions, Non-current [Member]", "documentation": "Other Non-Tax Provisions, Non-current" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails": { "parentTag": "mor_NonCurrentPrepaidExpensesAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofNonCurrentPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_OtherNoncurrentNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentNonfinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Non-Financial Assets", "label": "Other non-current non-financial assets" } }, "en": { "role": { "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } } }, "auth_ref": [ "r357" ] }, "ifrs-full_OtherNonfinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNonfinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "thereof Non-Financial Liabilities", "label": "Other non-financial liabilities" } }, "en": { "role": { "documentation": "The amount of non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]" } } }, "auth_ref": [ "r357" ] }, "mor_OtherOperatingExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherOperatingExpensesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Costs", "label": "Other operating expenses [member]", "documentation": "Other operating expenses." } } }, "auth_ref": [] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Provisions period start", "periodEndLabel": "Provisions period end", "label": "Other provisions" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r30", "r95" ] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other provisions [member]", "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r99" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r285" ] }, "mor_OtherReceivablesFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherReceivablesFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Receivables", "label": "OtherReceivables, financial assets", "documentation": "OtherReceivables, financial assets" } } }, "auth_ref": [] }, "mor_OtherReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherReceivablesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Receivables [Line Items]", "label": "Other Receivables [Line Items]", "documentation": "Other Receivables [Line Items]" } } }, "auth_ref": [] }, "mor_OtherReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherReceivablesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Receivables [Table]", "label": "Other Receivables [Table]", "documentation": "Other Receivables [Table]" } } }, "auth_ref": [] }, "mor_OtherReceivablesThereofNonFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "OtherReceivablesThereofNonFinancialAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Non-Financial Assets", "label": "Other receivables, thereof non-financial assets", "documentation": "Other receivables, thereof non-financial assets" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "periodStartLabel": "Current provision period start", "periodEndLabel": "Current provision period end", "label": "Other current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Other Effects", "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r33" ] }, "mor_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PatentsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Patents Member." } } }, "auth_ref": [] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment for transaction costs for repurchases of own convertible bonds", "label": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r378" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments for Costs from Issuing Shares", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r378" ] }, "mor_PaymentsFromDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PaymentsFromDerivativeFinancialInstruments", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments for Derivative Financial Instruments", "label": "Payments from derivative financial instruments", "documentation": "Payments from derivative financial instruments" } } }, "auth_ref": [] }, "mor_PaymentsFromHIBio": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PaymentsFromHIBio", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments from HI-Bio", "label": "Payments from HI-Bio", "documentation": "Payments from HI-Bio" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments for Principal Elements of Lease Payments", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r308" ] }, "ifrs-full_PaymentsToAndOnBehalfOfEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsToAndOnBehalfOfEmployees", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to and on behalf of employees", "label": "Payments to and on behalf of employees" } }, "en": { "role": { "documentation": "The cash outflow to, and on behalf of, employees." } } }, "auth_ref": [ "r304" ] }, "mor_PelabresibMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PelabresibMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pelabresib", "label": "Pelabresib [Member]", "documentation": "Pelabresib" } } }, "auth_ref": [] }, "mor_PercentageOfAccountsReceivable": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfAccountsReceivable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of accounts receivable", "label": "Percentage of accounts receivable", "documentation": "Percentage of accounts receivable." } } }, "auth_ref": [] }, "mor_PercentageOfBeneficiariesLeavingCompany": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfBeneficiariesLeavingCompany", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of beneficiaries leaving company", "label": "Percentage Of Beneficiaries Leaving Company", "documentation": "Percentage Of Beneficiaries Leaving Company" } } }, "auth_ref": [] }, "mor_PercentageOfFixedAnnualGrossSalaryForProvidentFund": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfFixedAnnualGrossSalaryForProvidentFund", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fixed annual gross salary for provident fund", "label": "Percentage Of Fixed Annual Gross Salary For Provident Fund", "documentation": "Percentage Of Fixed Annual Gross Salary For Provident Fund" } } }, "auth_ref": [] }, "mor_PercentageOfFixedAnnualGrossSalaryForRetirementPlanBenefit": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfFixedAnnualGrossSalaryForRetirementPlanBenefit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fixed annual gross salary for retirement plan benefit", "label": "Percentage Of Fixed Annual Gross Salary For Retirement Plan Benefit", "documentation": "Percentage Of Fixed Annual Gross Salary For Retirement Plan Benefit" } } }, "auth_ref": [] }, "mor_PercentageOfFutureDevelopmentCostsForClinicalTrials": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfFutureDevelopmentCostsForClinicalTrials", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of future development costs for clinical trials", "label": "Percentage Of Future Development Costs For Clinical Trials", "documentation": "Percentage of future development costs for clinical trials." } } }, "auth_ref": [] }, "mor_PercentageOfFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfFutureNetSales", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of future net sales", "label": "Percentage of future Net Sales", "documentation": "Percentage of future Net Sales" } } }, "auth_ref": [] }, "mor_PercentageOfPremiumOfferedVolumeWeightedAverageSharePrice": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfPremiumOfferedVolumeWeightedAverageSharePrice", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of premium offered", "label": "Percentage Of Premium Offered Volume-Weighted Average Share Price", "documentation": "Percentage Of Premium Offered Volume-Weighted Average Share Price" } } }, "auth_ref": [] }, "mor_PercentageOfRoyaltiesFromNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfRoyaltiesFromNetSales", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of royalties from net sales", "label": "Percentage of Royalties from net sales", "documentation": "Percentage of Royalties from net sales" } } }, "auth_ref": [] }, "mor_PercentageOfSharesDesignated": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfSharesDesignated", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares designated", "label": "Percentage Of Shares Designated", "documentation": "Percentage Of Shares Designated" } } }, "auth_ref": [] }, "mor_PercentageOfSharesInDevelopmentCost": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfSharesInDevelopmentCost", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares in development cost", "label": "Percentage Of Shares In Development Cost", "documentation": "Percentage of shares in development cost." } } }, "auth_ref": [] }, "mor_PercentageOfSharesVestedIfLessThanZeroPercentOfPerformanceCriteriaIsMet": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOfSharesVestedIfLessThanZeroPercentOfPerformanceCriteriaIsMet", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares vested", "label": "Percentage Of Shares Vested, If Less Than Zero Percent Of Performance Criteria Is Met", "documentation": "Percentage Of Shares Vested, If Less Than Zero Percent Of Performance Criteria Is Met" } } }, "auth_ref": [] }, "mor_PercentageOnShareOfProfitLossOfAssociatesAndJointVentures": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PercentageOnShareOfProfitLossOfAssociatesAndJointVentures", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage on share of profit loss of associates and joint ventures", "label": "Percentage On Share Of Profit Loss Of Associates And Joint Ventures", "documentation": "Percentage on share of profit loss of associates and joint ventures." } } }, "auth_ref": [] }, "mor_PerformanceCriteriaPercentageShareUnitPlan": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceCriteriaPercentageShareUnitPlan", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance criteria", "label": "Performance Criteria Percentage Share Unit Plan", "documentation": "Performance Criteria Percentage Share Unit Plan" } } }, "auth_ref": [] }, "ifrs-full_PerformanceObligationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [axis]", "label": "Performance obligations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_PerformanceObligationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations [member]", "label": "Performance obligations [member]" } }, "en": { "role": { "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used." } } }, "auth_ref": [ "r171" ] }, "ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsSatisfiedAtPointInTimeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At a Point in Time", "label": "Performance obligations satisfied at point in time [member]" } }, "en": { "role": { "documentation": "This member stands for performance obligations satisfied at a point in time. An entity satisfies a performance obligation at a point in time, if the performance obligation is not satisfied over time. [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r174" ] }, "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PerformanceObligationsSatisfiedOverTimeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over Time", "label": "Performance obligations satisfied over time [member]" } }, "en": { "role": { "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]" } } }, "auth_ref": [ "r173" ] }, "mor_PerformanceRelatedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceRelatedCompensation", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-related compensation", "label": "Performance-related compensation", "documentation": "Performance-related compensation" } } }, "auth_ref": [] }, "mor_PerformanceRequirementsForShareBasedPaymentArrangementPerformanceAndVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceRequirementsForShareBasedPaymentArrangementPerformanceAndVestingPeriod", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Term of Program in Years", "label": "Performance Requirements For Share-Based Payment Arrangement, Performance And Vesting Period", "documentation": "Performance Requirements For Share-Based Payment Arrangement, Performance And Vesting Period" } } }, "auth_ref": [] }, "mor_PerformanceShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceShareMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance share", "label": "Performance Share [Member]", "documentation": "Performance share." } } }, "auth_ref": [] }, "mor_PerformanceShareUnitProgramsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceShareUnitProgramsLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Unit Programs [Line Items]", "label": "Performance Share Unit Programs [Line Items]", "documentation": "Performance Share Unit Programs [Line Items]" } } }, "auth_ref": [] }, "mor_PerformanceShareUnitProgramsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceShareUnitProgramsTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Unit Programs [Table]", "label": "Performance Share Unit Programs [Table]", "documentation": "Performance Share Unit Programs [Table]" } } }, "auth_ref": [] }, "mor_PerformanceShareUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceShareUnits", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance share units (in shares)", "label": "Performance share units", "documentation": "Performance share units" } } }, "auth_ref": [] }, "mor_PerformanceShareUnitsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceShareUnitsGranted", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance share units granted (in shares)", "label": "Performance Share Units granted", "documentation": "Performance Share Units granted" } } }, "auth_ref": [] }, "mor_PerformanceSharesOfRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceSharesOfRelatedPartiesLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares of Related Parties [Line Items]", "label": "Performance Shares of Related Parties [Line Items]", "documentation": "Performance Shares of Related Parties [Line Items]" } } }, "auth_ref": [] }, "mor_PerformanceSharesOfRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceSharesOfRelatedPartiesTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares of Related Parties [Table]", "label": "Performance Shares of Related Parties [Table]", "documentation": "Performance Shares of Related Parties [Table]" } } }, "auth_ref": [] }, "mor_PerformanceUnrelatedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PerformanceUnrelatedCompensation", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-unrelated compensation", "label": "Performance-unrelated compensation", "documentation": "Performance-unrelated compensation" } } }, "auth_ref": [] }, "mor_PeriodOfAbsenceShareBasePaymentCriteria": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PeriodOfAbsenceShareBasePaymentCriteria", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of absence share base payment criteria", "label": "Period of Absence Share Base Payment Criteria", "documentation": "Period of Absence Share Base Payment Criteria" } } }, "auth_ref": [] }, "mor_PermanentImprovementsToPropertyOrBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PermanentImprovementsToPropertyOrBuildingsMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent Improvements to Property/Buildings", "label": "Permanent Improvements to Property or Buildings [member]", "documentation": "Permanent improvements to property or buildings." } } }, "auth_ref": [] }, "mor_PersonnelExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PersonnelExpensesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofCostofSalesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofGeneralandAdministrativeExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel Expenses", "label": "Personnel Expenses [member]", "documentation": "Personnel expenses." } } }, "auth_ref": [] }, "mor_PortionOfShareOptionsForfeitedInCaseOfAbsence": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PortionOfShareOptionsForfeitedInCaseOfAbsence", "presentation": [ "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion of share options forfeited in case of absence", "label": "Portion Of Share Options Forfeited In Case Of Absence", "documentation": "Portion Of Share Options Forfeited In Case Of Absence" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesAdditionalinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs for defined-contribution plans", "label": "Post-employment benefit expense, defined contribution plans" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r67" ] }, "mor_Pre2024LongTermIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "Pre2024LongTermIncentivePlansMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-2024 Long-Term Incentive Plans", "label": "Pre-2024 Long-Term Incentive Plans [Member]", "documentation": "Pre-2024 Long-Term Incentive Plans" } } }, "auth_ref": [] }, "mor_PremiumFromCapitalIncreaseByIncyte": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PremiumFromCapitalIncreaseByIncyte", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "auth_ref": [] }, "mor_PrepaidExpensesAndOtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PrepaidExpensesAndOtherCurrentAssetsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets [Line Items]", "label": "Prepaid Expenses and Other Current Assets [Line Items]", "documentation": "Prepaid Expenses and Other Current Assets [Line Items]" } } }, "auth_ref": [] }, "mor_PrepaidExpensesAndOtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PrepaidExpensesAndOtherCurrentAssetsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets [Table]", "label": "Prepaid Expenses and Other Current Assets [Table]", "documentation": "Prepaid Expenses and Other Current Assets [Table]" } } }, "auth_ref": [] }, "mor_PriorYearTaxLossesCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PriorYearTaxLossesCarryforwards", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax Losses from Prior Years", "label": "Prior Year Tax Losses Carryforwards", "documentation": "Prior Year Tax Losses Carryforwards." } } }, "auth_ref": [] }, "mor_ProceedsFromDerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ProceedsFromDerivativeFinancialInstruments", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Receipts from Derivative Financial Instruments", "label": "Proceeds from derivative financial instruments", "documentation": "Proceeds from derivative financial instruments." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Receipts from Sales of Other Financial Assets", "label": "Proceeds from disposal or maturity of available-for-sale financial assets" } }, "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } } }, "auth_ref": [ "r391" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Proceeds from Issuing Shares", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r307" ] }, "ifrs-full_ProceedsFromNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromNoncurrentBorrowings", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Receipts (+) / Cash Payments (-) from Financing from Collaborations", "label": "Proceeds from non-current borrowings" } }, "en": { "role": { "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r378" ] }, "ifrs-full_ProceedsFromSalesOfInterestsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromSalesOfInterestsInAssociates", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Income from Sales of Shares of Investment in Associates", "label": "Proceeds from sales of interests in associates" } }, "en": { "role": { "documentation": "The cash inflow from sales of interests in associates. [Refer: Associates [member]]" } } }, "auth_ref": [ "r377" ] }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Receipts from Sales of Property, Plant and Equipment", "label": "Proceeds from sales of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r306" ] }, "mor_ProceedsInConnectionWithConvertibleBondsGrantedToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ProceedsInConnectionWithConvertibleBondsGrantedToRelatedParties", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Proceeds in Connection with Exercised Stock (2021) and Convertible Bonds (2020)", "label": "Convertible Bonds", "documentation": "Proceeds in connection with convertible bonds granted to related parties." } } }, "auth_ref": [] }, "mor_ProductSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ProductSalesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product Sales, Net", "label": "Product Sales [Member]", "documentation": "Product Sales [Member]." } } }, "auth_ref": [] }, "mor_ProductionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ProductionMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Production", "label": "Production [Member]", "documentation": "Production" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Consolidated Net Profit / (Loss)", "terseLabel": "Consolidated Net Profit / (Loss)", "verboseLabel": "Consolidated Net Profit / (Loss)", "negatedTerseLabel": "Consolidated net loss", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r4", "r37", "r118", "r138", "r140", "r252", "r254", "r314", "r320" ] }, "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Profit used in calculating Diluted Earnings per Share", "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r87" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Profit / (Loss)", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r298", "r361" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r13", "r60" ] }, "mor_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Property, Plant and Equipment [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r61", "r299", "r319" ] }, "mor_PropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PropertyPlantAndEquipmentTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Property, Plant and Equipment [Table]" } } }, "auth_ref": [] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Utilization", "label": "Provision used, other provisions" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_Provisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Provisions", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Provisions" } }, "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } } }, "auth_ref": [ "r19" ] }, "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfAvailableforsaleFinancialAssets", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments to Acquire Other Financial Assets", "label": "Purchase of available-for-sale financial assets" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } } }, "auth_ref": [ "r391" ] }, "mor_PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PurchaseOfFinancialAssetsAtFairValueThroughOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Receipts from Sales of Shares at Fair Value through Other Comprehensive Income", "label": "Purchase of financial assets at fair value through other comprehensive income", "documentation": "Purchase of financial assets at fair value through other comprehensive income." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments to Acquire Intangible Assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r305" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments to Acquire Property, Plant and Equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r305" ] }, "mor_PurchaseOfSharesEstablishment": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PurchaseOfSharesEstablishment", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of Shares / Establishment", "label": "Purchase of Shares / Establishment", "documentation": "Purchase of Shares / Establishment" } } }, "auth_ref": [] }, "mor_PurchasePriceNominalValueBase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PurchasePriceNominalValueBase", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price nominal value base", "label": "Purchase Price Nominal Value Base", "documentation": "Purchase Price Nominal Value Base" } } }, "auth_ref": [] }, "mor_PurchasePricePerBaseNominalValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "PurchasePricePerBaseNominalValueAmount", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price nominal value per base", "label": "Purchase Price Per Base Nominal Value, Amount", "documentation": "Purchase Price Per Base Nominal Value, Amount" } } }, "auth_ref": [] }, "mor_RDProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RDProgramMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Program", "label": "R&D Program [Member]", "documentation": "R&D Program" } } }, "auth_ref": [] }, "mor_RDProgramsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RDProgramsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Programs [Line Items]", "label": "R&D Programs [Line Items]", "documentation": "R&D Programs" } } }, "auth_ref": [] }, "mor_RDProgramsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RDProgramsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Programs [Table]", "label": "R&D Programs [Table]", "documentation": "R&D Programs" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r165", "r190", "r206", "r315", "r316", "r389" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges [member]", "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r165", "r190", "r206", "r315", "r316", "r389" ] }, "mor_ReceivablesAndOtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReceivablesAndOtherAssetsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables and Other Assets", "label": "Receivables and other assets [member]", "documentation": "Receivables and other assets." } } }, "auth_ref": [] }, "ifrs-full_ReceivablesDueFromAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReceivablesDueFromAssociates", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables due from associates", "label": "Receivables due from associates" } }, "en": { "role": { "documentation": "The amount of receivables due from associates. [Refer: Associates [member]]" } } }, "auth_ref": [ "r358" ] }, "ifrs-full_ReceivablesFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReceivablesFromContractsWithCustomers", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable from customer", "label": "Receivables from contracts with customers" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due." } } }, "auth_ref": [ "r166", "r168" ] }, "mor_ReceivablesFromInputTaxSurplus": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReceivablesFromInputTaxSurplus", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails": { "parentTag": "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables due from Tax Authorities from Input Tax Surplus", "label": "Receivables due from Tax Authorities from Input Tax Surplus", "documentation": "Receivables from input tax surplus." } } }, "auth_ref": [] }, "mor_ReclassificationHierarchyLevelsFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReclassificationHierarchyLevelsFairValueMeasurementAssets", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification hierarchy levels", "label": "Reclassification Hierarchy Levels, Fair Value Measurement, Assets", "documentation": "Reclassification Hierarchy Levels, Fair Value Measurement, Assets" } } }, "auth_ref": [] }, "mor_ReclassificationToInvestmentsInAssociatesFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReclassificationToInvestmentsInAssociatesFairValueMeasurementAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification to investment in associates", "label": "Reclassification To Investments in Associates, Fair Value Measurement, Assets", "documentation": "Reclassification To Investments in Associates, Fair Value Measurement, Assets" } } }, "auth_ref": [] }, "mor_ReclassificationToTemporaryDifference": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReclassificationToTemporaryDifference", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total tax losses", "label": "Reclassification To Temporary Difference", "documentation": "Reclassification To Temporary Difference ." } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets and goodwill [abstract]", "label": "Reconciliation of changes in intangible assets and goodwill [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]", "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "mor_RedemptionPercentageBasedOnOutstandingNominalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RedemptionPercentageBasedOnOutstandingNominalAmount", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption percentage based on outstanding nominal amount", "label": "Redemption Percentage Based on Outstanding Nominal Amount", "documentation": "Redemption Percentage, Based on Outstanding Nominal Amount" } } }, "auth_ref": [] }, "mor_RedemptionPercentageOfDebtInstrumentWhenMarketPriceOfSharesFallDown": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RedemptionPercentageOfDebtInstrumentWhenMarketPriceOfSharesFallDown", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption percentage of debt instrument when market price of shares fall down", "label": "Redemption Percentage of Debt Instrument When Market Price of Shares Fall Down", "documentation": "Redemption Percentage of Debt Instrument When Market Price of Shares Fall Down" } } }, "auth_ref": [] }, "mor_ReductionInCashFlowForecast": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReductionInCashFlowForecast", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in cash flow forecast", "label": "Reduction in Cash Flow Forecast", "documentation": "Reduction in Cash Flow Forecast" } } }, "auth_ref": [] }, "mor_ReductionInConditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReductionInConditionalCapital", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in conditional capital", "label": "Reduction In Conditional Capital", "documentation": "Reduction In Conditional Capital" } } }, "auth_ref": [] }, "mor_ReductionInWorkforceDueToBusinessCombinationPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReductionInWorkforceDueToBusinessCombinationPercentage", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction In Workforce Due To Business Combination, Percentage", "label": "Reduction In Workforce Due To Business Combination, Percentage", "documentation": "Reduction In Workforce Due To Business Combination, Percentage" } } }, "auth_ref": [] }, "mor_RelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RelatedPartiesLineItems", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties [Line Items]", "label": "Related Parties [Line Items]", "documentation": "Related Parties [Line Items]" } } }, "auth_ref": [] }, "mor_RelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RelatedPartiesTable", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties [Table]", "label": "Related Parties [Table]", "documentation": "Related Parties [Table]" } } }, "auth_ref": [] }, "mor_RemainingPerformancePeriodForShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemainingPerformancePeriodForShareBasedPaymentArrangement", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Performance Term of Program in Years", "label": "Remaining Performance Period For Share-Based Payment Arrangement", "documentation": "Remaining Performance Period For Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "mor_RemunerationOfKeyManagementPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemunerationOfKeyManagementPersonnelLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration of Key Management Personnel [Line Items]", "label": "Remuneration of Key Management Personnel [Line Items]", "documentation": "Remuneration of Key Management Personnel [Line Items]" } } }, "auth_ref": [] }, "mor_RemunerationOfKeyManagementPersonnelTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemunerationOfKeyManagementPersonnelTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration of Key Management Personnel [Table]", "label": "Remuneration of Key Management Personnel [Table]", "documentation": "Remuneration of Key Management Personnel [Table]" } } }, "auth_ref": [] }, "mor_RemunerationOfSupervisoryBoard": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemunerationOfSupervisoryBoard", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration of supervisory board", "label": "Remuneration of Supervisory Board", "documentation": "Remuneration of Supervisory Board" } } }, "auth_ref": [] }, "mor_RemunerationOfSupervisoryBoardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemunerationOfSupervisoryBoardLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration of Supervisory Board [Line Items]", "label": "Remuneration of Supervisory Board [Line Items]", "documentation": "Remuneration of Supervisory Board [Line Items]" } } }, "auth_ref": [] }, "mor_RemunerationOfSupervisoryBoardTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RemunerationOfSupervisoryBoardTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remuneration of Supervisory Board [Table]", "label": "Remuneration of Supervisory Board [Table]", "documentation": "Remuneration of Supervisory Board [Table]" } } }, "auth_ref": [] }, "mor_RentDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RentDepositsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rent deposits", "label": "rent deposits[member]", "documentation": "Rent deposits." } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBondsNotesAndDebentures": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepaymentsOfBondsNotesAndDebentures", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Payments for Repurchases of own Convertible Bonds", "terseLabel": "Repayments of bonds, notes and debentures", "label": "Repayments of bonds, notes and debentures" } }, "en": { "role": { "documentation": "The cash outflow for repayments of bonds, notes and debentures." } } }, "auth_ref": [ "r378" ] }, "ifrs-full_RepaymentsOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepaymentsOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Receipts (+) / Cash Payments (-) from Financing from Collaborations", "label": "Repayments of non-current borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r378" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and Development", "terseLabel": "Research and development expenses", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r110" ] }, "mor_ResearchAndDevelopmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ResearchAndDevelopmentLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development [line items]", "label": "Research And Development [line items]", "documentation": "Research And Development [line items]" } } }, "auth_ref": [] }, "mor_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and development [member]", "documentation": "Research and development member." } } }, "auth_ref": [] }, "mor_ResearchAndDevelopmentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ResearchAndDevelopmentTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofResearchandDevelopmentExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research And Development [table]", "label": "Research And Development [table]", "documentation": "Disclosure of research and development." } } }, "auth_ref": [] }, "ifrs-full_ReserveOfChangeInValueOfTimeValueOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfChangeInValueOfTimeValueOfOptions", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve of change in value of time value of options", "label": "Reserve of change in value of time value of options" } }, "en": { "role": { "documentation": "A component of equity representing the accumulated change in the value of the time value of options when separating the intrinsic value and time value of an option contract and designating as the hedging instrument only the changes in the intrinsic value." } } }, "auth_ref": [ "r263", "r359" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherComprehensiveIncomeReserveDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve of exchange differences on translation", "label": "Reserve of exchange differences on translation" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r71" ] }, "mor_ReserveOfMiscellaneousOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ReserveOfMiscellaneousOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income Reserve", "label": "Reserve Of Miscellaneous Other Comprehensive Income", "documentation": "Reserve of miscellaneous other comprehensive income." } } }, "auth_ref": [] }, "ifrs-full_RestatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestatedMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Currently stated", "label": "Currently stated [member]" } }, "en": { "role": { "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used." } } }, "auth_ref": [ "r3", "r133", "r134", "r135", "r189", "r355" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [] }, "mor_RestrictedCashAsCollateralForCreditCards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RestrictedCashAsCollateralForCreditCards", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofPrepaidAssetsandOtherAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash as collateral for credit cards", "label": "Restricted Cash as Collateral for Credit Cards", "documentation": "Restricted Cash as Collateral for Credit Cards" } } }, "auth_ref": [] }, "mor_RestrictedStockUnitPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RestrictedStockUnitPlansLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Unit Plans [Line Items]", "label": "Restricted Stock Unit Plans [Line Items]", "documentation": "Restricted Stock -Unit Plans [Line Items]" } } }, "auth_ref": [] }, "mor_RestrictedStockUnitPlansTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RestrictedStockUnitPlansTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock -Unit Plans [Table]", "label": "Restricted Stock Unit Plans [Table]", "documentation": "Restricted Stock -Unit Plans [Table]" } } }, "auth_ref": [] }, "ifrs-full_RestructuringProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RestructuringProvision", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring provision", "label": "Restructuring provision" } }, "en": { "role": { "documentation": "The amount of provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions]" } } }, "auth_ref": [ "r300" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccumulatedDeficitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "negatedTerseLabel": "Accumulated deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r287", "r288" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r8", "r283" ] }, "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retrospective application and retrospective restatement [axis]", "label": "Retrospective application and retrospective restatement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r3", "r133", "r134", "r135" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues", "verboseLabel": "Revenue", "terseLabel": "Revenues", "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r40", "r148", "r220", "r247", "r253", "r259", "r260", "r262", "r281", "r282", "r314" ] }, "ifrs-full_RevenueFromGovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromGovernmentGrants", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_OtherIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Income", "label": "Income from government grants" } }, "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } } }, "auth_ref": [ "r368" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofOtherIncomeandExpensesFinanceIncomeandExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r152", "r248", "r257", "r353" ] }, "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsAdditionalDetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations fulfilled in previous periods", "label": "Revenue from performance obligations satisfied or partially satisfied in previous periods" } }, "en": { "role": { "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]" } } }, "auth_ref": [ "r170" ] }, "ifrs-full_RevenueFromRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromRoyalties", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalty income" } }, "en": { "role": { "documentation": "The amount of income arising from royalties." } } }, "auth_ref": [ "r353" ] }, "ifrs-full_RevenueFromSaleOfGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromSaleOfGoods", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product Sales", "label": "Revenue from sale of goods" } }, "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]" } } }, "auth_ref": [ "r353" ] }, "mor_RevenueRecognitionMilestoneMethodRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition milestone method revenue recognized", "label": "Revenue Recognition Milestone Method Revenue Recognized", "documentation": "Revenue recognition milestone method revenue recognized." } } }, "auth_ref": [] }, "mor_RevenueRecognizedForReceivedPrepaymentsAndServicesPerformed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RevenueRecognizedForReceivedPrepaymentsAndServicesPerformed", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues Recognized for Received Prepayments and Services Performed in the Financial Year", "label": "Revenue Recognized for Received Prepayments and Services Performed", "documentation": "Revenue Recognized for Received Prepayments and Services Performed." } } }, "auth_ref": [] }, "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Revenues Recognized in the Reporting Period that was included in the Contract Liability at the Beginning of the Period", "label": "Revenue that was included in contract liability balance at beginning of period" } }, "en": { "role": { "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]" } } }, "auth_ref": [ "r169" ] }, "mor_RightOfUseAssetsAndLeaseLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RightOfUseAssetsAndLeaseLiabilitiesLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use Assets and Lease Liabilities [Line Items]", "label": "Right of use Assets and Lease Liabilities [Line Items]", "documentation": "Right of use Assets and Lease Liabilities [Line Items]" } } }, "auth_ref": [] }, "mor_RightOfUseAssetsAndLeaseLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RightOfUseAssetsAndLeaseLiabilitiesTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use Assets and Lease Liabilities [Table]", "label": "Right of use Assets and Lease Liabilities [Table]", "documentation": "Right of use Assets and Lease Liabilities [Table]" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Assets", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r175", "r182" ] }, "ifrs-full_RightofuseAssetsIncreaseDecreaseInRevaluationSurplus": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssetsIncreaseDecreaseInRevaluationSurplus", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value adjustment", "label": "Right-of-use assets, increase (decrease) in revaluation surplus" } }, "en": { "role": { "documentation": "The increase (decrease) in the revaluation surplus that relates to right-of-use assets. [Refer: Revaluation surplus; Right-of-use assets]" } } }, "auth_ref": [ "r184" ] }, "mor_RiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RiskFreeInterestRate", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free Interest Rate in\u00a0%", "label": "Risk-free Interest Rate", "documentation": "Risk-free Interest Rate" } } }, "auth_ref": [] }, "mor_RoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RoyaltiesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalties [Member]", "documentation": "Royalties [Member] ." } } }, "auth_ref": [] }, "mor_RoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RoyaltyPharmaMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDFBInitialMeasurementLossDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialLiabilitiesfromFuturePaymentstoRoyaltyPharmaDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Pharma - Financial Liability", "label": "Royalty Pharma [Member]", "documentation": "Royalty Pharma" } } }, "auth_ref": [] }, "mor_RoyaltyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "RoyaltyPurchaseAgreementMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDevelopmentFundingBondAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty purchase agreement", "label": "Royalty Purchase Agreement [Member]", "documentation": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SaleOrIssueOfTreasuryShares", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Treasury Stock for Long-Term Incentive Programs", "negatedTerseLabel": "Sale or issue of treasury shares", "label": "Sale or issue of treasury shares" } }, "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r351" ] }, "mor_SaleOrIssueOfTreasurySharesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SaleOrIssueOfTreasurySharesShares", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of treasury stock for long-term incentive programs (in shares)", "label": "Sale or issue of treasury shares, shares", "documentation": "Sale or issue of treasury shares, shares." } } }, "auth_ref": [] }, "ifrs-full_SalesFairValueMeasurementAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesFairValueMeasurementAssets", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesInFairValueMeasurementFinancialAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Sales, fair value measurement, assets" } }, "en": { "role": { "documentation": "The decrease in the fair value measurement of assets resulting from sales. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r161" ] }, "mor_SatisfactionOfPerformanceObligationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SatisfactionOfPerformanceObligationsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Satisfaction of Performance Obligations [Line Items]", "label": "Satisfaction of Performance Obligations [Line Items]", "documentation": "Satisfaction of Performance Obligations [Line Items]" } } }, "auth_ref": [] }, "mor_SatisfactionOfPerformanceObligationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SatisfactionOfPerformanceObligationsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSatisfactionofPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Satisfaction of Performance Obligations [Table]", "label": "Satisfaction of Performance Obligations [Table]", "documentation": "Satisfaction of Performance Obligations [Table]" } } }, "auth_ref": [] }, "mor_SatisfactionOfPerformanceObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SatisfactionOfPerformanceObligationsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Satisfaction of Performance Obligations", "label": "Satisfaction of performance obligations [Table Text Block]", "documentation": "Satisfaction of performance obligations" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r390" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Previously Reported", "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [] }, "mor_ScheduleOfTreasuryStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ScheduleOfTreasuryStockTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Composition and Development of Treasury Stock", "label": "Schedule of Treasury Stock [Table Text Block]", "documentation": "Disclosure of detailed information about composition and development of treasury stock." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r339" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r341" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274" ] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [axis]", "label": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r92", "r167", "r252", "r296", "r322" ] }, "ifrs-full_SegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [member]", "label": "Segments [member]" } }, "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r92", "r167", "r258", "r296", "r322" ] }, "ifrs-full_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SellingExpense", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofSellingExpensesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling", "terseLabel": "Selling expenses", "label": "Selling expense" } }, "en": { "role": { "documentation": "The amount of expense relating to selling activities of the entity." } } }, "auth_ref": [ "r353" ] }, "mor_SellingExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SellingExpensesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAmortizationofIntangibleAssetsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofDepreciationofRightofUseAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling", "label": "Selling Expenses [member]", "documentation": "Selling expenses." } } }, "auth_ref": [] }, "mor_SellingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SellingMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfAverageNumberOfEmployeesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Selling", "label": "Selling [Member]", "documentation": "Selling [ Member] ." } } }, "auth_ref": [] }, "mor_SensitivityAnalysisAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis [axis]", "label": "Sensitivity Analysis [axis]", "documentation": "Sensitivity Analysis axis." } } }, "auth_ref": [] }, "mor_SensitivityAnalysisDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisDomain", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofForeignExchangeRateDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis [domain]", "label": "Sensitivity Analysis [domain]", "documentation": "Sensitivity analysis domain." } } }, "auth_ref": [] }, "mor_SensitivityAnalysisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis [Line Items]", "label": "Sensitivity Analysis [Line Items]", "documentation": "Sensitivity Analysis [Line Items]" } } }, "auth_ref": [] }, "mor_SensitivityAnalysisTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis [Table]", "label": "Sensitivity Analysis [Table]", "documentation": "Sensitivity Analysis [Table]" } } }, "auth_ref": [] }, "mor_SensitivityAnalysisVariableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisVariableLineItems", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis Variable [Line Items]", "label": "Sensitivity Analysis Variable [Line Items]", "documentation": "Sensitivity Analysis Variable [Line Items]" } } }, "auth_ref": [] }, "mor_SensitivityAnalysisVariableTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SensitivityAnalysisVariableTable", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofSensitivityAnalysisofVariableInterestRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis Variable [Table]", "label": "Sensitivity Analysis Variable [Table]", "documentation": "Sensitivity Analysis Variable [Table]" } } }, "auth_ref": [] }, "mor_ServiceFeesRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ServiceFeesRevenuesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Service Fees", "label": "Service Fees Revenues [Member]", "documentation": "Service Fees Revenues [Member] ." } } }, "auth_ref": [] }, "mor_ShareBasedCompensationByShareBasedPaymentArrangementAdjustmentDueToPerformanceCriteria": { "xbrltype": "sharesItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareBasedCompensationByShareBasedPaymentArrangementAdjustmentDueToPerformanceCriteria", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment due to performance criteria (in shares)", "label": "Share Based Compensation By Share Based Payment Arrangement Adjustment Due To Performance Criteria", "documentation": "Share Based Compensation By Share Based Payment Arrangement Adjustment Due To Performance Criteria" } } }, "auth_ref": [] }, "mor_ShareBasedPaymentArrangementIndividualPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareBasedPaymentArrangementIndividualPerformancePeriod", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Length for each performance period term", "label": "Share Based Payment Arrangement, Individual Performance Period", "documentation": "Share Based Payment Arrangement, Individual Performance Period" } } }, "auth_ref": [] }, "mor_ShareBasedPaymentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareBasedPaymentExpenseMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Expense", "label": "Share-based Payment Expense [Member]", "documentation": "Share-based Payment Expense" } } }, "auth_ref": [] }, "mor_ShareBasedPaymentsExpectedToBeMadeInNextTwelfeMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareBasedPaymentsExpectedToBeMadeInNextTwelfeMonths", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments expected to be made in next twelve months", "label": "Share-Based Payments Expected To Be Made In Next Twelfe Months", "documentation": "Share-Based Payments Expected To Be Made In Next Twelfe Months" } } }, "auth_ref": [] }, "mor_ShareBasedPaymentsVestingRightsMinimumShareholding": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareBasedPaymentsVestingRightsMinimumShareholding", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum shareholding percentage", "label": "Share Based Payments , Vesting Rights, Minimum Shareholding", "documentation": "Share Based Payments , Vesting Rights, Minimum Shareholding" } } }, "auth_ref": [] }, "mor_ShareCapitalAuthorisedIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareCapitalAuthorisedIncrease", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAuthorizedCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital authorised increase", "label": "Share Capital Authorised Increase", "documentation": "Share Capital Authorised Increase" } } }, "auth_ref": [] }, "mor_ShareCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShareCapitalPercentage", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital percentage", "label": "Share Capital Percentage", "documentation": "Share Capital Percentage" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAdditionalPaidinCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares issuance cost", "label": "Share issue related cost" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r351" ] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Share of Loss of Associates accounted for using the Equity Method", "label": "Share of profit (loss) of associates accounted for using equity method" } }, "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } } }, "auth_ref": [ "r361" ] }, "ifrs-full_ShareOfProfitLossOfContinuingOperationsOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfContinuingOperationsOfAssociatesAndJointVenturesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share of Loss of Associates accounted for using the Equity Method", "label": "Share of profit (loss) from continuing operations of associates and joint ventures accounted for using equity method" } }, "en": { "role": { "documentation": "The entity's share of the profit (loss) from continuing operations of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Continuing operations [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss) from continuing operations]" } } }, "auth_ref": [ "r155" ] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements", "label": "Share-based payment arrangements [member]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r207" ] }, "mor_SharedBasedPaymentPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SharedBasedPaymentPrograms", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofObligationsarisingfromLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment programs", "label": "Shared Based Payment Programs", "documentation": "Future minimum payments performance share and unit programs." } } }, "auth_ref": [] }, "mor_SharonCurranMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SharonCurranMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sharon Curran", "label": "Sharon Curran [Member]", "documentation": "Sharon Curran." } } }, "auth_ref": [] }, "mor_ShortTermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ShortTermDepositsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Deposits, Current Portion", "label": "Short term deposits [member]", "documentation": "Short term deposits [member]" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialInformationInvestmentinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentinAssociatesAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInvestmentsinAssociatesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associates [axis]", "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r82", "r83", "r157" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofConsolidationMethodsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries [axis]", "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r82", "r83", "r156" ] }, "mor_SimplifiedImpairmentModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SimplifiedImpairmentModelMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Simplified\u00a0Impairment\u00a0Model", "label": "Simplified Impairment Model [member]", "documentation": "Simplified impairment model." } } }, "auth_ref": [] }, "mor_SingleMostImportantCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SingleMostImportantCustomerMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Single most important customer", "label": "Single most important customer [member]", "documentation": "Single most important customer." } } }, "auth_ref": [] }, "mor_SocialSecurityContributionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SocialSecurityContributionsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Social Security Contributions", "label": "Social Security Contributions [Member]", "documentation": "Social Security Contributions" } } }, "auth_ref": [] }, "mor_SolidaritySurchargeRate": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SolidaritySurchargeRate", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Solidarity surcharge", "label": "Solidarity surcharge rate", "documentation": "Solidarity surcharge rate." } } }, "auth_ref": [] }, "mor_StageOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StageOneMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stage 1", "label": "Stage One [member]", "documentation": "Stage one." } } }, "auth_ref": [] }, "mor_StageThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StageThreeMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stage 3", "label": "Stage three [member]", "documentation": "Stage three." } } }, "auth_ref": [] }, "mor_StageTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StageTwoMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stage 2", "label": "Stage Two [member]", "documentation": "Stage two." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r266", "r275" ] }, "mor_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StatementLineItems", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [LineItems]", "label": "Statement [line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of cash flows [abstract]", "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [abstract]", "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of comprehensive income [abstract]", "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of financial position [abstract]", "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [] }, "mor_StepUpExpenseOnActuals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StepUpExpenseOnActuals", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Step-up expense on actuals", "label": "Step-Up Expense On Actuals", "documentation": "Step-Up Expense On Actuals" } } }, "auth_ref": [] }, "mor_StockOptionsOfRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StockOptionsOfRelatedPartiesLineItems", "presentation": [ "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options of Related Parties [Line Items]", "label": "Stock Options of Related Parties [Line Items]", "documentation": "Stock Options of Related Parties [Line Items]" } } }, "auth_ref": [] }, "mor_StockOptionsOfRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StockOptionsOfRelatedPartiesTable", "presentation": [ "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options of Related Parties [Table]", "label": "Stock Options of Related Parties [Table]", "documentation": "Stock Options of Related Parties [Table]" } } }, "auth_ref": [] }, "mor_StockOptionsPlansLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StockOptionsPlansLineItems", "presentation": [ "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options Plans [Line Items]", "label": "Stock Options Plans [Line Items]", "documentation": "Stock Options Plans [Line Items]" } } }, "auth_ref": [] }, "mor_StockOptionsPlansTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StockOptionsPlansTable", "presentation": [ "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options Plans [Table]", "label": "Stock Options Plans [Table]", "documentation": "Stock Options Plans [Table]" } } }, "auth_ref": [] }, "mor_StrikePriceShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "StrikePriceShareOptionsGranted", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price in \u20ac", "label": "Strike price, share options granted", "documentation": "Strike price, share options granted" } } }, "auth_ref": [] }, "mor_SubLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SubLicensesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCurrentPrepaidExpensesandOtherAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments for Sublicenses", "label": "Sub licenses [member]", "documentation": "Sub licenses." } } }, "auth_ref": [] }, "mor_SubTotalOfLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SubTotalOfLiabilitiesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Sub Total of Liabilities [Member]", "documentation": "Sub Total of Liabilities." } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subclassifications of assets, liabilities and equities [abstract]", "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "mor_SubscriptionRight": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SubscriptionRight", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription right", "label": "Subscription right", "documentation": "Subscription right" } } }, "auth_ref": [] }, "mor_SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounts Payable and Accrued Liabilities", "label": "Summary of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Disclosure of accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "mor_SummaryOfAccountsReceivableByRegionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAccountsReceivableByRegionTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounts Receivable by Region", "label": "Summary of Accounts Receivable by Region [Table Text Block]", "documentation": "Summary of Accounts Receivable by Region" } } }, "auth_ref": [] }, "mor_SummaryOfAccruedExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAccruedExpensesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued Expenses", "label": "Summary of Accrued Expenses [Table Text Block]", "documentation": "Detailed information of accrued expenses explanatory." } } }, "auth_ref": [] }, "mor_SummaryOfAmortizationOfIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAmortizationOfIntangibleAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Amortization of Intangible Assets", "label": "Summary of Amortization of Intangible Assets [Table Text Block]", "documentation": "Summary of Amortization of Intangible Assets" } } }, "auth_ref": [] }, "mor_SummaryOfAntiDilutionRightOtherReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAntiDilutionRightOtherReceivableTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Anti-dilution Right (Other Receivable)", "label": "Summary of Anti-dilution Right (Other Receivable) [Table Text Block]", "documentation": "Summary of Anti-dilution Right (Other Receivable)" } } }, "auth_ref": [] }, "mor_SummaryOfAuditFeesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfAuditFeesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Audit fees", "label": "Summary of Audit fees [Table Text Block]", "documentation": "Summary of Audit fees" } } }, "auth_ref": [] }, "mor_SummaryOfCapitalManagementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfCapitalManagementTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Capital Management", "label": "Summary of Capital Management [Table Text Block]", "documentation": "Disclosure of capital management information." } } }, "auth_ref": [] }, "mor_SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfCarryingAmountOfFinancialInstrumentsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Carrying Amount of Financial Instruments", "label": "Summary of Carrying Amount of Financial Instruments [Table Text Block]", "documentation": "Summary of Carrying Amount of Financial Instruments" } } }, "auth_ref": [] }, "mor_SummaryOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash and Cash Equivalents", "label": "Summary of Cash and Cash Equivalents [Table Text Block]", "documentation": "Summary of Cash and Cash Equivalents" } } }, "auth_ref": [] }, "mor_SummaryOfChangesInFairValueMeasurementFinancialAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfChangesInFairValueMeasurementFinancialAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes In Fair Value Measurement Financial Assets", "label": "Summary of Changes In Fair Value Measurement Financial Assets [Table Text Block]", "documentation": "Summary of Changes In Fair Value Measurement Financial Assets" } } }, "auth_ref": [] }, "mor_SummaryOfContractLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfContractLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Contract Liabilities", "label": "Summary of Contract Liabilities [Table Text Block]", "documentation": "Summary of Contract Liabilities" } } }, "auth_ref": [] }, "mor_SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfContractualCashFlowsOfFinancialLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Contractual Cash Flows of Financial Liabilities", "label": "Summary of Contractual Cash Flows of Financial Liabilities [Table Text Block]", "documentation": "Disclosure of license payments." } } }, "auth_ref": [] }, "mor_SummaryOfDepreciationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDepreciationTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Depreciation", "label": "Summary of Depreciation [Table Text Block]", "documentation": "Summary of Depreciation" } } }, "auth_ref": [] }, "mor_SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDetailedInformationOfLiabilitiesArisingFromFinancialActivitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Liabilities and Other Changes which are presented in Operating Activities", "label": "Summary of Detailed Information Of Liabilities Arising From Financial Activities [Table Text Block]", "documentation": "Disclosure Of Detailed Information Of Liabilities Arising From Financial Activities Explanatory." } } }, "auth_ref": [] }, "mor_SummaryOfDevelopmentFundingBondTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDevelopmentFundingBondTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Development Funding Bond", "label": "Summary of Development Funding Bond [Table Text Block]", "documentation": "Summary of Development Funding Bond" } } }, "auth_ref": [] }, "mor_SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDevelopmentOfCashSettledProgramsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Development of Cash-settled Programs", "label": "Summary of Development of Cash-settled Programs [Table Text Block]", "documentation": "Summary of Development of Cash-settled Programs" } } }, "auth_ref": [] }, "mor_SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDevelopmentOfPerformanceSharesUnderMorphosysUSIncRSUPlansTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Development of RSU Plans", "label": "Summary of Development of Performance Shares under Morphosys US Inc., RSU Plans [Table Text Block]", "documentation": "Summary of Development of Performance Shares under Morphosys US Inc., RSU Plans" } } }, "auth_ref": [] }, "mor_SummaryOfDevelopmentOfStockOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDevelopmentOfStockOptionsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Development of Stock Options", "label": "Summary Of Development of Stock Options [Table Text Block]", "documentation": "Summary Of Parameters Of Share Based Compensation." } } }, "auth_ref": [] }, "mor_SummaryOfDevelopmentOfTheLTIPlansTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfDevelopmentOfTheLTIPlansTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Development of the LTI plans", "label": "Summary of Development of the LTI plans [Table Text Block]", "documentation": "Summary of Development of the LTI plans" } } }, "auth_ref": [] }, "mor_SummaryOfEarningsPerShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfEarningsPerShareTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Earnings per Share", "label": "Summary of Earnings per Share [Table Text Block]", "documentation": "Summary of Earnings per Share" } } }, "auth_ref": [] }, "mor_SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Impact of Lease Agreements", "label": "Summary of expected impact of initial application of new standards or interpretations [Table Text Block]", "documentation": "Summary of expected impact of initial application of new standards or interpretations" } } }, "auth_ref": [] }, "mor_SummaryOfFairValueOfCashSettledProgramsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFairValueOfCashSettledProgramsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Cash-settled Programs", "label": "Summary of Fair Value of Cash-settled Programs [Table Text Block]", "documentation": "Summary of Fair Value of Cash-settled Programs" } } }, "auth_ref": [] }, "mor_SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFairValueOfFinancialAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities", "label": "Summary of Fair Value of Financial Assets and Liabilities [Table Text Block]", "documentation": "Summary of Fair Value of Financial Assets and Liabilities" } } }, "auth_ref": [] }, "mor_SummaryOfFairValueOfStockOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFairValueOfStockOptionsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Stock Options", "label": "Summary of Fair Value of Stock Options [Table Text Block]", "documentation": "Summary of Fair Value of Stock Options" } } }, "auth_ref": [] }, "mor_SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFinancialAssetsAtAmortizedCostTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Financial Assets at Amortized Cost", "label": "Summary of Financial Assets at Amortized Cost [Table Text Block]", "documentation": "Summary of Financial Assets at Amortized Cost" } } }, "auth_ref": [] }, "mor_SummaryOfFinancialAssetsFromCollaborationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFinancialAssetsFromCollaborationsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Assets from Collaborations", "label": "Summary of Financial Assets from Collaborations [Table Text Block]", "documentation": "Summary of Financial Assets from Collaborations" } } }, "auth_ref": [] }, "mor_SummaryOfFinancialInformationInvestmentInAssociatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFinancialInformationInvestmentInAssociatesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Information Investment in Associates", "label": "Summary of Financial Information Investment in Associates [Table Text Block]", "documentation": "Summary of Financial Information Investment in Associates" } } }, "auth_ref": [] }, "mor_SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfFinancialLiabilitiesFromFuturePaymentsToRoyaltyPharmaTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Liabilities from Future Payments to Royalty Pharma", "label": "Summary of Financial Liabilities from Future Payments to Royalty Pharma [Table Text Block]", "documentation": "Summary of Financial Liabilities from Future Payments to Royalty Pharma" } } }, "auth_ref": [] }, "mor_SummaryOfForeignCurrencyRiskTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfForeignCurrencyRiskTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Exposure to Foreign Currency Risk", "label": "Summary of Foreign Currency Risk [Table Text Block]", "documentation": "The disclosure of foreign currency risk." } } }, "auth_ref": [] }, "mor_SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfGrossCarryingAmountsOfFinancialAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Gross Carrying Amounts of Financial Assets by Credit Risk", "label": "Summary of Gross Carrying Amounts of Financial Assets [Table Text Block]", "documentation": "Summary of Gross Carrying Amounts of Financial Assets" } } }, "auth_ref": [] }, "mor_SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfGrossGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Gross Gains or Losses resulted from Financial Instruments", "label": "Summary of Gross Gains or Losses resulted from Financial Instruments [Table Text Block]", "documentation": "Summary of Gross Gains or Losses resulted from Financial Instruments" } } }, "auth_ref": [] }, "mor_SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfImpairmentLossesOnFinancialAssetsAndProvisionsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Impairment Losses for Credit Risk", "label": "Summary of Impairment Losses on Financial Assets and Provisions [Table Text Block]", "documentation": "Summary of Impairment Losses on Financial Assets and Provisions" } } }, "auth_ref": [] }, "mor_SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfInitialMeasurementDevelopmentFundingBondTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Initial Measurement - Development Funding Bond", "label": "Summary of Initial Measurement - Development Funding Bond [Table Text Block]", "documentation": "Summary of Initial Measurement - Development Funding Bond" } } }, "auth_ref": [] }, "mor_SummaryOfIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfIntangibleAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Intangible Assets", "label": "Summary of Intangible Assets [Table Text Block]", "documentation": "Summary of Intangible Assets" } } }, "auth_ref": [] }, "mor_SummaryOfInventoriesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfInventoriesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Inventories", "label": "Summary of Inventories [Table Text Block]", "documentation": "Summary of Inventories" } } }, "auth_ref": [] }, "mor_SummaryOfInvestmentsInAssociatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfInvestmentsInAssociatesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Investments in Associates", "label": "Summary of Investments in Associates [Table Text Block]", "documentation": "Summary of Investments in Associates" } } }, "auth_ref": [] }, "mor_SummaryOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfInvestmentsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Financial Assets", "label": "Summary of Investments [Table Text Block]", "documentation": "Summary of Investments" } } }, "auth_ref": [] }, "mor_SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfNetGainsOrLossesResultedFromFinancialInstrumentsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Gains or Losses resulted from Financial Instruments", "label": "Summary of Net Gains or Losses resulted from Financial Instruments [Table Text Block]", "documentation": "Summary of Net Gains or Losses resulted from Financial Instruments" } } }, "auth_ref": [] }, "mor_SummaryOfNonCurrentPrepaidExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfNonCurrentPrepaidExpensesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Non-current Prepaid Expenses", "label": "Summary of Non-current Prepaid Expenses [Table Text Block]", "documentation": "Summary of Non-current Prepaid Expenses" } } }, "auth_ref": [] }, "mor_SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfPerformanceSharesOfRelatedPartiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Performance Shares of Related Parties", "label": "Summary of Performance Shares of Related Parties [Table Text Block]", "documentation": "Summary of Performance Shares of Related Parties" } } }, "auth_ref": [] }, "mor_SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfPrepaidExpensesAndOtherAssetsTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Current Prepaid Expenses and Other Assets", "label": "Summary of Prepaid Expenses and Other Assets [Table Text Block]", "documentation": "Summary of Prepaid Expenses and Other Assets" } } }, "auth_ref": [] }, "mor_SummaryOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfPropertyPlantAndEquipmentTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property, Plant and Equipment", "label": "Summary of Property, Plant and Equipment [Table Text Block]", "documentation": "Summary of Property, Plant and Equipment" } } }, "auth_ref": [] }, "mor_SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfQuantitativeInformationAboutRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Right of use Assets and Lease Liabilities", "label": "Summary Of Quantitative Information About Right of use Assets and Lease Liabilities [Table Text Block]", "documentation": "Summary Of Quantitative Information About Right of use Assets and Lease Liabilities" } } }, "auth_ref": [] }, "mor_SummaryOfRegionalDistributionOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRegionalDistributionOfRevenueLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Regional Distribution of Revenue [Line Items]", "label": "Summary of Regional Distribution of Revenue [Line Items]", "documentation": "Summary of Regional Distribution of Revenue [Line Items]" } } }, "auth_ref": [] }, "mor_SummaryOfRegionalDistributionOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRegionalDistributionOfRevenueTable", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Regional Distribution of Revenue [Table]", "label": "Summary of Regional Distribution of Revenue [Table]", "documentation": "Summary of Regional Distribution of Revenue [Table]" } } }, "auth_ref": [] }, "mor_SummaryOfRegionalDistributionOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRegionalDistributionOfRevenueTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Regional Distribution of Revenue", "label": "Summary of Regional Distribution of Revenue [Table Text Block]", "documentation": "Summary of Regional Distribution of Revenue" } } }, "auth_ref": [] }, "mor_SummaryOfRemunerationOfSupervisoryBoardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRemunerationOfSupervisoryBoardTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Remuneration of Supervisory Board", "label": "Summary of Remuneration of Supervisory Board [Table Text Block]", "documentation": "Disclosure of supervisory board personnel compensation." } } }, "auth_ref": [] }, "mor_SummaryOfRevenuesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRevenuesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Revenue", "label": "Summary of Revenues [Table Text Block]", "documentation": "Summary of Revenues" } } }, "auth_ref": [] }, "mor_SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Royalty Pharma - Financial Liability", "label": "Summary of Royalty Pharma - Financial Liability [Table Text Block]", "documentation": "Summary of Royalty Pharma - Financial Liability" } } }, "auth_ref": [] }, "mor_SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfSensitivityAnalysisOfForeignExchangeRatesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Sensitivity Analysis of Foreign Exchange Rates", "label": "Summary of Sensitivity Analysis of Foreign Exchange Rates [Table Text Block]", "documentation": "Summary of Sensitivity Analysis of Foreign Exchange Rates" } } }, "auth_ref": [] }, "mor_SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfSensitivityAnalysisOfInterestRateRiskTableTextBlock", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Sensitivity Analysis of Variable Interest Rate Risk", "label": "Summary of Sensitivity Analysis of Interest Rate Risk [Table Text Block]", "documentation": "Summary of Sensitivity Analysis of Interest Rate Risk" } } }, "auth_ref": [] }, "mor_SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfSensitivityAnalysisOfRoyaltyPharmaFinancialLiabilityTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability", "label": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability [Table Text Block]", "documentation": "Summary of Sensitivity Analysis of Royalty Pharma - Financial Liability" } } }, "auth_ref": [] }, "mor_SummaryOfSharesOfRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfSharesOfRelatedPartiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Shares of Related Parties", "label": "Summary of Shares of Related Parties [Table Text Block]", "documentation": "Summary of Shares of Related Parties" } } }, "auth_ref": [] }, "mor_SummaryOfStockOptionsOfRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfStockOptionsOfRelatedPartiesTableTextBlock", "presentation": [ "http://www.morphosys.com/role/RemunerationSystemfortheManagementBoardandEmployeesoftheGroupTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Options of Related Parties", "label": "Summary of Stock Options of Related Parties [Table Text Block]", "documentation": "Summary of Stock Options of Related Parties" } } }, "auth_ref": [] }, "mor_SummaryOfTaxLiabilitiesCurrentAndNonCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SummaryOfTaxLiabilitiesCurrentAndNonCurrentTableTextBlock", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Tax Liabilities and Other Provisions", "label": "Summary of Tax Liabilities Current and Non-current [Table Text Block]", "documentation": "Summary of Tax Liabilities Current and Non-current" } } }, "auth_ref": [] }, "mor_SungLeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SungLeeMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofPerformanceSharesofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofStockOptionsofRelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sung Lee", "label": "Sung Lee [Member]", "documentation": "Sung Lee" } } }, "auth_ref": [] }, "mor_SupervisoryBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "SupervisoryBoardMember", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofRelatedPartiesDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supervisory Board", "label": "Supervisory Board [member]", "documentation": "Supervisory board." } } }, "auth_ref": [] }, "mor_TafasitamabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TafasitamabMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tafasitamab", "label": "Tafasitamab [Member]", "documentation": "Tafasitamab" } } }, "auth_ref": [] }, "mor_TargetAchievement": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TargetAchievement", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target achievement", "label": "Target Achievement", "documentation": "Target Achievement" } } }, "auth_ref": [] }, "mor_TaxEffectAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectAbstract", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Effects Resulting from:", "label": "Tax effect [abstract]", "documentation": "Tax effect." } } }, "auth_ref": [] }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectFromChangeInTaxRate", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 8.0 } }, "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } } }, "auth_ref": [ "r49" ] }, "mor_TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Derecognition of Deferred Tax Assets on Tax Losses", "label": "Tax effect from non recognition of deferred tax assets on current year tax losses1", "documentation": "Tax effect from non recognition of deferred tax assets on current year tax losses1." } } }, "auth_ref": [] }, "mor_TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectFromNonRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Derecognition of Deferred Tax Assets on Temporary Differences", "label": "Tax effect from non recognition of deferred tax assets on temporary differences1", "documentation": "Tax effect from non recognition of deferred tax assets on temporary differences1." } } }, "auth_ref": [] }, "mor_TaxEffectFromRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectFromRecognitionOfDeferredTaxAssetsOnCurrentYearTaxLosses1", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "auth_ref": [] }, "mor_TaxEffectFromRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectFromRecognitionOfDeferredTaxAssetsOnTemporaryDifferences1", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 13.0 } }, "auth_ref": [] }, "mor_TaxEffectOfDifferencesInProfitAndLossAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectOfDifferencesInProfitAndLossAdjustment", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-Tax-Deductible Items", "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax Rate Differences to Local Tax Rates", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r49" ] }, "mor_TaxEffectOfPriorYearAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectOfPriorYearAdjustments", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Prior Year Taxes", "label": "Tax effect of prior year adjustments", "documentation": "Tax effect of prior year adjustments." } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfRevenuesExemptFromTaxation2011": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfRevenuesExemptFromTaxation2011", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-taxable income", "label": "Tax effect of revenues exempt from taxation" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to revenues that are exempt from taxation. [Refer: Accounting profit]" } } }, "auth_ref": [ "r49" ] }, "mor_TaxEffectOfSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectOfSharebasedCompensation", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Share-based Payment", "label": "Tax Effect of Share-based Compensation", "documentation": "Tax effect of share-based compensation." } } }, "auth_ref": [] }, "mor_TaxEffectsOfPermanentDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxEffectsOfPermanentDifferences", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Permanent Differences", "label": "Tax Effects Of Permanent Differences", "documentation": "Tax Effects Of Permanent Differences." } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected Income Tax", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r49" ] }, "mor_TaxLiabilitiesCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxLiabilitiesCurrentAndNonCurrent", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Liabilities", "label": "Tax liabilities, current and non-current", "documentation": "Tax liabilities, current and non-current" } } }, "auth_ref": [] }, "mor_TaxLossesCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxLossesCarryforwards", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Assets on Tax Losses", "label": "Tax Losses Carryforwards", "documentation": "Tax Losses Carryforwards." } } }, "auth_ref": [] }, "mor_TaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxLossesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Losses", "verboseLabel": "Tax Losses", "label": "Tax Losses [Member]" } } }, "auth_ref": [] }, "mor_TaxLossesRelativeToUSTaxGroup": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxLossesRelativeToUSTaxGroup", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax losses relative to US tax group", "label": "Tax losses relative to US tax group", "documentation": "Tax losses relative to US tax group" } } }, "auth_ref": [] }, "mor_TaxProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxProvisionsLineItems", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Provisions [Line Items]", "label": "Tax Provisions [Line Items]", "documentation": "Tax Provisions [Line Items]" } } }, "auth_ref": [] }, "mor_TaxProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxProvisionsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Liabilities", "label": "Tax Provisions [Member]", "documentation": "Tax Provisions" } } }, "auth_ref": [] }, "mor_TaxProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TaxProvisionsTable", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsAdditionalInformationDetailsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofIncomeTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofReconciliationofExpectedIncomeTaxExpensewithActualIncomeTaxExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Provisions [Table]", "label": "Tax Provisions [Table]", "documentation": "Tax Provisions [Table]" } } }, "auth_ref": [] }, "mor_TecDAXIndexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TecDAXIndexMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TecDAX index", "label": "TecDAX Index [member]", "documentation": "TecDAX index." } } }, "auth_ref": [] }, "mor_TechnicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TechnicalEquipmentMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRightofuseAssetsandLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technical Equipment", "label": "Technical Equipment [Member]" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]", "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofChangesinDeferredTaxesDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementScheduleofDeferredTaxAssetsandDeferredTaxLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]", "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r53" ] }, "mor_ThereofFinancialAssetsFromEscrowNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ThereofFinancialAssetsFromEscrowNonCurrent", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Financial Asset from Escrow Account", "label": "Thereof Financial Assets from Escrow Non Current", "documentation": "Thereof Financial Assets from Escrow Non Current" } } }, "auth_ref": [] }, "mor_ThereofForwardExchangeContractsUsedForHedging": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ThereofForwardExchangeContractsUsedForHedging", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof Anti-Dilution Right HI-Bio", "label": "Thereof forward exchange contracts used for hedging", "documentation": "Thereof forward exchange contracts used for hedging" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofConditionalCapitalDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofFinancialAssetsfromCollaborationsAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r165", "r190", "r206", "r315", "r316", "r389" ] }, "mor_TradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TradeAccountsPayable", "crdr": "credit", "calculation": { "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails": { "parentTag": "mor_AccountsPayableAndAccruedExpensesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofContractualCashFlowsofFinancialLiabilitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Trade Accounts Payable", "documentation": "Trade accounts payable." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofFairValueLevelofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "thereof Accounts Payable", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r18" ] }, "mor_TradeReceivablesAndContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TradeReceivablesAndContractAssets", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Trade receivables and contract assets", "documentation": "Trade receivables and contract assets." } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r232", "r235", "r330", "r353" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.morphosys.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "mor_TransferOfAssignedLicenseRevenuesToRoyaltyPharma": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TransferOfAssignedLicenseRevenuesToRoyaltyPharma", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofNetLiabilitiesandOtherChangeswhicharepresentedinOperatingActivitiesDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Assigned License Revenues to Royalty Pharma", "label": "Transfer of Assigned License Revenues to Royalty Pharma", "documentation": "Transfer of Assigned License Revenues to Royalty Pharma" } } }, "auth_ref": [] }, "mor_TransferOfPerformanceSharesToBeneficiariesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TransferOfPerformanceSharesToBeneficiariesPeriod", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of performance shares to beneficiaries period", "label": "Transfer Of Performance Shares To Beneficiaries Period", "documentation": "Transfer Of Performance Shares To Beneficiaries Period" } } }, "auth_ref": [] }, "mor_TransitionPeriodBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TransitionPeriodBusinessCombination", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition period business combination", "label": "Transition Period Business Combination", "documentation": "Transition Period Business Combination" } } }, "auth_ref": [] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheet", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury Stock (53,685 and 65,980 shares for 2023 and 2022, respectively), at Cost", "terseLabel": "Treasury stock balance", "label": "Treasury shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r84", "r287" ] }, "mor_TreasurySharesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TreasurySharesLineItems", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Shares [Line Items]", "netLabel": "Treasury Shares [Line Items]", "label": "Treasury Shares [Line Items]", "documentation": "Treasury Shares [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/ConsolidatedStatementofChangesinStockholdersEquity", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury shares [member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r8" ] }, "mor_TreasurySharesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TreasurySharesTable", "presentation": [ "http://www.morphosys.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Shares [Table]", "netLabel": "Treasury Shares [Table]", "label": "Treasury Shares [Table]", "documentation": "Treasury Shares [Table]" } } }, "auth_ref": [] }, "mor_TwoThousandNineteenLongTermIncentiveProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TwoThousandNineteenLongTermIncentiveProgramMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2019 Long-Term Incentive Program", "label": "Two Thousand Nineteen Long Term Incentive Program [Member]", "documentation": "Two thousand nineteen long term incentive program" } } }, "auth_ref": [] }, "mor_TypeOfDebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TypeOfDebtInstrumentAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Debt Instrument [Axis]", "label": "Type of Debt Instrument [Axis]", "documentation": "Type of Debt Instrument" } } }, "auth_ref": [] }, "mor_TypeOfDebtInstrumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "TypeOfDebtInstrumentDomain", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSubsequentEventsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Debt Instrument [Domain]", "label": "Type of Debt Instrument [Domain]", "documentation": "Type of Debt Instrument" } } }, "auth_ref": [] }, "ifrs-full_TypesOfCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfCustomersAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Types of customers [axis]", "label": "Types of customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r318" ] }, "ifrs-full_TypesOfCustomersMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfCustomersMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementRevenueNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Types of customers [member]", "label": "Types of customers [member]" } }, "en": { "role": { "documentation": "This member stands for all types of customers. It also represents the standard value for the 'Types of customers' axis if no other member is used." } } }, "auth_ref": [ "r318" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r191", "r192", "r193", "r195", "r227", "r230", "r231" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofCreditriskAdditionalInformationDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails", "http://www.morphosys.com/role/AdditionalNotesSummaryofGrossCarryingAmountofFinancialAssetsbyCreditRiskDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risks", "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r191", "r192", "r193", "r195", "r227", "r230", "r231" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesEquityInvestmentsNarrativeDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTreasuryStockAdditionalInformationDetails", "http://www.morphosys.com/role/RSDevelopmentofLongTermIncentivePlansandFVAdditionalInformationDetails", "http://www.morphosys.com/role/RSFairValueStockOptionsAdditionalInformationDetails", "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofLongtermIncentivePlansandFVDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofDevelopmentofequitysettledRestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails", "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2020RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2021PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettledLongtermIncentiveCashPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021RestrictedStockUnitPlansDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2022RestrictedStockUnitPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2023RestrictedStockUnitPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r207" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofGeographicalDisclosuresDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofAccountsReceivablebyRegionDetails", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfRegionalDistributionofRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "USA", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofExposuretoForeignCurrencyRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US$", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "mor_UnlimitedCarryForwardOfTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UnlimitedCarryForwardOfTaxLossesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carry-Forward of Tax Losses", "label": "Unlimited Carry Forward Of Tax Losses [Member]", "documentation": "Unlimited Carry Forward Of Tax Losses (Member)." } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [axis]", "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r160", "r387" ] }, "ifrs-full_UnobservableInputsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisFinancialAssetsfromCollaborationsDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofSensitivityAnalysisRoyaltyPharmaFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable inputs [member]", "label": "Unobservable inputs [member]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r160", "r387" ] }, "mor_UnsecuredConvertibleBondMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UnsecuredConvertibleBondMember", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured convertible bond", "label": "Unsecured Convertible Bond [Member]", "documentation": "Unsecured Convertible Bond" } } }, "auth_ref": [] }, "mor_UnusedProvisionAmountsReversed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UnusedProvisionAmountsReversed", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofChangesinImpairmentLossesforCreditRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused Amounts Reversed", "label": "Unused provision amounts reversed", "documentation": "Unused provision amounts reversed." } } }, "auth_ref": [] }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofTaxLiabilitiesandOtherProvisionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Release", "label": "Unused provision reversed, other provisions" } }, "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r98" ] }, "mor_UpfrontLicensePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UpfrontLicensePaymentsMember", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront license payments", "label": "Upfront License Payments [Member]", "documentation": "Upfront License Payments" } } }, "auth_ref": [] }, "mor_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UpfrontPayment", "crdr": "debit", "presentation": [ "http://www.morphosys.com/role/AdditionalNotesSummaryofAgreementsRelatedtoClinicalDevelopmenttroughPartnersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Upfront Payment", "documentation": "Upfront Payment" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillDetail", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofUsefulLivesofIntangibleAssetsIncludingGoodwillNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Useful Life", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r102" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesSummaryofEstimatedUsefulLifeofPropertyPlantandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Useful Life", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r54" ] }, "mor_UtilizationOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "UtilizationOfTaxLosses", "crdr": "debit", "calculation": { "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail": { "parentTag": "mor_TaxLossesCarryforwards", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfDetailedInformationAboutInLimitedUnlimitedCarryForwardTaxLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derecognition of Deferred Tax Assets on Tax Losses", "label": "Utilization Of Tax Losses", "documentation": "Utilization Of Tax Losses ." } } }, "auth_ref": [] }, "mor_ValueInUsePatentTermUsedForCalculation": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "ValueInUsePatentTermUsedForCalculation", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value in use patent term", "label": "Value-In-Use Patent Term Used For Calculation", "documentation": "Value-In-Use Patent Term Used For Calculation" } } }, "auth_ref": [] }, "mor_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2022PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofcashsettled2023PerformanceShareUnitProgramDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019LongtermIncentivePlanMORAGDetails", "http://www.morphosys.com/role/SummaryofMaterialAccountingPoliciesStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vesting period requirements for share-based performance shares", "terseLabel": "Vesting period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period" } } }, "auth_ref": [] }, "mor_WagesAndSalariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "WagesAndSalariesMember", "presentation": [ "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryofPersonnelExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Wages and Salaries", "label": "Wages and Salaries [Member]", "documentation": "Wages and Salaries" } } }, "auth_ref": [] }, "mor_WeightedAverageCostOfCapitalBeforeTaxPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "WeightedAverageCostOfCapitalBeforeTaxPercentage", "presentation": [ "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofGoodwillDetails", "http://www.morphosys.com/role/NotestotheBalanceSheetSummaryofInprocessRDProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "WACC before tax", "label": "Weighted Average Cost of Capital Before Tax Percentage", "documentation": "Weighted average cost of capital before tax percentage." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value at measurement date, share options granted (in Eur per share)", "label": "Weighted average fair value at measurement date, share options granted" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average", "label": "Weighted average [member]" } }, "en": { "role": { "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average." } } }, "auth_ref": [ "r165", "r190", "r315", "r316", "r389" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.morphosys.com/role/RSSummaryofDevelopmentofStockOptionPlansandFairValueDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2017StockOptionPlanGroupDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2018StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2019StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2020StockOptionPlanDetails", "http://www.morphosys.com/role/RSSummaryofequitysettled2021StockOptionPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average price (eur per share)", "label": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://www.morphosys.com/role/RSSummaryofFairValueofcashsettledPerformanceShareUnitProgramsDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledLongtermIncentivePlanDetails", "http://www.morphosys.com/role/RSSummaryofFairValueofequitysettledStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price on grant date (in Eur per share)", "label": "Weighted average share price, share options granted" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.morphosys.com/role/ConsolidatedStatementofProfitorLoss", "http://www.morphosys.com/role/NotestotheProfitorLossStatementEarningsPerShareAdditionalInformationDetail", "http://www.morphosys.com/role/NotestotheProfitorLossStatementSummaryOfReconciliationOfEarningPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in computing earnings per share, basic (in shares)", "verboseLabel": "Weighted average ordinary shares used in calculating basic earnings per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r88" ] }, "mor_WeightedTargetPerformanceAchievement": { "xbrltype": "pureItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "WeightedTargetPerformanceAchievement", "presentation": [ "http://www.morphosys.com/role/RSRelatedPartiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted target performance achievement", "label": "Weighted Target Performance Achievement", "documentation": "Weighted Target Performance Achievement" } } }, "auth_ref": [] }, "mor_WendyJohnsonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.morphosys.com/20231231", "localname": "WendyJohnsonMember", "presentation": [ "http://www.morphosys.com/role/RSSummaryofRemunerationofSupervisoryBoardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wendy Johnson", "label": "Wendy Johnson [member]", "documentation": "Wendy Johnson." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_m&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "74", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_74_c&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "148", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_148_d_v&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_d&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "129", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "122", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_e&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_d&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_e&doctype=Standard", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "49", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_c&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_23_b&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_b&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "116", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_c&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_c&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_d&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "57", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_57&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "m", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "11A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "11A", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11A_d&doctype=Standard", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "11B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11B_b&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "11B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_11B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "6.5.15", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_6.5.15&doctype=Standard", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_7&doctype=Standard&forcepdf=true", "URIDate": "2023-03-23" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_91_a&doctype=Standard&forcepdf=true", "URIDate": "2023-03-23" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2023-03-23" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r289": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_a&doctype=Standard", "URIDate": "2023-03-23" }, "r290": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_c&doctype=Standard", "URIDate": "2023-03-23" }, "r291": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23" }, "r292": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2023-03-23" }, "r293": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2023-03-23" }, "r294": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2023-03-23" }, "r295": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r296": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2023-03-23" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_d&doctype=Standard", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r306": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r307": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r308": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r309": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2023-03-23" }, "r310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2023-03-23" }, "r312": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r314": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r316": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r317": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r318": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r319": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r320": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r321": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r322": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2023-03-23" }, "r323": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2023-03-23" }, "r324": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r326": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r327": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I_a&doctype=Standard", "URIDate": "2023-03-23" }, "r328": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I_c&doctype=Standard", "URIDate": "2023-03-23" }, "r329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard", "URIDate": "2023-03-23" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard", "URIDate": "2023-03-23" }, "r363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard", "URIDate": "2023-03-23" }, "r367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "20", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2023-03-23" }, "r369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard", "URIDate": "2023-03-23" }, "r375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2023-03-23" }, "r382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2023-03-23" }, "r388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expired 2023-01-01", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2023-03-23" } } }